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This report, cosponsored by the Center for Inter-
national Blood and Marrow Transplant Research
(CIBMTR), National Marrow Donor Program
(NMDP), European Blood and Marrow Transplant
Group (EBMT), American Society for Blood and
Marrow Transplant (ASBMT), Canadian Blood and
Marrow Transplant Group (CBMTG), Infectious
Diseases Society of America (IDSA), Society for
Healthcare Epidemiology of America (SHEA), Associ-
ation of Medical Microbiology and Infectious Diseases
(AMMI), the Center for Disease Control and Preven-
tion (CDC), and the Health Resources and Services
Administration, represents an update of the guidelines
published in 2000 for preventing infections among
hematopoietic cell transplantion (HCT) recipients
[1]. An international group of experts in infectious dis-
eases, HCT, and public health worked together to
compile this document with 4 goals in mind: (1) to sum-
marize the current available data in the field, (2) to pro-
vide evidence-based recommendations regardingprevention of infectious complications among HCT
patients, (3) to serve as a reference for health care pro-
viders worldwide who care for HCT recipients, and (4)
to serve as a reference for HCT recipients and their
nonmedical caregivers. In updating these guidelines,
the committee sought to summarize the currently
available data and present them as concisely as possible
in an evidence-based fashion.
Significant changes in the field of HCT since the
publication of the original guidelines necessitated
this update. These changes include new antimicrobial
agents, broader use of reduced-intensity conditioning
(RIC), the increasing age of HCT recipients, and
more frequent use of alternative donor stem cell sour-
ces such as haploidentical donors and umbilical cord
blood. Furthermore, as with any field of medicine,
published studies continue to add to the evidence
regarding supportive medical care. Despite—or per-
haps because of—these changes, infections still occur
with increased frequency or severity among HCT
recipients as a patient population.
In presenting these guidelines, the committee is not
intending to dictate standards of practice. Although con-
siderable effort has gone into ensuring that the guide-
lines have a global perspective based on the currently
available medical evidence, adherence to a particular
recommendation may be inconsistent with national or
regional guidelines, the availability of specific proce-
dures or medications, or local epidemiological condi-
tions. Individual clinicians may follow practice
patterns that, although deviating from these recommen-
dations, are nevertheless effective and sound.USING THESE GUIDELINES
For the purposes of this report, HCT is defined as
transplantation of any blood- or marrow-derived
hematopoietic stem cells (HSCs), regardless of trans-
plant type (ie, allogeneic or autologous) or cell source
(ie, bone marrow [BM], peripheral blood [PB], or um-
bilical cord blood [UCB]). The definition of immune
competence following transplant is loosely defined by
the ability of the HCT recipient to receive live vaccine
following recovery from transplant. Conventionally,
this is thought to occur at approximately 24 months fol-
lowing HCT in patients who are not receiving immu-
nosuppressive therapy and do not have active graft-
versus-host disease (GVHD) [1]. For patients with
on-going GVHD or continued use of immunosuppres-
sive therapy, it is recommended to consider the patient
as immune deficient and still at risk for significant
infectious complications.
Unless otherwise noted, the recommendations pre-
sented in this report address allogeneic and autologous
and pediatric and adult HCT recipients. These recom-
mendations are intended for use by the recipients, their
household and other close contacts, transplant and
Table 1. Evidence-Based Rating System Used in the Hematopoietic Cell Transplantation (HCT) Guidelines [2]
Strength of Recommendation
Category Definition
A Both strong evidence for efficacy and substantial clinical benefit support recommendation for use. Should always be offered.
B Moderate evidence for efficacy—or strong evidence for efficacy, but only limited clinical benefit—supports recommendation for
use. Should generally be offered.
C Evidence for efficacy is insufficient to support a recommendation for or against use, or evidence for efficacy might not
outweigh adverse consequences (eg, drug toxicity, drug interactions), or cost of the chemoprophylaxis or alternative approaches. Optional.
D Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should generally not be offered.
E Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should never be offered.
Quality of Evidence Supporting the Recommendation
Category Definition
I Evidence from at least one well-executed randomized, controlled trial
II Evidence from at least one well-designed clinical trial without randomization; cohort or case-controlled analytic studies (preferably
from more than one center); multiple time-series studies; or dramatic results from uncontrolled experiments
III Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees
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and public health professionals. For most recommen-
dations, prevention strategies are rated by the strength
of the recommendation and the quality of the evidence
supporting the recommendation (Table 1). The princi-
ples of this rating system were developed by the IDSA
and the U.S. Public Health Service for use in guidelines
for preventing opportunistic infections among HIV-
infected persons [2]. This rating system allows assess-
ments of the strength of recommendations.EXECUTIVE SUMMARY
In the past decade, modifications in HCT manage-
ment and supportive care have resulted in changes in
recommendations for the prevention of infection in
HCT patients. These changes are fueled by new
antimicrobial agents, increased knowledge of immune
reconstitution, and expanded conditioning regimens
and patient populations eligible for HCT. Despite
these advances, infection is reported as the primary
cause of death in 8% of autologous HCT patients and
17% to 20% of allogeneic HCT recipients [3]. The
major changes in this document, including changes in
recommendation ratings, are summarized here.
The organization of this document is similar to the
previous guidelines. Specifically, the prevention of
exposure and disease among pediatric and adult autolo-
gous and allogeneic HCT recipients is discussed. The
current recommendations consider myeloablative
(MA) conditioning and RIC for allogeneic HCT
similarly, because data on infectious complications fol-
lowing RIC compared to MA conditioning are sparse
[4-7]. However, increased information regarding post-
transplant immune recovery highlighting differences
between MA and RIC HCT are included.
The sections of the document have been rear-
ranged in an attempt to follow the time course ofpotential infectious risks for patients receiving HCT.
Following the background section, information on he-
matopoietic cell product safety is provided. The subse-
quent sections discuss prevention of infection by
specific microorganisms. Following organism-specific
information, the sections then discuss means of pre-
venting nosocomial infections as well as ‘‘dos and
don’ts’’ for patients following discharge posttrans-
plant. Finally, information on vaccinations is provided.
This will hopefully allow the reader to follow the pre-
vention practices needed from the time a donor is
selected until the patient regains immune competence.
Several topics are new or expanded from the prior
document (Table 2). These include information on
multiple organisms that were previously not discussed,
but have seemingly become more clinically relevant in
HCT patients over the past decade. Data, and where
possible, recommendations, are provided regarding
the following organisms that were not included in
the previous document: Bordetella pertussis; the polyo-
maviruses BK and JC; hepatitis A, B, and C viruses
(HAV, HBV, HCV); human herpesviruses (HHV) 6,
7, and 8; human metapneumovirus; human immuno-
deficiency virus (HIV); tuberculosis; nocardiosis; ma-
laria; and leishmaniasis. In recognition of our global
society, several organisms are discussed that may be
limited to certain regions of the world. Included in
that section are also those infections that may be ubiq-
uitous but occur infrequently, such as Pneumocystis jir-
oveci and Nocardia.
Several other changes should be noted. For bacte-
rial infections, these guidelines now recommend qui-
nolone prophylaxis for patients with neutropenia
expected to last as least 7 days (BI). Additionally, the
recommendations for contact precautions (AIII), vacci-
nation (BI), and prophylaxis for patients with GVHD
(AIII) against Streptococcus pneumoniae have been
strengthened. The subsection on central line-associated
Table 2. Summary of Changes Compared to the Guidelines Published in 2000 [1]
Major Changes Starting Page
Updated background on immune recovery following HCT including differences based on conditioning regimen and stem cell sources 7
Changes to the Bacterial Section
1) Quinolone prophylaxis is recommended for patients with neutropenia expected to last $7 days (BI) 14
2) Added recommendations regarding Central Line-Associated Bloodstream Infections (CLABSI) (in addition to the section in Infection
Prevetion and Control)
15
3) Streptococcus pneumoniae
a) Contact precautions now an AIII (prior BIII)
b) Antimicrobial prophylaxis in patients with GVHD now an AIII (prior BIII)
c) Vaccination with PCV now a BI recommendation (prior BIII)
15
Changes to the Fungal Section
1) Micafungin is an alternative for prevention of candidiasis during preengraftment (BI) 32
2) Voriconazole and Posaconazole may be used for prevention of candidiasis postengraftment (BI) 33
3) Itraconazole oral solution as prevention of mold infections (BI—prior, no data) 34
4) Posaconazole for prevention of mold infections in patients with GVHD (BI) 34
PCR screening for Toxoplama gondii can be considered in high-risk patients when unable to tolerate prophylaxis (BII) 37
Changes in Vaccination Recommendations
1) Pneumococcal Vaccine: Use PCV vaccine and start 3-6 months post-HCT 63
2) Optional to use acellular pertussis vaccine in all patients 64
3) Varicella vaccine (Varivax) is optional. Zostavax is contraindicated 64
4) Vaccinations with inactivated vaccines may be started as early as 6 months post-HCT (and earlier for PCV and influenza) 31
5) Information regarding use of HPV vaccine 32
Sections added to the Infection Prevention and Control Section
1) Recommendations regarding multiply drug-resistant Gram-negative bacilli 49
2) Recommendations regarding adenovirus 52
3) Recommendation regarding viral gastroenteritis 52
Section added to the Safe Living after Hematopoietic Cell Transplantation
Recommendations regarding household contacts who receive live-attenuated vaccines
55
Appendix 1 (Dosing) changes
1) Alternative CMV prophylaxis/treatment: Foscarnet now AI (prior CIII) and added Valganciclovir and Cidofovir 89
2) EBV prophylaxis/treatment with Rituximab 89
3) VZV: added alternatives to VZIG for exposure and new information on prophylaxis 90
4) Influenza: added dosing information for Oseltamivir and Zanamivir 91
5) RSV: Added dosing information 91
6) Split the fungal section into data for standard-risk and high-risk patients 92
7) Added dosing information for Micafungin, Posaconazole, and Voriconazole 92
8) Alternative PCP prophylaxis: Added atovaquone and changed aerosolized Pentamidine to CII (prior CIII) 92
New Organisms
Bordatella pertussis 16
Human Metapneumovirus 23
Polyomaviruses BK and JC 24
Hepatitis A 25
Hepatitis B 25
Hepatitis C 26
Human Herpes Virus 6 and 7 27
Human Herpes Virus 8 28
Human Immunodeficiency Virus 28
Mycobacterium tuberculosis 34
Nocardia 38
Leishmania 39
Malaria 39
GVHD indicates graft-versus-host disease; HCT, hematopoietic cell transplantation; CVM, cytomegalovirus; EBV, Epstein-Barr virus; VZV, varicella zos-
ter virus; PCP, Pneumocystis jiroveci pneumonia; RSV, respiratory syncytial virus; VZIG, varicella-zoster immunoglobulin.
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The vaccination section has been dramatically ex-
panded. Changes include the recommendations for
pneumococcal conjugate vaccine (PCV) rather than
polysaccharide vaccine (PPSV-23) for pneumococcal
vaccination, starting some vaccinations earlier post-
transplant, and the addition of recommendations for
Varivax, HPV vaccine, and (the nonuse of) Zostavax
vaccine are included. Two additional appendices were
added to provide information on desensitization to
sulfa drugs and visitor screening questionnaires. Fi-
nally, the dosing appendix has merged both adult and
pediatric dosing, and provides recommendations forseveral newer antimicrobial agents that were not previ-
ously available.
In summary, the changes and expansion
to this document reflect the growing body of
literature detailing infectious complications in
HCT patients.BACKGROUND TO HCT, INCLUDING
POSTTRANSPLANT IMMUNE RECOVERY
C. Mackall, T. Fry, R. Gress, K. Peggs, J. Storek, A.
Toubert
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defined as the transfer of hematopoietic stem cells
(HSCs) from 1 individual to another (allogeneic
HCT) or the return of previously harvested cells to
the same individual (autologous HCT) after manipula-
tion of the cells and/or the recipient. The goal of HCT
is lifelong engraftment of the administered cells, re-
sulting in some or all of the recipient’s lymphohemato-
poietic system being derived from the HCT graft. Full
donor engraftment occurs when the recipient lympho-
hematopoietic system is fully replaced by progeny of
the HCT graft. This is the ultimate goal of many
HCT protocols, especially for achieving optimal
graft-versus-tumor (GVT) activity in patients with
malignant disease [8-10]. In some clinical settings,
however, a state of ‘‘mixed chimerism,’’ wherein ele-
ments of both the donor and recipient lymphohemato-
poietic system survive, may be sufficient to cure the
underlying condition [11,12].
Allogeneic HCT can cure or improve outcome in
a wide variety of diseases, including leukemia,
lymphoma, myeloproliferative disorders, myelodysplas-
tic syndrome (MDS), bone marrow (BM) failure syn-
dromes, congenital immunodeficiencies, enzyme
deficiencies, and hemoglobinopathies [13-17]. How-
ever, because allogeneic HCT is associated with signifi-
cant morbidity and mortality because of regimen-related
toxicity (RRT) [18], infection [19], and graft versus host
disease (GVHD) [20], a recommendation regarding
transplantation for the individual patient requires careful
risk assessment that takes into account disease status
[21], comorbidities, previous therapies, other standard
therapies available for the underlying disease [22], donor
stem cell source [23], and histoincompatibility [24].
Autologous HCT can improve outcomes in neoplastic
diseases [25] and autoimmune conditions [26], and con-
tinues to be investigated as a platform for gene therapy
[27]. RRT and infections contribute to the morbidity
and mortality associated with autologous HCT; how-
ever, morbidity because of GVHD generally does not
occur after this procedure.
Substantial progress has been made in allogeneic
HCT during the past 15 years as a result of improve-
ments in 4 distinct, but interrelated, areas. First,
improvements in the supportive care of patients with
severe immunosuppression and myelosuppression
have diminished morbidity and mortality because of
infection [19,28,29]. Second, the critical contribution
of immune-mediated GVT effects toward eradicating
malignant disease and facilitating engraftment is now
well established, and factors prominently in the design
of individual HCT regimens [21]. Third, alternative do-
nor (nonsibling) transplants and new stem cell sources
now provide HCT options for a larger percentage of po-
tential candidates [23,30,31]. Fourth, newer, less toxic
preparative regimens have been developed that allow
reliable engraftment with a lower risk for treatment-related mortality (TRM) and long-term adverse effects
[18,32].
Classically, transfer of the hematopoietic cell
graft was seen as a means to rescue the recipient’s
lymphohematopoietic system from an otherwise lethal
myeloablative (MA) preparative regimen. In this
model, the preparative regimen was used as the pri-
mary tool to eradicate malignant disease, or to eradi-
cate the recipient’s immune system when HCT was
used to treat benign diseases. However, careful clinical
studies over the last 4 decades have revealed that the ef-
fectiveness of allogeneic HCT in eradicating malig-
nant disease is intimately linked to the activity of
immunoreactive cells in the graft, most notably T cells
and, in some cases, natural killer (NK) cells [24,33,34].
Indirect demonstration of this graft-versus-leukemia
(GVL) effect comes from reports of increased leuke-
mic relapse following syngeneic (identical twin)
HCT and increased leukemia relapse following T
cell-depleted HCT. Direct demonstration has been
provided by the ability of donor lymphocyte infusions
(DLIs) to induce remission in substantial numbers of
patients with chronic myelogenous leukemia (CML)
[35]. Evidence for a GVT effect also exists for other
malignancies [36], but the effect appears to be less po-
tent than that observed in CML. Furthermore, even
when HCT is performed for benign diseases, the rate
and degree of donor engraftment can be enhanced
with the use of donor leukocyte infusions, demonstrat-
ing that immune cells also contribute to the engraft-
ment process. Thus, HCT has evolved from
a therapy designed primarily to provide lymphohema-
topoietic rescue after MA conditioning to a form of
immunotherapy wherein mature immune cells con-
tained within the graft and/or reconstituted from do-
nor progenitors play an active role in eradicating the
underlying neoplastic disease and in facilitating donor
engraftment.
Expansion of graft sources has contributed to sub-
stantial progress in allogeneic HCT. Traditionally,
allogeneic HCT involved transfer of marrow grafts
harvested from HLA-matched sibling donors, in
which case histoincompatibility was limited to minor
antigens, for which reliable typing is not routinely
available. Approximately 25% to 30% of potential
HCT recipients will have a matched sibling donor
available. Through the efforts of the NMDP in the
United States and donor registries throughout the
world, approximately 12 million individuals have
undergone preliminary HLA typing over the last 20
years, and as a result, 75% of Caucasian individuals
will find a suitably matched unrelated donor (URD).
For other racial or ethnic groups, however, the chance
of finding a suitable donor using existent registries is
substantially less. Recent studies have demonstrated
that with proper HLA matching, outcomes following
matched URD HCT approach those reported for
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(UCB) transplants have also shown promise. The
benefits of UCB as a stem cell source are ready acces-
sibility and the ability to cross HLA barriers
[23,31,37,38]. Mismatched related and haploidentical
donor grafts also continue to have a role in clinical
HCT, especially for patients with congenital immuno-
deficiency [39] and in specialized centers where this
approach continues to be optimized [40,41]. Beyond
the multitude of choices regarding donor source,
progress during the last 15 years has also demonstrated
that granulocyte colony-stimulating factor (G-CSF)-
mobilized peripheral blood stem cell (PBSC) allografts
provide a reliable source for engraftment, and offer the
advantage of improved myelogenous and T cell recov-
ery [30,42] than with traditional marrow grafts and
thus fewer infections. However, G-CSF-mobilized
blood grafts also appear to carry a greater risk for
chronic GVHD (cGVHD) compared with marrow
grafts [23,43,44].
New approaches have been developed to minimize
the likelihood of graft failure, conditioning toxicity,
GVHD, and infections [45-48]. The addition of T
cell-depleting agents (eg, antithymocyte globulin
[ATG] or alemtuzumab) to conditioning regimens
has been associated with a reduced incidence of
GVHD and diminished graft rejection, but may delay
immune recovery. Nonmyeloablative (NMA) prepara-
tive regimens that use cytotoxic drugs or low-dose
total body irradiation (TBI) in conditioning regimens
have been associated with reduced nonrelapse mortal-
ity (NRM), and have provided new options for HCT
among the elderly and in patients with substantial co-
morbidities. The choice of preparative regimen and
the decision regarding the relative merit of an MA ver-
sus an NMA regimen is complex and should involve
a risk-adapted strategy that takes into account the
underlying disease, patient age, comorbidities, stem
cell source, histoincompatibility, and other relevant
factors.
In summary, HCT plays a central role in the
treatment of a variety of benign and malignant dis-
eases and the field continues to evolve rapidly, with
new options for donor sources and preparative regi-
mens. At the same time, standard treatments for
many of the diseases wherein HCT historically pro-
vided the mainstay of therapy have also evolved, ren-
dering the decision of whether, when, and how to
proceed to HCT highly complex and requiring care-
ful consideration of the individual case in light of ev-
idence-based data. For patients who undergo HCT,
the major causes of early morbidity and mortality
are disease relapse, acute GVHD (aGVHD), infec-
tion, RRT, and graft failure. Long-term survivors of
HCT are at risk for a variety of long-term adverse ef-
fects, including cGVHD, infections, hypothyroidism,
sterility, growth failure and other endocrine distur-bances, cataracts, avascular necrosis, disease relapse,
and second malignancy. The incidence of each of
those adverse effects varies greatly with differing pre-
parative regimens, comorbidities, age at transplanta-
tion, and whether the individual experiences
cGVHD [49].Immune System Recovery following HCT
Following MA conditioning, HCT recipients typ-
ically experience a period of profound pancytopenia
spanning days to weeks depending upon the donor
source. The rapidity of neutrophil recovery varies
with the type of graft: approximate recovery time is 2
weeks with G-CSF-mobilized PBSC grafts, 3 weeks
with marrow grafts, and 4 weeks with UCB grafts.
Neutrophil, monocyte, and NK-cell recovery is fol-
lowed by platelet and red cell recovery, which is fol-
lowed by B and T cell recovery (Figure 1).
Simultaneously, MA regimens damage mucosal sur-
faces and thereby provide a source for bloodstream
seeding of commensal pathogens that inhabit the gas-
trointestinal tract. As a result, infectious complications
in the immediate posttransplant period usually present
as febrile neutropenia, with the severity of risk related
to the depth and duration of neutropenia and the de-
gree of mucosal damage induced.
Recipients of NMA allogeneic transplants exhibit
substantial heterogeneity in the depth and duration
of pancytopenia, with some regimens accomplishing
reliable engraftment without clinically significant
myelosuppression. In regimens with minimal myelo-
suppression and minimal mucosal toxicity, the risk
for infection in the immediate posttransplant period
is reduced. In fact, regimens based on low-dose TBI
and fludarabine (Flu) can sometimes be performed in
the outpatient setting, with a virtual elimination of
neutropenic complications.
Although the degree of myelosuppression is milder
following NMA regimens, the depth and extent of lym-
phodepletion tends to be similar, with prolonged pe-
riods of immune incompetence observed in recipients
of both MA and NMA regimens. This is because en-
graftment of allogeneic hematopoietic progenitor cells
requires significant recipient immunosuppression to
prevent graft rejection, even in the context of full
HLA matching. With some regimens, essentially com-
plete eradication of recipient lymphocytes is accom-
plished by the preparative regimen itself. However,
with other regimens, depletion of recipient lympho-
cytes occurs more gradually via the use of donor leuko-
cyte infusions following transplant. In both cases, the
vast majority of HCT recipients experience near-total
lymphocyte depletion, and thus must undergo lym-
phoid reconstitution via mature lymphocytes and lym-
phoid progenitors contained in the graft. Furthermore,
except when T cell-depleted HCT grafts are
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Figure 1. Approximate immune cell counts (expressed as percentage of normal counts) peri- and post-MAHCT.Nadirs are higher and occur later after
NMA than MA transplantation, as recipient cells persist after NMA transplant for several weeks to months (in the presence of GVHD) or longer (in the
absence of GVHD). The orange line represents the innate immune cells (eg, neutrophils, monocytes, and natural killer [NK] cells), the recovery of which
is influenced by the graft type (fastest with filgrastim-mobilized blood stem cells, intermediate with marrow, and slowest with UCB). The green line
represents the recovery of CD81 T cells and B cells, the counts of which may transiently become supranormal. B cell recovery is influenced by graft
type (fastest after CB transplant), and is delayed by GVHD and/or its treatment. The blue line represents the recovery of relatively radiotherapy/che-
motherapy-resistant cells such as plasma cells, tissue dendritic cells (eg, Langerhans cells) and, perhaps, tissue macrophages/microglia. The nadir of these
cells may be lower in patients with aGVHD because of graft-versus-host plasma cell/Langerhans cell effect. The red line represents CD41 T cells, the
recovery of which is influenced primarily by T cell content of the graft and patient age (faster in children than adults). From Storek J. Immunological
reconstitution after hematopoietic cell transplantation—its relation to the contents of the graft. Expert Opin Biol Ther (Informa). 2008;8:583-597.
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receive some form of immunosuppression to prevent
GVHD, further limiting immune competence.
Unlike recovery of other hematopoietic lineages,
which typically occurs over the course of weeks follow-
ing HCT, lymphocyte recovery is a prolonged process.
Reestablishment of immunocompetence requires at
least several months, and some patients continue to
demonstrate immune deficits for several years after
HCT. In general, NK cells are the first lymphocyte sub-
set to recover, followed by CD81 T cells, which often
reach supranormal levels within 2 to 8 months after
HCT. Subsequently, B cells and ultimately CD41 T
cells recover. The pace and extent of recovery of each
lymphocyte subset is highly dependent upon several fac-
tors, which ultimately determine the degree, extent, and
duration of immune incompetence experienced by the
individual HCT recipient (Figure 1).
Regeneration of lymphocytes in humans is an inef-
ficient process, which primarily involves 2 distinct
pathways. In the first pathway, lymphocytes regenerate
from bone marrow (BM) lymphoid progenitors, thus
recapitulating ontogeny and regenerating a naı¨ve im-
mune system, similar to that found in a newborn child
[50]. NK cell recovery uses this pathway exclusively.
Full recovery of NK cell counts is typically achieved
within 1 to 2 months following HCT. B cells are also
primarily regenerated from lymphoid progenitor cells,
as evidenced by the appearance of primitive B cell sub-
sets as the harbinger of B cell immune reconstitution
[51]. Unlike NK cell recovery, however, B cell lympho-
poiesis is highly dependent upon a specialized marrow
microenvironment termed the ‘‘bursal equivalent,’’
which is susceptible to damage by the preparativeregimen and is exquisitely sensitive to the toxic effects
of GVHD and/or its treatment. Indeed, patients who
experience even a limited episode of steroid-responsive
GVHD show significantly diminished B cell reconsti-
tution in the long term, compared with patients who
do not experience GVHD [52]. Although recent data
have demonstrated that mature B cells can also contrib-
ute to B cell reconstitution via homeostatic expansion,
this pathway appears to be minor compared with the
marrow-derived pathway for B cell regeneration.
Restoration of full humoral immune competence
following HCT requires reconstitution not only of
naı¨ve B cells, but of a memory B cell pool as well.
The latter occurs as a result of environmental or vac-
cine-based exposure to common pathogens and also
requires help from CD41 T cells. Therefore, even
HCT recipients who do not experience GVHD and
who demonstrate recovery of total B cell numbers
within 6 months posttransplant should not be consid-
ered to have regained full humoral immunocompe-
tence by this time. For at least 1 year following
transplantation, essentially all HCT recipients remain
predisposed to infections from encapsulated bacteria
and viruses, against which neutralizing antibodies
provide a first line of defense. Serum IgG levels pro-
vide little insight into B cell reconstitution, because
long-lived, radioresistant plasma cells survive many
preparative regimens [53] and can produce substantial
circulating IgG without providing humoral responses
to specific pathogens. The only reliable means by
which one can assess humoral immune competence
following transplantation is by documenting clinically
significant rises in antigen-specific antibodies follow-
ing vaccination or infection. Indeed, some medical
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administration of a killed vaccine as a prerequisite for
use of live-attenuated vaccines.
T cell regeneration ispredominantly drivenby a thy-
mic-independent pathway, termed homeostatic periph-
eral expansion. Here, mature T cells contained within
the graft dramatically expand in vivo in response to T
cell lymphopenia. This process is driven by a combina-
tion of factors, among which are increased availability
of homeostatic cytokines, including interleukin (IL)-7
and IL-15, which accumulate during lymphopenia; in-
flammatory cytokines associated with tissue damage in-
duced by the preparative regimen; and exposure to viral
antigens (either environmentally or via reactivation)
during the period of profound lymphopenia. Peripheral
homoeostatic expansion is much more efficient for
CD81 T cells than for CD41 T cells [54], resulting in
chronically reduced CD4/CD8 ratios in HCT recipi-
ents for several months following HCT. Memory T cells
are the first to expand after HCT, and may be either of
donor origin, in the case of non-T cell-depleted HCT,
or originate from host T cells that have survived the con-
ditioning regimen, in the case of T cell-depleted HCT
[55]. Memory T cells respond quickly to previously
encountered pathogens such as herpesviruses.
Of all factors analyzed thus far, CD41 counts may
provide the most readily available and predictive
marker of the restoration of immune competence
following HCT. Although the predictive value of low
CD41 counts has not been as extensively studied in re-
cipients of HCT as they have in HIV infection, several
studies have demonstrated that CD41 recovery is asso-
ciated with diminished infectious risk and improved
transplant outcomes [56-59]. When T cell regenera-
tion occurs via the ontogenic or thymic-dependent
pathway, there is a substantial rise in CD41 T cell
numbers, with recovery of naı¨ve CD41 and CD81 T
cells and diversification of the T cell repertoire [60].
However, because the microenvironment of the thy-
mus is highly susceptible to damage from age, therapy,
and GVHD, many adult HCT recipients show little or
no thymic-dependent T cell regeneration for months
to years following HCT [61-63]. A study of adult
recipients of autologous HCT for breast cancer
revealed that with each advancing decade of patient
age between 30 and 60 years, a decreasing percentage
of patients achieved effective CD41 immune reconsti-
tution after 2 years of follow-up [64].
Beyond the general rule that all HCT recipients
experience profound immunosuppression at some
point, the degree of immunosuppression experienced
by individual patients varies greatly and is influenced
by several factors. First and foremost is the profound
adverse effect of GVHD on the overall process. In
essentially every series, GVHD severity correlates
with the degree of immunosuppression and infectious
complications. This correlation is because of a varietyof factors that compound one another, including dam-
age to lymphoid microenvironments, adverse effects of
GVHD on homeostatic peripheral expansion, as well
as the obvious impact that chronic immunosuppres-
sion has on a reconstituting immune system. Second,
recipient factors such as age, comorbidities, and infec-
tious exposure prior to transplant contribute substan-
tially to the risk for posttransplant infectious
complications. This is illustrated in studies of severe
combined immunodeficiency (SCID) patients,
wherein outcomes are most successful in children
who undergo transplantation before experiencing se-
vere, life-threatening infection [65]. Third, graft-asso-
ciated factors also play an important role. Recent
studies have suggested that PBSC graft recipients
show more rapid immune reconstitution, as measured
by lymphocyte subsets [42], whereas UCB transplanta-
tion in adults [66,67] and transplantation of pro-
foundly T cell-depleted haploidentical grafts result in
poor immune reconstitution and high rates of infec-
tious complications. CD34 dose is crucial and levels
of 3 106 CD341 cells/kg or more are associated
with an improved hematopoietic recovery, a decreased
incidence of fungal infections, and improved overall
survival (OS) in recipients of unmanipulated BM trans-
plants from HLA-identical sibling donors [68].
Models that distinguish between infectious com-
plications occurring during different posttransplanta-
tion phases have been put forth, based largely upon
an MA paradigm. Such a model is shown in Figure 2,
in which phase I is the preengraftment phase (\15-
45 days after HCT); phase II, the postengraftment
phase (30-100 days after HCT); and phase III, the
late phase (.100 days after HCT). During phase I,
prolonged neutropenia and breaks in the mucocutane-
ous barrier result in substantial risk for bacteremia and
fungal infections involving Candida species and, as
neutropenia continues, Aspergillus species. Addition-
ally, herpes simplex virus (HSV) reactivation occurs
during this phase. During phase II, infections relate
primarily to impaired cell-mediated immunity. The
scope and impact of this defect is determined by the ex-
tent of GVHD and immunosuppressive therapy for it.
Herpesviruses, particularly cytomegalovirus (CMV),
are common infectious agents during this period.
Other dominant pathogens during this phase include
Pneumocystis jiroveci and Aspergillus species. During
phase III, persons with cGVHD and recipients of al-
ternate-donor allogeneic transplants remain most at
risk for infection. Common pathogens include CMV,
varicella-zoster virus (VZV), and infections with en-
capsulated bacteria (eg, Streptococcus pneumoniae). The
relative risk for these infections is approximately pro-
portional to the severity of the patient’s GVHD during
phases II and III. For recipients of NMA grafts, sub-
stantial differences may be observed during phase I,
but the susceptibility to infections during phases II
Figure 2. Phases of opportunistic infections among allogeneic HCT recipients Abbreviations: EBV, Epstein-Barr virus; HHV6, human herpesvirus 6;
PTLD, posttransplant lymphoproliferative disease.
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status of the underlying disease, a history of GVHD,
and/or the need for ongoing immunosuppression.
The risk of disease from community-acquired respira-
tory viruses (CRV) is elevated during all 3 phases; in
phase III, however, the outpatient status of HCT re-
cipients can complicate efforts to reduce exposure
and provide timely intervention.
Thus, the risk of infection is primarily determined
by the time from transplant and the presence or
absence of GVHD. Other factors include donor/host
histocompatibility, disease status, graft type, graft con-Table 3. Factors Affecting the Risk of Infection
Factor
Type of transplant Higher risk with allogeneic, lower risk
setting, including previous therapie
Time from transplant Lower risk with more time elapsed fr
Pretransplant factors Higher risk with extensive pretranspl
pretransplant neutropenia, or pretr
GVHD Higher risk with grade III-IV acute GV
HLA match Higher risk with HLA-mismatched do
Disease (eg, leukemia) status Higher risk with more advanced disea
Donor type Higher risk with marrow unrelated do
Graft type Highest risk with cord blood, interme
factor-mobilized blood stem cells. H
Immunosuppression after transplant Higher with immunosuppressive drug
Conditioning intensity Lower risk in the first 1-3 months po
Neutrophil engraftment Higher risk with delayed engraftment
GVHD indicates graft-versus-host disease.tents, conditioning intensity, and neutrophil engraft-
ment (Table 3) [6,7,52,69-74]. Unfortunately, there
is currently no definitive laboratory marker of immune
reconstitution that would predict infectious risk that
could be used to tailor infection prophylaxis. It is likely
that the degree of immune recovery measured by
various assays is associated with clinical outcomes
including infection rates, based on retrospective stud-
ies that included relatively small numbers of patients
(Table 4). However, a rigorous proof of the association
is lacking. Moreover, most of the published studies
have focused on the association of immune assayRisk of Infection
with autologous or syngeneic, depending on graft manipulation and clinical
s
om transplant
ant immunosuppressive therapy (eg, fludarabine, clofaribine), prolonged
ansplant infection
HD or extensive chronic GVHD
nors, particularly with haploidentical donors
se at the time of transplant
nor than with a fully matching sibling donor
diate risk with bone marrow and lowest risk with colony stimulating
igher risk with T cell-depleted grafts (depending upon method used)
s, in particular with corticosteroids, antithymocyte globulin, alemtuzumab
sttransplant with low-dose chemo/radiotherapy
/nonengraftment
Table 4. Parameters Reported to Correlate with Clinical Outcomes after HCT
Parameter (Ref.) Timing Result Outcome Multivariate Analysis
Lymphocyte count
[814,815]
Day 15 <500/mL Decreased OS and
PFS (autologous HCT)
Yes
Lymphocyte count
[816,817]
Day 30 <300/mL Decreased OS and LFS, Increased
NRM (allogeneic HCT)
Yes
B cells and
monocyte counts [818]
Day 80 Low (cutoff value not given) Increased infections Yes
CD4 T cell count [59] 3 months <200/mL Decreased OS, Increased
NRM and infections
Yes (OS and NRM),
No (infections)
CD8 T cell and B
cell counts [819]
6 months Low (cutoff value not given) Increased treatment failure
(death, relapse or graft failure)
No
CMV peptide–specific
CD8 T cell counts*
[820]
Every 2 weeks
during days 0 to 65
<7 cells/mL in all samples Increased risk of recurrent
or persistent CMV reactivation
Not specified
CMV-specific
lymphoproliferation [248]
4 months Undetectable proliferation Increased late CMV disease No
NK-cell chimerism [817] First 100 days Incomplete chimerism Decreased RFS Yes
NK-cell count [821] Day 15 <80/mL Decreased OS and PFS (autologous HCT) Yes
CD56high
NK-cell count [822]
Day 14 <7/mL† Decreased OS, increased NRM Yes (OS),
No (NRM)
Non-HLA
genetics [823-826]
Pretransplant At risk allele in
donor or recipient
Increased infections, survival No
OS indicates overall survival; PFS, progression-free survival; LFS, leukemia-free survival; NRM, nonrelapse mortality; CMV, cytomegalovirus; HCT, he-
matopoietic cell transplant.
Adapted from Geddes et al. [811] with publisher’s permission. Additional studies are needed before any one of the immune tests presented here can be
recommended for use in decision making on infection prophylaxis (see text).
*Assay measuring the quantity but not quality of CMV-specific T cells.
†Patients were split into low, intermediate, and high groups with cutoffs of 4/mL and 9/mL.
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captured (eg, survival or NRM) rather than with infec-
tions. Additionally, information from the published
studies is limited because of publication bias (ie, there
is a tendency to publish studies that find an association
rather than negative studies). Tools are now available
to precisely monitor viral-specific (Epstein-Barr virus
[EBV], CMV) immune responses (HLA tetramers, in-
terferon-g production assays), and may help in under-
standing this issue [75]. Large (ideally, prospective)
studies are needed, first to conclusively determine
what immune monitoring test has prognostic value
and ultimately to determine whether outcomes would
improve if such a test were used to tailor infection pro-
phylaxis.
In summary, HCT is characterized by a variable
period of early infectious complications caused largely
by neutropenia and mucosal damage because of the
preparative regimen, and such complications are read-
ily predictable based upon clinical findings of mucosi-
tis and absolute neutrophil count (ANC). In addition,
essentially all HCT recipients experience a prolonged
period of immunosuppression characterized by pro-
found defects in cell-mediated and humoral immunity.
Unfortunately, there are no readily available surrogate
markers to accurately measure the relative risk for
individual patients. Consequently, these patients
must be monitored carefully and receive early inter-
vention for signs or symptoms of an infectious disease.
In most patients, immunocompetence improves pro-
gressively with increasing time after transplant, anobservation that has led to the current recommenda-
tions for revaccination at 6 to 24 months, including
with some live vaccines at 24 months for patients
who are no longer receiving immunosuppression and
show no signs of GVHD. However, it is important
to realize that many HCT recipients remain immuno-
compromised far beyond 2 years after transplant—es-
pecially individuals with cGVHD, for whom infection
remains the most important cause of morbidity and
mortality. Future work is needed to augment the de-
gree of immune reconstitution toward pathogens and
malignancy and to identify accurate surrogate markers
of immunocompetence to guide the long-term
management of this high-risk population.HEMATOPOIETIC CELL GRAFT SAFETY
D. Confer, R. Gress, M. Tomblyn, G. Ehninger
With allogeneic HCT, the life of the recipient
may depend on the timely selection of an acceptable
HLA-matched donor. Only a limited number of HLA-
matched donors might be identified. Hence, the trans-
plant physician may have to accept a higher risk for
transmission of an infectious agent through HCT
than would be permitted for routine blood transfusion.
This section provides strategies for the HCT physician
to minimize transmission of infectious diseases, when-
ever possible, from donors to recipients. In general,
these strategies are dictated by national regulations,
and, therefore, ratings are not included.
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recognize the donor role and the potential impact
upon the donor of the product safety determination
[76-79]. Assessment of the donor should include
elements related to safety for the donor (eg, uncon-
trolled hypertension, diabetes mellitus, and coronary
artery disease) in addition to determination of
product safety. A donor may be cleared to donate
from a product safety perspective, but be unsuitable
because of medical conditions that render the dona-
tion unsafe [76-78]. Because of these potential risks,
individuals who donate must provide informed
consent.
Assessment of product safety is complicated by the
high frequency of international exchange. A survey by
the World Marrow Donor Association found that, in
2006, 3269 (39%) adult products and 829 (40%)
UCB units were shipped from 1 country to transplant
centers in another country. This robust international
activity creates further challenges for ensuring product
safety related to regional differences in disease risks,
regulatory structures, and medical practices.
The desire for HLA tissue matching (which pre-
sumably underlies much of the international exchange),
results in the potential need to recruit in poorly repre-
sented populations. For any given individual, outside
of the immediate family, the highest likelihood of an
HLA match occurs among persons of the same or sim-
ilar ethnicity. There is a strong ethical impetus for par-
ity in the likelihood of HLA matching, regardless of the
patient’s ethnic origins. This may necessitate recruit-
ment of HCT donors from geographic regions where
endemic conditions would make the residents unsuit-
able as routine blood or tissue donors.Regulations
In the United States, the FDA issues regulations
covering product safety and donor eligibility, includ-
ing screening for the relevant communicable disease
agents and disease, as well as laboratory and test kit
requirements [80]. FDA Guidance documents on
these topics can be found at http://www.fda.gov/
cber/index.html. In the European Union, general re-
quirements are defined in the European Commission
Directive 2004/23/EC [81], and donor eligibility
defined in Commission Directive 2006/17/EC [82].
Requirements similar to those of the FDA and
European Union have been or are being developed
in Canada (http://www.hc-sc.gc.ca/dhp-mps/brgtherap/
reg-init/cell/cto_draft_gd-cto_ebauche_ld-eng.php),
Australia, Japan, and elsewhere.Donor Conditions Affecting Product Safety
Disorders pertinent to HCT can be categorized
according to prevalence and severity. Prevalenceconcerns the likelihood of the disorder within the po-
tential donor population and may be highly dependent
upon the donor’s geographic location. Severity refers
to both the usual consequences of the disorder and
the ease of managing those consequences. Highly
pertinent disorders [76-78,80,82,83] include infections
caused by HIV, hepatitis B virus (HBV), hepatitis
C virus (HCV), human T cell leukemia viruses type I
and II (HTLV-I and HTLV-II), and West Nile virus
[84-90]. Other pertinent disorders [76-78,82,83,91]
include transmissible spongiform encephalopathy
(TSE) [92-95], CMV infection [96,97], EBV infection,
syphilis, toxoplasmosis [98,99], and vaccinia [80], as
well as viruses used in other live-attenuated vaccines.
Persons acutely infected with CMV or EBV should
not donate. Similarly, those with acute toxoplasmosis
should not donate until the acute illness has resolved.
However, physicians should be aware that in rare cases,
persons who are asymptomatically seropositive for
Toxoplasma gondii might transmit this infection
through HCT [100].
Uncommon disorders include malaria [101-108]
and tick-borne diseases such as Rocky Mountain spot-
ted fever, babesiosis, Q fever (infection caused by Cox-
iella species), and Colorado tick fever [99,109-114].
Prospective HCT donors who reside in or have trav-
eled to areas endemic for rickettsia or other tick-borne
pathogens and who are suspected of having an acute
tick-borne infection should be temporarily deferred
as donors until infection with these pathogens is
excluded. Blood banking standards strongly recom-
mend deferral for a past history of Q fever or babesiosis
because these infections can be chronic and Babesia
parasites might persist despite appropriate therapy
[115]. Additionally, researchers have recommended
deferring persons with acute human ehrlichiosis (eg,
active human granulocytic anaplasmosis [116], human
monocytic ehrlichiosis, as well as any infections from
species within the genus Ehrlichia) from HCT
donation.
Chagas disease is transmissible by transfusion
[99,117-119]. Potential donors who reside in or have
emigrated from endemic areas should be screened
serologically for Trypanosoma cruzi infection.
Researchers also recommend deferral of HCT dona-
tion if a past history exists because the parasite can per-
sist despite therapy [115,120-122].
Prospective donors with symptoms of active tuber-
culosis (TB) should be evaluated for that disease
[123,124], and those with active TB should not donate
until the TB is well controlled (eg, no longer conta-
gious as determined by the donor’s primary physician)
after appropriate medical therapy. However, trans-
planting marrow from an untreated, tuberculin skin
test-positive donor who has no evidence of active dis-
ease poses no known risk. Screening potential donors
for TB with tuberculin skin tests is not necessary.
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Donors to Recipients
All prospective HCT donors should be evaluated
to determine their general state of health and whether
they pose a risk for transmitting infectious diseases to
the recipient. Evaluation of donors is achieved through
screening and laboratory testing [76-78,80]. Screening
and testing of autologous donors is recommended to
ensure the safety of laboratory personnel and to pre-
vent cross contamination. If autologous donors are
not screened and tested, their autologous units should
be specially labeled and handled as if potentially
infected [76-78,80]. To detect transmissible infections,
all HCT donor collection site personnel should follow
up-to-date published guidelines and standards for
donor screening and testing.
Complete donor screening, which includes his-
tory, physical examination, and review of medical
records, must be performed within 6 months preced-
ing donation. Prior to each donation procedure,
screening must be repeated or updated. Abbreviated
screening may be used if complete screening has
been performed within the previous 6 months
[80,83]. Abbreviated screening is an inquiry about
any changes in history, risk factors, or physical find-
ings. This practice is critical because if new risk find-
ings have developed, the potential donor might
require further evaluation or deferral. When the donor
is 1 month of age or younger, including all UCB dona-
tions, the infant’s mother should be screened [80,83].
The donor history includes direct questioning of
the donor (which can be done over the telephone),
with documentation of all donor responses, review of
available medical records, and completion of a risk fac-
tor questionnaire (eg, the NMDP questionnaire)
[125]. The physical examination of the donor is tar-
geted to detect stigmata associated with transfusion-
transmissible disease or high-risk activities.
In addition to donor screening, laboratory testing
must be performed to assess for relevant infectious dis-
eases. In the United States, for lymphocyte and UCB
donations, a specimen for testing must be obtained
within 7 days before or after the donation. For PBSC
and BM donations, the specimen may be obtained up
to 30 days before donation. In the European Union,
the testing specimen must be obtained at the time of do-
nation or within 7 days after donation unless the product
can be stored. If storage is possible, the sample may be
obtained up to 30 days prior to donation; however,
this invokes a further requirement for retesting of the
donor 180 days or more after donation. Retesting is
not required, however, if nucleic acid testing for HIV,
HCV, and HBV is included on the initial specimen. As
in the United States, for PBSC or BM that will not be
stored, the specimen may be obtained up to 30 days be-
fore donation, and there is no requirement for retesting.In the United States, positive results on screening
tests are used for the determination of disease risk regard-
less of the results obtained with confirmatory tests. The
sole exception is testing for syphilis, where a syphilis-
specific test is used for determination of eligibility [80].
Use of Potentially Unsafe Products
Oversight by governments and unrelated donor
registries generally precludes the use of a volunteer un-
related donor at risk for infectious diseases transmissi-
ble by HCT [78-80,82,83]. Whether to select a related
donor who is at risk for or who has an infectious disease
transmissible by HCT should be determined on a case-
by-case basis, and is the final responsibility of the HCT
physician. If the only possible donor is at risk for, or
known to have, infection with a blood-borne pathogen,
but the patient is likely to succumb rapidly from his or
her disease if an HCT is not received, the physician
must carefully weigh the risks and benefits of using po-
tentially infected donor cells. No person should be de-
nied a potentially life-saving HCT procedure solely on
the basis of the risk for an infectious disease. However,
HCT physicians should avoid transplanting any hema-
topoietic cell product from an infected or infectious do-
nor unless no other stem cell product can be obtained
and the risk for death if transplantation is not per-
formed is deemed to be greater than the risk for mor-
bidity or death from the infection that may be
transmitted. If the HCT physician judges that the cir-
cumstances of the case justify the use of such a product,
the following should be noted in the recipient’s chart:
 Knowledge and authorization of the recipient’s
HCT physician regarding the potential for trans-
mission of an infectious agent during HCT; and
 Informed consent from the recipient or recipient’s
legal guardian acknowledging the possible transmis-
sion of an infectious agent during the transplantation.
Subsequently, the HCT physician should include
the infectious agent in the differential diagnosis of
any illness that the HCT recipient experiences so
that the infection, if transmitted, can be diagnosed
early and treated preemptively, if possible.
Infectious products (except those in which CMV
seropositivity as the only evidence of infectiousness)
should be labeled as being a biohazard or as untested
for biohazards, as applicable. A warning label should
list all disease agents or diseases for which the donor
has shown reactive test results. Tissue intended for
autologous use should be labeled ‘‘For Autologous
Use Only—Use Only for (Patient’s Name).’’
Safe Handling, Processing, and Storage of
Donated Units
Personnel of donation, collection, or transplanta-
tion centers, cell-processing laboratories, and courier
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and preventing extrinsic bacterial and fungal contami-
nation of collected stem cell units at the collection site,
during processing and transportation, and at the trans-
plant center [126-141]. Current, comprehensive dis-
cussions of these issues are detailed in the Food and
Drug Administration (FDA) ‘‘Good Tissue Practice’’
regulations [142], in the European Commission regu-
lations [81], and in international standards established
by the professional organizations [76,77,143].BACTERIAL INFECTION PREVENTION
AFTER HCT
D. Engelhard, M. Akova, M.A. Boeckh, A. Freifeld, K.
Sepkowitz, C. Viscoli, J. Wade, I. Raad
In addition to general recommendations regarding
bacterial infections, this section provides specific rec-
ommendations regarding S. pneumoniae, viridans
streptococci (mainly the S. mitis and S. anginosus
groups), H. influenzae type b, and central line-associ-
ated blood stream infections (CLABSI). Recommen-
dations regarding specific nosocomial infections,
including those from Legionella species, methicillin-re-
sistant Staphylococcus aureus (MRSA), Staphylococcus spe-
cies with reduced susceptibility to vancomycin,
vancomycin-resistant Enterococcus (VRE), and Clostrid-
ium difficile are found in the Infection Prevention and
Control in Health care Facilities section.General Recommendations
Preventing exposure
Health care workers (HCWs) and others in contact
with hematopoietic cell transplantation (HCT) recipi-
ents should routinely follow appropriate hand hygiene
practices to avoid exposing recipients to bacterial path-
ogens (AIII) (see Infection Prevention and Control in
Health care Facilities). Additional precautions for pa-
tients colonized with certain contagious pathogens
(eg, MRSA, VRE) and for special situations (eg, diar-
rhea or respiratory diseases) and instructions with re-
gard to visitors, pets, and plants are described in the
Infection Prevention and Control in Health care Facil-
ities section and in the 2007 CDC guidelines [144].
Guidelines for the management of neutropenic fever
are published elsewhere [145].
Preventing early disease (0-100 days after HCT)
Antibacterial prophylaxis with a fluoroquinolone
(ie, levofloxacin) to prevent bacterial infections should
be strongly considered for adult HCT patients with an-
ticipated neutropenic periods of 7 days or more (BI)
[146-150] (Appendix 1). Because of lack of data, there
are currently no antimicrobial prophylactic regimens
that can be recommended for children. Some expertsuse levofloxacin for pediatric antibacterial prophylaxis
(CIII). Antibacterial prophylaxis is generally started at
the time of stem cell infusion and continued until re-
covery from neutropenia or initiation of empirical
antibacterial therapy for fever during neutropenia
[148-152]. The prophylaxis should not be continued
after recovery from neutropenia. Local epidemiologi-
cal data should be carefully considered before applying
fluoroquinolone prophylaxis, and once it is applied, the
emergence of resistance in bacterial pathogens should
be monitored closely because of increasing quinolone
resistance worldwide among Gram-negative bacteria
(eg,Escherichia coli,Klebsiella pneumoniae, and Pseudomo-
nas aeruginosa) [153] and staphylococci [154-157]; plas-
mid-mediated quinolone resistance in Enterobacteriaceae
that is closely related to the beta lactamases that inacti-
vate third-generation cephalosporins [158-160]; and
quinolone-related development of a hypervirulent
strain of C. difficile (AIII) [161].
The addition of an anti-Gram-positive agent to the
prophylaxis regimen is not indicated (DIII) [151]. Spe-
cifically, glycopeptides (eg, vancomycin, teicoplanin)
should not be used for routine bacterial prophylaxis,
either systemically or for prevention of catheter-
related infections (DIII). These agents lack benefit
for prophylaxis and their use may promote the
emergence of resistant microorganisms [151].
Growth factors (eg, granulocyte-macrophage-
colony-stimulating factor [GM-CSF] and G-CSF)
shorten the duration of neutropenia after HCT
[162,163] and may slightly reduce the risk of infection
[164,165], but have not been shown to reduce mortal-
ity [164,165]. Therefore, the routine use of growth
factors after HCT is controversial and no recommen-
dation for their use can be made (CI).
Prophylaxis with metronidazole has been shown to
reduce anaerobic bacterial growth in the gut, and was
associated with a reduction in acute graft-versus-host
disease (aGVHD) in recipients of transplants from
HLA-identical sibling donors (but not from other do-
nors) in 1 open-labeled randomized trial [166]. How-
ever, the evidence is insufficient to recommend
routine gut decontamination for HCT candidates, ei-
ther with metronidazole or with nonabsorbable antibi-
otics (DIII).
Although intravenous immunoglobulin (IVIG) has
been recommended for use in producing immune sys-
tem modulation for GVHD Prevention, IVIG should
not be routinely administered to HCT recipients for
prophylaxis of bacterial infection within the first 100
days after transplantation (DI). Some centers check to-
tal IgG levels in high-risk HCT recipients (eg, those
with unrelated marrow grafts). For patients with severe
hypogammaglobulinemia (ie, IgG \400 mg/dL),
IVIG prophylaxis may be considered (Appendix 1)
(CIII). The IVIG dose and frequency for a hypo-
gammaglobulinemic HCT recipient should be
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trations .400 mg/dL, as the half-life of IVIG among
HCT recipients (generally, 1-10 days) is much shorter
than the half-life among healthy adults (generally, 18-
23 days) (BII) [167-169].
Preventing late disease (.100 days after HCT)
Prolonged antibiotic prophylaxis is recommended
only for preventing infection with S. pneumoniae
among allogeneic recipients with chronic (cGVHD)
for as long as active cGVHD treatment is administered
(AIII) [170]. Antibiotic selection should be guided by
local antibiotic resistance patterns.
In the absence of severe hypogammaglobulinemia
(ie, IgG levels\400 mg/dL, which might be associ-
ated with bacteremia or recurrent sinopulmonary
infections), routine monthly IVIG administration to
HCT recipients .100 days after allogeneic or autolo-
gous HCT is not recommended (DI) [171,172] as
a means of preventing bacterial infections.
Recommendations for preventing late bacterial
infections are the same among pediatric or adult
HCT recipients.Recommendations Regarding CLABSI
Catheter-associated infections are a leading cause
of bloodstream infections in HCT recipients, particu-
larly during the preengraftment phase and in patients
with GVHD [173,174]. These infections often result
in catheter removal and, much less commonly, in death
[175,176].
In HCT recipients, all central venous catheters
(CVCs), whether tunneled or nontunneled, should be
inserted using maximal sterile barrier precautions (AI)
[177]. The preferred approach is the CLABSI preven-
tion bundle, which consists of hand hygiene, full barrier
precautions, cleaning the insertion site with chlorhexi-
dine, avoiding femoral sites for insertion, and removing
unnecessary catheters [178]. Although the efficacy of
the CLABSI prevention bundle has not been studied
in HCT recipients, all 5 elements of the bundle are rec-
ommended for this patient population (AII).
Other measures to decrease the risk of CLABSI
have been studied. Catheters impregnated with mino-
cycline/rifampin [179-181] have been shown to
decrease CLABSI in patients requiring nontunneled
subclavian central venous access, including HCT
patients. In 1 retrospective study, the minocycline/
rifampin impregnated catheters did not affect the sus-
ceptibility of staphylococci to tetracyclines or
rifampin [181]. For HCT centers with high CLABSI
rates (more than 1 per 1000 catheter days) despite
effective implementation of the CLABSI bundle
elements, use of additional interventions, such as mino-
cycline/rifampin antimicrobial-impregnated catheters,
to prevent CLABSIs should be considered (BIII) [182].Additional prevention strategies (eg, catheter-site
dressing regimens, antimicrobial/antiseptic ointments,
and antimicrobial lock prophylaxis) have been evaluated
but not extensively assessed among the HCT patient
population. A review found a similar risk of infection re-
gardless of whether catheter dressings consisted of
a transparent, semipermeable polyurethane dressing,
or of sterile gauze and tape [183]. Povidone-iodine oint-
ment, mupirocin ointment, and other antimicrobial
ointments applied at the catheter insertion site have
failed to show a consistent advantage when compared
with no antimicrobial ointment. Recently, data have
shown in non-HCT patients that chlorhexadine-im-
pregnated sponges have decreased the rates of catheter
related infections [184,185]. Topical antimicrobials
should be avoided because of the risk of antimicrobial
resistance or increased fungal colonization in immuno-
suppressed HCT patients (DIII).
Antimicrobial lock prophylaxis using antimicrobial
solutions, including those that contain vancomycin,
have been studied in patients with long-term venous ac-
cess devices and who develop neutropenia. A meta-
analysis of the prospective, randomized trials testing
the vancomycin-lock solution reported a decreased
rate of bloodstream infections with vancomycin-sus-
ceptible organisms and a delay in the onset of the first
bloodstream infection. However, the use of vancomy-
cin-containing locks is not recommended, because of
the increased risk of selecting for staphylococci with re-
duced vancomycin susceptibility [186] (DIII). Other al-
ternatives, including lock solutions containing
minocycline/EDTA, taurolidine citrate, or ethanol,
have shown success in preventing CLABSI and salvag-
ing vascular access [187-190]. These approaches,
though promising, cannot be recommended in routine
catheter care until further investigation is completed
(DIII)
When adopting prevention practices such as these,
HCT programs should institute prospective data
collection and reporting that allows for analysis of
the success of the practices. HCT teams can also
make use of a systemic review that defines benchmark
rates of CLABSI for a wide range of catheter types
[191]. Although not all of the studies included in the
meta-analysis were conducted exclusively among
HCT patients, HCT teams can use the results to assess
their own center’s relative performance, as an aspect of
quality improvement efforts.
Recommendations Regarding
Streptococcus pneumoniae
Preventing exposure
Standard precautions should be taken with hospi-
talized patients infected with S. pneumoniae (AIII),
including patients with infection caused by drug-
resistant strains [192].
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Invasive pneumococcal infection (IPI) is a life-
threatening complication that may occur months to
years after HCT. The annual incidence of IPI
is 8.23/1000 transplants among allogeneic HCT recip-
ients, and higher still among those with cGVHD
(20.8/1000 transplants) [193]. Although IPI occurs
less frequently in autologous HCT recipients (annual
incidence, 3.8/1000 transplants), the risk remains
much higher than in an immunocompetent population
[193]. Efforts to prevent IPI should include active im-
munization and prophylactic antibiotics (Table 6 and
Appendix 1). Vaccination against S. pneumoniae is rec-
ommended for all HCT recipients, preferably with
pneumococcal 7-valent conjugate vaccine (BI) (see
HCT Recipient Vaccinations).
Antibiotic prophylaxis against pneumococcal
infection is indicated in patients with cGVHD and
those with low IgG levels (AIII). Antibiotic prophy-
laxis should be administered even to patients who
have received pneumococcal vaccine, because not all
strains are included in the vaccines, the immunogenic-
ity of vaccines against the vaccine strains in HCT
patients is only, at most, about 80% [194,195], and
because of the theoretic concern that strains not
included in the vaccine will replace vaccine strains.
Oral penicillin remains the preferred choice, but
antibiotic selection depends on the local pattern of
pneumococcal resistance to penicillin and other anti-
biotics (ie, second-generation cephalosporins, macro-
lides, and quinolones) [196-199]. Early empirical
antibiotic treatment is required in any HCT patient
with suspected IPI, regardless of the time since
transplant, the immunization status, and the use of
chemoprophylaxis (AIII) [193].Recommendations Regarding
Viridans Streptococci
Preventing exposure
Viridans streptococci are normal commensals, pri-
marily of the oral surfaces. Hence, preventive efforts
must focus on preventing systemic infection and
disease rather than preventing exposure.
Preventing disease
Chemotherapy-induced oral mucositis is a potential
source of viridans streptococcal bacteremia and sepsis.
Consequently, before the start of conditioning, dental
consults should be considered for all HCT candidates
to assess their state of oral health and to perform any
needed dental procedures to decrease the risk for oral
infections after transplant (AIII) [200]. Many experts
recommend that antibiotics active against viridans
streptococci be given from the time of transplantation
until a minimum of day121 afterward (CIII). However,this approach has not been systematically studied. Pen-
icillin-, quinolone-, and vancomycin-resistant strains of
viridans streptococci have been reported [201,202].
Empiric treatment of any HCT recipient with fever,
severe mucositis, and neutropenia should include an
agent active against viridans streptococci to prevent
complications from this potentially fatal infection [203].
Recommendations Regarding Haemophilus
influenzae Type b
Preventing exposure
Vaccination campaigns have markedly reduced the
incidence of H. influenzae type b (Hib) disease. How-
ever, in the rare event of a patient being hospitalized
with Hib, standard precautions are recommended,
with droplet precautions added for the first 24 hours
after initiation of appropriate antibiotic therapy
(BIII) [144,204].
Preventing disease
Vaccination against Hib is recommended for all
HCT recipients, as at least one-third of HCT recipi-
ents do not have protective antibody levels of Hib cap-
sular polysaccharide antibodies after HCT, and the
Hib conjugate vaccine has excellent efficacy among
HCT recipients (BII) [194,205] (see HCT Recipient
Vaccinations).
All HCT recipients who are exposed to persons
with Hib disease should receive prophylaxis with 4
days of rifampin [204], or with an alternative antimicro-
bial agent if rifampin would likely interfere with other
prophylactic agents the patient is receiving (eg, ex-
tended-spectrum azoles) (BIII) (Appendix 1). Antibiotic
prophylaxis is especially indicated for allogeneic HCT
recipients with cGVHD, who are at increased risk for
developing infections from Hib and other encapsulated
organisms (see section on S. pneumoniae) [206].
Recommendations Regarding
Bordetella pertussis
Preventing exposure
HCT recipients may be exposed to persons with
pertussis, as this disease is increasingly frequent in
the general community. Pertussis in an adolescent re-
cipient of an unrelated cord blood transplant (CBT)
has been reported [207]. In addition to standard pre-
cautions, droplet precautions should be used in pa-
tients hospitalized with pertussis; droplet precautions
are recommended for 5 days after initiation of effective
therapy or, if antibiotic treatment is not given, until 3
weeks after the onset of paroxysmal cough (BIII) [208].
Preventing disease
All HCT recipients who are exposed to persons with
pertussis should receive prophylaxis with azithromycin
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[TMP-SMZ] may be an alternative antimicrobial agent)
regardless of age and immunization status (BIII) [208].
Following HCT, all HCT recipients should receive
vaccination with acellular pertussis (see HCT Recipient
Vaccinations).VIRAL DISEASE PREVENTION AFTER HCT
J. Zaia, L. Baden, M.A. Boeckh, S. Chakrabarti, H.
Einsele, P. Ljungman, G.B. McDonald, H. HirschRecommendations Regarding Cytomegalovirus
Preventing exposure
Hematopoietic Cell Transplantation (HCT) candi-
dates should be tested for the presence of serum anti-cy-
tomegalovirus (CMV) IgG antibodies before
transplantation to determine their risk for primary
CMV infection and reactivation after HCT (AII).
CMV is shed intermittently from the oropharynx and
the genitourinary tract of both immunocompetent
and immunosuppressed subjects. There are no data
demonstrating that avoiding these body fluids is feasible
or effective in preventing acquisition of CMV in CMV-
seronegative HCT recipients. Because CMV-seroneg-
ative pregnant health care workers may be at risk for
contracting CMV from these and other patients,
standard universal precautions should be used in these
situations.
With proper management, CMV-seronegative
patients have a low risk for contracting CMV infec-
tion. To reduce the risk of CMV transmission, blood
products from CMV-seronegative donors or leuko-
cyte-depleted blood products should be used in
CMV-seronegative allogeneic HCT recipients (AI)
[209-211]. The benefit of using either of these prod-
ucts in autologous HCT recipients to prevent CMV
transmission is less clear. However, because many
autologous HCT recipients have received previous T
cell suppressive therapy such as fludarabine (Flu) or
alemtuzumab, the use of CMV-safe blood products is
recommended (BII). In many centers, and even in en-
tire countries, leukocyte filtration of blood products is
mandatory. No controlled study has examined the po-
tential benefit of the combination of seronegative
blood products and filtered blood products. Leukocyte
filtration should be performed at the blood bank and
the established quality standard of\5 106 residual
leukocytes/unit should be followed (AII) [212,213].
Preventing disease and disease recurrence
HCT recipients at risk for posttransplant CMV
disease (ie, all CMV-seropositive HCT recipients,
and all CMV-seronegative recipients with a CMV-
seropositive donor) should be placed on a CMVdisease prevention program from the time of engraft-
ment until at least 100 days after HCT (ie, phase II)
(AI). Physicians should use either prophylaxis or pre-
emptive treatment for allogeneic recipients (AI). In se-
lecting a CMV disease prevention strategy, physicians
should assess the risks and benefits of each strategy, the
needs and condition of the patient, and the hospital’s
virology laboratory support capability.
A prophylaxis strategy against early CMV replica-
tion (ie,\100 days after HCT) for allogeneic recipi-
ents involves administering prophylaxis to all
allogeneic recipients at risk throughout the period
from engraftment to 100 days after HCT (Appendix
1) (AI). Ganciclovir, high-dose acyclovir, and valacy-
clovir have all shown efficacy in randomized studies
in reducing the risk for CMV infection after HCT
[214-216]. If ganciclovir is used, the induction course
is usually started at engraftment (AI) [214,217,218],
although a brief prophylactic course can be added
during pretransplant conditioning (CIII). If acyclovir
or valacyclovir is used, the patient must also undergo
viral monitoring and receive preemptive antiviral ther-
apy if evidence of CMV replication is found (AI)
[215,216]. IVIG is not recommended for CMV disease
prophylaxis among HCT recipients (EIII).
In patients with CMV disease documented before
transplantation, transplantation should be delayed
until the disease is adequately treated (BII), and use
of secondary anti-CMV prophylaxis during HCT
should be considered (BIII) [219]. Such patients should
be closely monitored during the HCT procedure, in-
cluding during the preengraftment phase if the trans-
plant center usually starts monitoring for CMV
reactivation following engraftment, and a low thresh-
old for preemptive treatment is used (BIII) [219].
The preemptive strategy targets antiviral treatment
to those patients who have evidence of CMV replica-
tion after HCT (Appendix 1). It requires the use of sen-
sitive and specific laboratory tests to rapidly diagnose
CMV replication after HCT and to enable immediate
administration of effective antiviral therapy after
CMV replication has been detected. Allogeneic recipi-
ents at risk should be screened for the presence of CMV
in blood samplesz1 time/week from 10 days to at least
100 days after HCT (ie, phase II) (AIII). CMV-seropos-
itive cord blood transplant (CBT) recipients are at in-
creased risk of CMV reactivation and disease
[220,221]. Thus, some researchers use acyclovir or va-
lacyclovir prophylaxis [215,216] in combination with
preemptive therapy in these patients (CIII). A preemp-
tive strategy against early CMV replication (ie,\100
days after HCT) for allogeneic recipients is preferred
over prophylaxis for CMV-seronegative HCT recipi-
ents of seropositive donor cells (ie, D-positive and R-
negative) because of the low attack rate of CMV repli-
cation if screened or filtered blood product support is
used (BII).
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tive treatment include the detection of CMV pp65 anti-
gen in leukocytes (antigenemia) [217,222], CMV DNA
by quantitative polymerase chain reaction (PCR)
[223-225], or the detection of CMV RNA [226].
HCT centers performing allogeneic transplants should
have the capacity to perform 1 of these tests (AIII). Viral
cultures of urine, saliva, blood, or bronchoalveolar
washings by rapid shell-vial culture [227] or routine cul-
ture [228,229] are today rarely used because these tech-
niques are less sensitive than CMV-DNA PCR or CMV
pp65 antigenemia tests. However, it should be recog-
nized that CMV pp65 antigenemia tests may be falsely
negative in patients with neutropenia.
Ganciclovir is often used as a first-line drug for
preemptive therapy. Although foscarnet is as effective
as ganciclovir [230], it is currently more commonly
used as a second-line drug, because of practical reasons
(eg, requirement for prehydration and electrolyte
monitoring). Allogeneic recipients who are #100
days after HCT should begin preemptive treatment
if CMV viremia, antigenemia, or DNA is detected
(AI). Preemptive therapy should be given for a mini-
mum of 2 weeks (A1) [217]. If CMV is still detected
after 2 weeks of therapy, maintenance therapy can be
given until CMV is undetectable [230] or it can be con-
tinued to day 100 (AI) [217]. After discontinuation of
preemptive therapy, routine weekly screening is neces-
sary to at least day 100 because recurrent episodes of
CMV viremia commonly occur (BII).
Presently, only the intravenous formulation of
ganciclovir has been approved for use in CMV prophy-
lactic or preemptive strategies (AI). Valganciclovir,
a prodrug of ganciclovir, has been increasingly used
in preemptive therapy [231-234], and an interim anal-
ysis of a randomized, controlled study has shown com-
parable results in patients treated with i.v. ganciclovir
or valganciclovir [235]. Dose adjustment for renal
insufficiency is necessary with either drug to avoid
hematologic toxicity. Patients who are ganciclovir-
intolerant should be treated with foscarnet (AI)
[236]. HCT recipients receiving ganciclovir should
have absolute neutrophil counts (ANCs) checked $2
times/week (BIII). Experts report managing ganciclo-
vir-associated neutropenia by adding granulocyte
colony-stimulating factor (G-CSF) [237] or temporar-
ily stopping ganciclovir for z2 days if the patient’s
ANC is \1000 (CIII). Ganciclovir can be restarted
when the patient’s ANC is z1000 for 2 consecutive
days. Alternatively, foscarnet can be substituted for
ganciclovir if CMV can still be detected in blood.
Because neutropenia accompanying ganciclovir
administration is usually brief, such patients do not
require antifungal or antibacterial prophylaxis (DIII).
True CMV antiviral resistance is quite rare in
HCT patients, especially in patients who have never
been previously treated with antiviral agents. Increasingantigenemia or CMV DNA load early after initiation
of antiviral therapy is usually not a sign of treatment
failure in patients who have not been previously
treated with antiviral agents, and, therefore, does not
necessitate change of therapy [238,239]. However, if
the patient develops signs of CMV disease or if the
level of antigenemia or the CMV DNA load continues
to rise after more than 2 weeks of therapy, resistant
CMV should be suspected and a change of therapy
considered (BIII). Development of CMV drug resis-
tance early after HCT has been observed in children
transplanted for immunodeficiency or those who re-
ceived T cell-depleted grafts or anti-T cell antibodies
[240]. Ganciclovir or foscarnet can be considered as an
alternative drug for second-line preemptive therapy
(AI) [230]. Cidofovir, a nucleoside analog, can be con-
sidered for second-line preemptive therapy, but careful
monitoring of renal function is required, and it should
be noted that crossresistance with ganciclovir can
occur (BII) [241-243]. If possible, samples should be
sent to a laboratory capable of documenting antiviral
resistance (CIII) [244].
Certain CMV-seropositive autologous recipients
are at increased risk for symptomatic CMV replication
or disease [245]. These include patients undergoing
conditioning regimens including total body irradiation
(TBI); patients receiving grafts manipulated to remove
T cells; and patients who have recently (eg, within 6
months prior to HCT) received alemtuzumab, Flu,
or 2-chlorodeoxyadenosine (CDA). Such patients
may benefit from the use of a preemptive strategy
that includes monitoring for CMV reactivation until
60 days after HCT (CII). Patients transplanted with
CD341-selected grafts should be treated at any level
of antigenemia [245] (BII). Other autologous recipi-
ents at high risk who experience moderately high levels
of CMV antigenemia (ie, blood levels of $5 positive
cells/slide) or CMV DNA should receive 2 weeks of
preemptive treatment with ganciclovir or foscarnet
(CIII) [222]. A prophylactic approach to CMV disease
prevention is not recommended for CMV-seropositive
autologous recipients (DII) [246].
Because HCT recipients might develop 2 or more
reactivations, patients considered to be at increased
risk for late CMV disease should be routinely screened
for evidence of CMV reactivation as long as substantial
immunocompromise persists (BII) [247] (Appendix 1).
Risk factors for late CMV disease include allogeneic
HCT accompanied by chronic graft-versus-host dis-
ease (cGVHD), steroid use, low CD4 counts (\50/
mm3), use of grafts from CMV-seronegative donors
in CMV-seropositive recipients, and use of unrelated,
haploidentical, CB, or T cell-depleted HCTs [248-
251]. The indication for antiviral therapy if CMV is
detected after day 100 has to be determined on an in-
dividual basis depending on the patient’s risk factors
for developing late CMV disease (BIII). The choice
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for CMV infection that occurs during the first 100
days posttransplant.
Strategies for preventing late CMV disease in
high-risk patients include the use of continued surveil-
lance and preemptive antiviral therapy [247], as well as
prophylaxis with antiviral drugs and cellular immuno-
therapy for patients with deficient or absent CMV-
specific immune system function. Several small phase
I/II studies have been published using adoptive trans-
fer of CMV-specific CD41 and/or CD81 T cells,
especially in patients developing repeated episodes of
CMV disease [252-255]. However, none of these
adoptive T cell transfer techniques are in routine clin-
ical practice, and, therefore, they cannot be recom-
mended.
Recommendations Regarding Epstein Barr
Virus
Preventing exposure
HCT donors and candidates should be tested for
the presence of serum anti-EBV IgG antibodies before
transplantation to determine risk for primary Epstein-
Barr virus (EBV) after HCT. The recommendation is
stronger in pediatric patients (AII) than in adults (BII).
Although fever and mononucleosis can occur in pri-
mary EBV infection, the most significant clinical syn-
drome associated with EBV replication in HCT
recipients, particularly following primary infection, is
posttransplant lymphoproliferative disease (PTLD)
[256]. This disorder occurs principally in recipients
with profound T cell cytopenia (eg, after T cell deple-
tion (TCD), use of anti-T cell antibodies, UCB trans-
plants, and haplo identical transplants) [257-259].
Assessment of blood EBV DNA loads with quantita-
tive PCR testing can identify those at risk for PTLD
[260-262].
EBV disease in HCT recipients typically results
from reactivation of endogenous infection or transmis-
sion of EBV from the graft [258]. Nevertheless, all
transplant candidates, particularly those who are
EBV-seronegative, should be advised of behaviors
that would decrease the likelihood of EBV exposure
(AII) (see Strategies for Safe Living after HCT).
Preventing disease
For prevention of EBV-related PTLD (Appendix
1), it is important to monitor high-risk (eg, after T
cell depletion, use of anti-T cell antibodies, UCB
transplants, and haplo-identical transplants) patients
for EBV DNA load using a blood EBV PCR assay
(BII). EBV DNA loads have been shown to rise as early
as 3 weeks prior to disease onset. Monitoring for blood
EBV DNA loads allows preemptive reduction in im-
munosuppression, if possible, as the first part of patient
management. Because of the variability of PCR tech-niques and the difference in risk for EBV-related
PTLD depending on the degree of T cell lymphope-
nia, no firm recommendation on the threshold for ini-
tiation of preemptive therapy can be made. If there is
no response to reduction in immunosuppression, pre-
emptive treatment with rituximab can prevent PTLD
(BII) [263]. Infusion of donor-derived, EBV-specific
CTL has demonstrated promise in the prophylaxis of
EBV lymphoma among recipients of T cell-depleted
unrelated or mismatched allogeneic recipients (CII)
[264,265]. In addition, expanded donor-derived
EBV-specific T cells have been used to control blood
EBV DNA loads in this setting, but this procedure
remains experimental (CII) [266,267]. Use of B cell de-
pletion to minimize the risk of EBV PTLD has also
been proposed (CII) [268]. Finally, prophylaxis or pre-
emptive therapy with currently available antiviral
agents is not recommended because of lack of
efficacy (DII) [257-259].Recommendations Regarding HSV
Preventing exposure
HCT candidates should be tested for serum anti-
HSV IgG before transplant (AII); however, type-
specific anti-HSV IgG serology testing is not necessary.
All HCT candidates, particularly those who are HSV
seronegative, should be informed of the importance of
avoiding HSV infection while immunocompromised,
and should be advised of behaviors that will decrease
the likelihood of HSV exposure (AII) (see Strategies
for Safe Living after HCT). Any person with dissemi-
nated, primary, or severe mucocutaneous HSV disease
should be placed under contact precautions for the
duration of the illness (AII) [144] to prevent transmis-
sion of HSV to HCT recipients.
Preventing disease and disease recurrence
Acyclovir. Acyclovir prophylaxis should be of-
fered to all HSV-seropositive allogeneic recipients to
prevent HSV reactivation during the early posttrans-
plant period (AI) [269-273]. The standard approach is
to begin acyclovir prophylaxis at the start of the condi-
tioning therapy and continue until engraftment occurs
or until mucositis resolves, whichever is longer, or ap-
proximately 30 days after HCT (AI) [272] (Appendix
1). Continued use of acyclovir appears to prevent
HSV reactivation disease in patients who received it
for VZV or CMV prophylaxis (CII) [274]. Routine acy-
clovir prophylaxis is not indicated for HSV-seronega-
tive HCT recipients, even if the donor is HSV
seropositive (DIII). Use of ganciclovir prophylaxis for
CMV in HCT recipients is sufficient for prevention
of HSV because of this drug’s in vitro activity against
HSV-1 and HSV-2 (AII) [214,275], although ganciclo-
vir has not been approved for use against HSV.
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in the setting of low-dose prophylaxis, intermittent
treatment, or with HSV-seronegative donors
[274,276,277]. Foscarnet is the treatment of choice
for resistant disease (BI); cidofovir may serve as an
alternative (CIII). If postengraftment acyclovir pro-
phylaxis is given, experts recommend a sufficiently
high dose to prevent the emergence of resistance
(Appendix 1) [274].
Valacyclovir. Although valacyclovir is not ap-
proved for use in preventing HSV disease among
HCT recipients, comparative studies have shown
that valacyclovir and acyclovir are equally effective in
suppression of HSV after autologous HCT [278,279]
for patients who can tolerate oral medications (CIII).
Regarding safety, valacyclovir has been used for 1
year in HCT recipients for suppression of VZV with-
out toxicity [280]. Physicians wishing to use valacyclo-
vir among recipients with renal impairment should
exercise caution and decrease the dose as needed.
Foscarnet. Because of its substantial renal and
infusion-related toxicity, foscarnet is not recommen-
ded for routine HSV prophylaxis among HCT recipi-
ents (DIII). However, patients who receive foscarnet
for other reasons (eg, CMV prophylaxis) do not
require additional acyclovir prophylaxis (DIII).
Famciclovir. Presently, data regarding safety and
efficacy of famciclovir among HCT recipients are
limited; therefore, no recommendations for HSV
prophylaxis with famciclovir can be made.
Other recommendations
HSV prophylaxis lasting .30 days after HCT
might be considered for persons with frequent recur-
rences of HSV infection (BIII) (Appendix 1). Acyclovir
or valacyclovir can be used during phase I (preengraft-
ment) for administration to HSV-seropositive autolo-
gous recipients who are likely to experience substantial
mucositis from the conditioning regimen (CIII). Acy-
clovir prophylaxis doses should be modified for use
among children (Appendix 1). Because of limited pub-
lished data regarding valacyclovir safety and efficacy
among children, no recommendations for the pediatric
population can be made [281].Recommendations Regarding VZV
Preventing exposure
HCT candidates should be tested for the presence
of serum anti-varicella zoster virus (VZV) IgG anti-
bodies (AII). However, these tests are not 100% reli-
able, particularly among severely immunosuppressed
patients. All HCT candidates and recipients, particu-
larly those who are VZV seronegative, should be in-
formed of the potential seriousness of VZV disease
among immunocompromised persons and advised ofstrategies to decrease their risk for VZV exposure
(AII) [282].
Although the majority of VZV disease after HCT is
caused by reactivation of endogenous VZV, HCT can-
didates and recipients who are VZV seronegative, or
VZV seropositive and immunocompromised, should
avoid exposure to persons with active VZV infections
(AII) [283]. Health care workers (HCWs), family mem-
bers, household contacts, and visitors who are healthy
and do not have a reported history of varicella infection
or who are VZV-seronegative should receive VZV vac-
cination before being allowed to visit or have direct
contact with an HCT recipient (AIII). Ideally, VZV-
susceptible family members, household contacts, and
potential visitors of immunocompromised HCT recip-
ients should be vaccinated as soon as the decision is
made to perform HCT and the vaccination schedule
completedz4-6 weeks before the HCT is performed
(BIII). To date, no serious disease has been reported
among immunocompromised patients from transmis-
sion of VZV vaccine virus, and the VZV vaccine strain
is susceptible to acyclovir. However, HCT recipients
undergoing conditioning therapy should avoid contact
with any VZV vaccine recipient who experiences a rash
after vaccination (BIII). Rash after vaccination can be
because of the wild-type VZV (median: 8 days; range:
1-20 days) or the VZV vaccine strain (median: 21
days; range: 5-42 days) [284,285].
All HCT recipients with multidermatomal VZV
disease should be placed under airborne and contact
precautions (AII) [144] to prevent transmission to other
HCT recipients. Dermatomal zoster requires contact
precautions until all skin lesions are crusted (AII), and
some researchers also recommend airborne precau-
tions because in immunocompromised patients there
is a high risk for dissemination of the zoster rash
(CII). Airborne precautions should be instituted 8
days after exposure to VZV and continued until 21
days after last exposure (AII) or 28 days postexposure
if the patient received varicella-zoster immunoglobulin
(VZIG) (BII) [144] because a person infected with VZV
can be inectious before the rash appears. The VZIG
product currently available in the United States is
VariZIG [286].
Preventing disease
Antiviral drugs. Long-term acyclovir prophy-
laxis to prevent recurrent VZV infection is routinely
recommended for the first year after HCT for VZV-
seropositive allogeneic (BI) [280,287] and autologous
(CII) HCT recipients (Appendix 1). The 1-year regi-
men of acyclovir is highly effective in reducing the
risk of VZV disease during the year of acyclovir admin-
istration (BI) [280,287]. Acyclovir prophylaxis may be
continued beyond 1 year in allogeneic HCT recipients
who have cGVHD or require systemic immunosup-
pression (BII) [280,288]. The optimal duration of
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as there appears to be a persistent risk of VZV reacti-
vation disease even if the acyclovir is continued until
all systemic immunosuppressive drugs are discontin-
ued and the CD41 count exceeds 200 cells/mL [288].
Some clinicians advocate continuing acyclovir prophy-
laxis until 6 months after discontinuation of all
systemic immunosuppressive agents (CIII).
Valacyclovir is a prodrug of acyclovir, and may be
used as an alternative to acyclovir at any time that oral
medications are used. Valacyclovir may provide higher
drug levels in severely immunosuppressed patients
than acyclovir (BII). Although valacyclovir is not
licensed in the United States for use in HCT recipi-
ents, a large randomized trial in HCT recipients found
no safety issues with valacyclovir, even when used at
very high doses [216]. No data on famciclovir in
HCT recipients were found; consequently, no recom-
mendations can be made regarding its use in place of
acyclovir or valacyclovir.
Resistance to acyclovir has been rarely docu-
mented to date in HCT recipients [289]; however,
when clinically suspected or virologically documented
acyclovir resistance occurs among patients, HCT phy-
sicians should use foscarnet for preemptive treatment
of VZV disease (BIII) [289,290].
Any HCT recipient or candidate undergoing con-
ditioning therapy who experiences a VZV-like rash
(whether after exposure to a person with wild-type var-
icella or shingles or exposure to a VZV vaccinee with
a rash) should receive preemptive intravenous acyclo-
vir until z2 days after all lesions have crusted (BII).
Treatment may be completed with oral valacyclovir
if the patient can tolerate oral medication.
Passive immunization and VZV-seronegative
HCT recipients
Because of the high morbidity of VZV-associated
disease among severely immunocompromised HCT
recipients and until further data are published, there
are situation-specific indications for the administra-
tion of VZIG or VariZIG, where available, for VZV-
seronegative HCT recipients. Immunocompromised
HCT recipients (ie, an allogeneic patient\24 months
after HCT, $24 months after HCT and on immuno-
suppressive therapy, or having cGVHD) should
receive VZIG or VariZIG as soon as possible and no
later than 96 hours after close or household contact
with a person having either chickenpox or shingles
(AII). Postexposure acyclovir or valacyclovir (Appen-
dix 1) may be used as an alternative if VZIG or Vari-
ZIG is not available (CII) [291,292]. VZIG or
VariZIG, acyclovir, or valacyclovir should also be
administered to all VZV-seronegative HCT recipients
undergoing conditioning therapy who are exposed to
a VZV vaccinee having a varicella-like rash (BIII). If
VZV-seronegative HCT recipients undergoing condi-tioning therapy are closely exposed to varicella .3
weeks after receiving VZIG or VariZIG, they should
receive another dose of VZIG or VariZIG, or another
course of valacyclovir if VZIG or VariZIG is not avail-
able (BIII) [282].
Passive immunization and VZV-seropositive
HCT recipients
VZIG or VariZIG, acyclovir, or valacyclovir can
be used following VZV exposure, including exposure
to a VZV vaccinee having a varicella-like rash, for
HCT recipients who were VZV-seropositive before
HCT and are highly immunosuppressed (ie, because
of high-dose steroid therapy, or T CD) (CIII) [292].
These recommendations are made because the vacci-
nee might be unknowingly incubating wild-type vari-
cella, particularly during the first 14 days after
varicella vaccination, and because vaccine-strain
VZV has been rarely transmitted by VZV vaccinees
with postvaccination vesicular rashes [282]. Further-
more, varicella vaccination is only approximately
85% effective. Thus, vaccine recipients may still be-
come infected with wild-type virus years after vaccina-
tion [293] and may thus be a source of transmission to
immunocompromised patients.
VZVVaccines. Use of VZV vaccines (Varivax and
Zostavax) is discussed in the HCT Recipient Vaccina-
tion section. A vaccine-associated rash occurs in ap-
proximately 1% to 5% and 0.5% of recipients of the
varicella and zoster vaccine, respectively [294,295].
This rash is a potential source of transmission of vac-
cine virus strain to HCT recipients. Because the risk
of vaccine virus transmission is low, particularly in
the absence of a vaccine-associated rash, household
members should receive varicella vaccine to protect
HCT recipients from potential exposure to wild-type
disease (AIII). Individuals who experience a vaccine-as-
sociated rash should avoid close contact with HCT re-
cipients in the home setting (BIII). If contact occurs,
the HCT recipient should be considered for postexpo-
sure prophylaxis with valacyclovir, as outlined earlier
(CIII).
An inactivated VZV vaccine has been used investi-
gationally among HCT recipients [296]. Studies are
ongoing to further define its utility and no recommen-
dation regarding its use can be made at this time.
Other recommendations
Recommendations for VZV prevention are the
same for allogeneic or autologous recipients. Recom-
mendations are also the same for allograft recipients
with different-intensity conditioning regimens. Rec-
ommendations for preventing VZV disease among
pediatric or adult HCT recipients are the same, except
that appropriate dose adjustments for acyclovir deriv-
atives and VZIG should be made for pediatric HCT
recipients (AIII) (Appendix 1).
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Influenza, Respiratory Syncytial Virus, Human
Metapneumovirus, and Parainfluenza Virus
Preventing exposure
Preventing CRV exposure is critical in preventing
CRV disease [297,298]. Measures for preventing noso-
comial CRV transmission are presented in the Infection
Prevention and Control in Health care Facilities: Rec-
ommendations Regarding CRV Infections section.
Use of PCR testing in donors with respiratory infections
remains investigational (CIII). Viral cultures of asymp-
tomatic HCT candidates are unlikely to be useful.
Whether multiplex PCR testing can identify asymp-
tomatic shedders before HCT is presently being stud-
ied. PCR-based routine surveillance of asymptomatic
patients after HCT remains investigational.
HCT recipients with symptoms of an upper respi-
ratory infection (URI) or lower respiratory infection
(LRI) should be placed under contact precautions to
avoid transmitting infection to other HCT candidates
and recipients, HCWs, and visitors until the etiology
of the illness is identified (BIII) [144]. Optimal isola-
tion precautions should be modified as needed after
the etiology is identified (BIII). HCT recipients and
candidates, their family members and visitors, and all
HCWs should be informed regarding CRV infection
control measures and the potential severity of CRV in-
fections among HCT recipients (BIII) [297-299].
Preventing disease
HCT physicians should determine the etiology of
a URI in an HCT recipient, if possible, because
respiratory syncytial virus (RSV), influenza, parain-
fluenza, and adenovirus URIs can progress to more
serious LRI, and certain CRVs can be treated
(BIII). Appropriate diagnostic samples include naso-
pharyngeal washes, swabs or aspirates; throat swabs
(in combination with nasal samples); and bronchoal-
veolar lavage (BAL) fluid. HCT candidates with
URI symptoms at the time conditioning therapy is
scheduled to start should postpone their conditioning
regimen until the URIs resolve, if possible, because
certain URIs might progress to LRI during immuno-
suppression (BIII) [298,300-302]. The clinical rele-
vance of recently discovered viruses (eg, human
bocavirus, non-SARS coronaviruses, human rhinovi-
ruses, human metapneumovirus) that are detectable
by molecular methods is currently undefined, and
no recommendations can be made for routine screen-
ing for these viruses (CIII).
Recommendations regarding influenza
Life-long seasonal influenza vaccination with the
trivalent inactivated vaccine is recommended for all
HCT candidates and recipients (see Vaccination sec-
tion) (AII). Additionally, influenza vaccination of fam-ily members and close or household contacts is strongly
recommended during each influenza season (eg, Octo-
ber-May in the Northern Hemisphere), starting the
season before HCT and continuingz24 months after
HCT (AII) [303] to prevent influenza. All family mem-
bers and close or household contacts of HCT recipi-
ents should continue to be vaccinated annually as
long as the HCT recipient’s immunocompromise per-
sists, even if beyond 24 months after HCT (AII) [303].
Seasonal influenza vaccination is strongly recommen-
ded for all HCWs of HCT recipients (AI) [304].
If HCWs, family members, or other close contacts
of HCT recipients receive influenza vaccination during
an influenza outbreak, they should receive chemopro-
phylaxis, if feasible, for 2 weeks after influenza vaccina-
tion (BI) while the immunologic response to the vaccine
develops. However, if an outbreak occurs with an influ-
enza strain that is not contained in the available influ-
enza vaccine, all healthy family members, close and
household contacts, and HCWs of HCT recipients
and candidates should receive influenza chemoprophy-
laxis with an active agent against the current circulating
strain of influenza until the end of the outbreak (BIII)
[303]. Zanamivir may be given for prevention of influ-
enza A and B, including influenza from strains resistant
to oseltamivir. The duration of prophylaxis depends on
the type of exposure. Zanamivir can be administered to
persons 5 years of age and older for prevention of influ-
enza, and 7 years and older for treatment of influenza.
Oseltamivir can be administered to persons z1 year
of age and older. Patients with influenza should be
placed under droplet and standard precautions (AIII)
to prevent transmission of influenza to HCT recipients.
HCWs with influenza should be excused from patient
care until they are no longer infectious (AIII).
HCT recipients \6 months after HCT should
receive chemoprophylaxis with neuraminidase inhibi-
tors during community influenza outbreaks that lead
to nosocomial outbreaks (AII). During community
outbreaks, all HCT recipients who have not yet
received a current influenza vaccination should be vac-
cinated against influenza immediately if it is more than
4 months after HCT (BIII). Additionally, to allow
sufficient time for the patient to experience an immu-
nologic response to influenza vaccine, chemoprophy-
laxis can be used for these HCT recipients for
2 weeks after vaccination during a nosocomial or
community influenza outbreak (CIII). Influenza
chemoprophylaxis has been recommended for all
influenza-exposed HCT recipients who are \24
months after HCT or who are .24 months after
HCT and substantially immunocompromised regard-
less of vaccination history, because of their likely
suboptimal immunologic response to influenza
vaccine (BII) [305,306]. Drug resistance patterns of
circulating influenza strains should guide the choice
of prophylactic agent.
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tion for the first time might not generate protective
antibodies until 2 weeks after receipt of the second
dose of influenza vaccine. Therefore, during an influ-
enza A outbreak, pediatric recipients who are\9 years
old, #6 months after HCT, and receiving their first
influenza vaccination, should be givenz6 weeks of in-
fluenza A chemoprophylaxis after the first dose of
influenza vaccine (BIII) (Appendix 1) [307,308]. To
prevent severe disease, HCT patients with influenza
URI should receive early preemptive therapy with
drugs shown to be susceptible to the circulating strain.
(AII) [309,310].
Recommendations regarding RSV
Respiratory secretions of any hospitalized HCT
candidate or recipient who experiences signs or symp-
toms of CRV infection should be tested promptly by
viral culture and rapid diagnostic tests for RSV
(BIII). If 2 diagnostic samples taken z2 days apart
do not identify a respiratory pathogen despite persis-
tence of lower respiratory symptoms, BAL and further
testing are advised (BIII). This testing is critical be-
cause of the high morbidity and case fatality of RSV
disease and the frequent presence of significant co-
pathogens among HCT recipients when it occurs dur-
ing the peritransplant period [311,312]. HCT
recipients, particularly those who are preengraftment
and lymphopenic or those who have preexisting ob-
structive airway disease, are at highest risk for severe
RSV pneumonia. These patients should have their ill-
ness diagnosed early (ie, during RSV URI) and receive
aggressive treatment to prevent fatal RSV disease
(BIII).
On the basis of retrospective studies as well as
a prospective trial with inadequate accrual, some
researchers recommend preemptive aerosolized riba-
virin for patients with RSV URI, especially those
with lymphopenia (during the first 3 months after
HCT) and preexisting obstructive lung disease (late
after HCT) (CIII) [310,313]. Although a definitive,
uniformly effective preemptive therapy for RSV infec-
tion among HCT recipients has not been identified,
certain other strategies have been proposed, including
systemic ribavirin [314-316], RSV antibodies (ie, pas-
sive immunization with high-RSV-titer IVIG, RSV
immunoglobulin) in combination with aerosolized
ribavirin [301,317], and RSV monoclonal antibody
(mAb) [314,318]. No randomized trial has been com-
pleted to test the efficacy of these strategies; therefore,
no specific recommendation regarding any of these
strategies can be given at this time. To prevent RSV
disease, some centers provide monthly palivizumab
prophylaxis during RSV season (eg, November-April
in the Northern Hemisphere) for pediatric recipients
at risk for primary RSV disease (ie, children\4 years
old) (CIII). Routine IVIG therapy would still berequired if indicated [319] (ie, for those with hypogam-
maglobulinemia) (Appendix 1).
Recommendations regarding parainfluenza virus
Immunoprophylaxis, withdrawal of immunosup-
pression to prevent progression, and preemptive treat-
ment for parainfluenza virus infections among HCT
recipients have been proposed [320]. However, no rec-
ommendation can be made in these guidelines because
of insufficient data. No commercially licensed drugs or
vaccines against parainfluenza viruses are currently
available.
Recommendations regarding human
metapneumovirus
Human metapneumovirus can cause pneumonia in
HCT recipients [321]. Ribavirin has in vitro and ani-
mal model activity against human metapneumovirus
[322,323]. However, no recommendations can be
made in these guidelines because of lack of treatment
data.
Other disease prevention recommendations
The recommendations for preventing CRV infec-
tions and their recurrence are the same for allogeneic
or autologous recipients. Generally, these recommen-
dations apply to children [308,319,324,325] and adults,
but with appropriate adjustments in antiviral drug and
influenza vaccine doses for children (Appendix 1).
Progression to lower tract disease appears to be less
common in HCT recipients with nonmyeloablative
(NMA) conditioning, but no specific recommenda-
tions for these patients can be made at this time.Recommendations Regarding Adenoviruses
Preventing exposure
Adenovirus infections after HCT can result from re-
activation or de novo acquisition. Because many
different serotypes exist and knowledge about crossreac-
tive immunity is limited, pretransplant serologic testing
of either the patient or the donor is likely not helpful.
Because cellular immune responses are crossreactive
across various serotypes and are likely to provide long-
term protection against adenovirus reactivation, serious
adenovirus infections in adults are uncommon
[326,327]. HCT recipients should follow similar pre-
ventive measures as for other respiratory or enteric vi-
ruses (see recommendations regarding CRV, CMV,
and enteric viruses) with regard to contact and nosoco-
mial spread (see Infection Prevention and Control in
Health care Facilities and Safe Living after HCT).
Preventing infection and disease
HCT patients can be stratified according to their
risk for adenoviral disease:
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 Intermediate risk—T cell replete, related-donor
allograft recipients without GVHD
 Higher risk—recipients of T cell-depleted (2-3
log10), related- or unrelated-donor transplants
[331,332]; HLA mismatched transplant recipients
other than allele DRB1 mismatch [333]; patients
with GVHD who are receiving systemic steroids
[328,334,335], and pediatric recipients.
 Highest risk—refractory GVHD, UCB transplanta-
tion, haploidentical transplantation, stem cell graft
T cell depletion of .2-3 log10, use of anti-T cell
antibodies (eg, antithymocyte globulin [ATG],
alemtuzumab) [331,336].
For patients at highest risk, weekly monitoring for
active adenovirus infection by PCR for either the first 6
months after HCT or the duration of severe immuno-
suppression/lymphopenia could be considered (CII)
[333,337]. Quantitative PCR testing should be strongly
considered for monitoring progression of adenovirus
infection and response to treatment (BII). There are
no definitive data on a critical value for viral load in
peripheral blood to indicate initiation of intervention;
thus, no recommendation can be made.
Clearance of adenovirus has been shown to be
associated with recovery of adenovirus-specific T cell
immunity [338,339]. When possible, rapid tapering
or withdrawal of immunosuppression constitutes the
best way to prevent progression of adenovirus infec-
tion (AII) [331,332,340,341]. However, this strategy
might not always be feasible in severe GVHD or
with severe lymphopenia because of use of anti-T
cell antibodies or T CD of the graft. Few antiviral
agents have in vivo activity against adenoviruses, and
no randomized, placebo-controlled study of antiviral
drug therapy for adenoviral infection has been per-
formed. The available data suggest that cidofovir or ri-
bavirin could be used as preemptive antiviral therapy of
adenoviral disease in selected high-risk HCT patients
(CII) (Appendix 1). A reduction of DNA load has been
shown mainly with cidofovir [342,343], but the evi-
dence of its efficacy in preventing mortality in HCT
patients is inconsistent [344]. Differences in responses
may be because of strain-specific susceptibilities [345].
The duration of preemptive therapy is subject to toler-
ance and clearance of viral load.
Current evidence strongly supports the role of
adenovirus-specific T cells in controlling the progres-
sion of adenoviral disease [346]. However, this ap-
proach is at an early stage of development and should
not be used outside the context of a clinical trial.
Recommendations Regarding Polyomaviruses
BK and JC
Human polyomavirus type I, commonly called BK
virus (BKV), and human polyomavirus type II, com-monly called JC virus (JCV), infect 50% to 90% of hu-
mans worldwide before the age of 10 years, without
known symptoms or signs [347,348]. Urinary shedding
of BKV and/or JCV occurs in 5% to 20% of healthy
immunocompetent blood donors [349]. BKV and
JCV are nonenveloped virions found in urban sewage
and fairly resistant to environmental inactivation [350].
Polyomavirus disease in HCT patients most often
corresponds to secondary BKV replication with im-
paired polyomavirus-specific cellular immunity. Uri-
nary shedding of BKV occurs in 60% to 80% of
HCT recipients [347,348,351-353]. The major disease
linked to high-level polyomavirus replication is BKV-
associated hemorrhagic cystitis (PVHC), which affects
5% to 15% of HCT recipients at 3 ro 6 weeks post-
transplant [352,354]. PVHC occurs typically after
engraftment, and must be distinguished from hemor-
rhagic cystitis caused by other pathogens (eg, adenovi-
rus or CMV) and from early-onset hemorrhagic
cystitis, which arises preengraftment and has been
linked to urotoxic conditioning regimens with cyclo-
phosphamide (Cy), ifosfamide, busulfan (Bu), and/or
TBI [352,354]. BKV viruria reaching high viral loads
of.107 genome equivalents/mL (geq/mL) is observed
in 20% to 80% of HCT patients, but less than one-
fifth of HCT recipients develop PVHC [354].
PVHC is diagnosed in HCT patients with posten-
graftment cystitis who have pain and urinary urgency
together with hematuria of grade II (macrohematuria
[352]) or higher, high-level BKV replication (ie,
$107 gEq/mL), and exclusion of other pathogens.
There are reports of sporadic cases of JCV-associated
PVHC [355], BKV- or JCV-associated polyomavirus
nephropathy (PVAN) [347,356-359], and JCV- or
BKV-mediated polyomavirus multifocal leukoence-
phalopathy (PVML) [360,361].
Preventing exposure
There is no evidence to support routine testing of
HCT recipients or donors for the presence of BKV-
specific or JCV-specific antibodies (DIII). There are
no commercially available, standardized, or FDA-ap-
proved assays to measure BKV- or JCV-specific anti-
bodies. The role of primary infection, of donor-
recipient mismatch, and of BKV-specific antibody
titers in HCT recipients is presently unknown.
There is no evidence to support specific infection-
control measures for HCT patients with BKV viruria
(DIII). In patients with disseminated BKV replication
involving the respiratory and the gastrointestinal (GI)
tract, separation from other patients with significant
immunodeficiency should be considered (CIII).
Preventing disease and disease recurrence
There is no evidence to support the use of quino-
lones or cidofovir as specific universal prophylaxis for
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(DIII). There is insufficient evidence to support the use
of quinolones for preemptive treatment of asymptom-
atic HCT patients who develop BKV viruria or viremia
(DIII). Fluoroquinolones can inhibit BKV replication in
tissue culture, and have been reported to reduce BKV
loads in HCT patients, but a significant reduction of
PVHC has not been demonstrated [362]. Ciprofloxacin
and levofloxacin are frequently used, alone or in combi-
nation with other antibiotics, in patients undergoing
HCT in antibacterial prophylaxis during neutropenia,
in empiric or specific antibiotic therapy, and seemingly
resistant BKV isolates have been reported [362,363].
There is no evidence to support the use of cidofovir
for preemptive treatment of asymptomatic HCT
patients who develop BKV viruria or viremia (DIII). Ci-
dofovir has been administered intravenously in a low
dose (ie, up to 1 mg/kg 3 times weekly, without proben-
ecid) or a high dose (ie, 5 mg/kg per week with proben-
ecid) to HCT patients with PVHC, but no randomized
trials are available proving its clinical efficacy (CIII).Recommendations Regarding Hepatitis A virus
(HAV)
The seroprevalence of HAV varies widely, with
higher rates in resource-limited societies. Testing of
HCT candidates or donors for HAV IgG antibodies
is generally not recommended, as its sole positivity in
the absence of IgM indicates remote exposure and
has no impact on HCT outcome (DIII). However,
testing for IgM is indicated as part of the workup of pa-
tients with signs of acute hepatitis (AII). If an HCT
candidate tests positive for HAV IgM, transplantation
should be delayed because of an increased risk of sinu-
soidal obstruction syndrome (SOS) following liver-
toxic myeloablative (MA) conditioning regimens
(DII). If the HCT donor tests positive for HAV
IgM, transplantation should be delayed because of
a high risk of transmission and increased morbidity
and mortality (EII). HAV vaccination recommenda-
tions for HCT recipients are provided in Table 7.Recommendations Regarding Hepatitis B virus
(HBV)
HBV can cause severe hepatitis following HCT.
However, rates of HBV-associated cirrhosis and hepa-
tocellular carcinoma do not appear higher in HCT pa-
tients than in non-HCT patients [364]. Severe
hepatitis B has been observed in HCT recipients in
the following situations:
 1. HBV-naı¨ve HCT recipients exposed to HBV via
an infected donor, infected blood products, or
through sexual contact;
 2. HCT recipients with chronic hepatitis B experi-
encing prolonged immune suppression; 3. HCT recipients with serologic evidence of
resolved HBV infection who have reverse serocon-
version following prolonged immune suppression;
 4. HCT patients—generally in countries with
endemic HBV—with latent occult hepatitis B (all
serologic markers negative) that activates following
prolonged immune suppression [365].
Risk factors for reactivation and exacerbation of
HBV replication in HCT recipients include treatment
with high-dose steroids [366,367], Flu/rituximab
[368], or alemtuzumab [366,367,369]. Clinical hepati-
tis may become further exacerbated during immune
recovery and discontinuation of immunosuppression.
Preventing exposure
Testing both recipients and potential donors for
evidence of active or past HBV infection is critical to
preventing HBV exposure and disease in HCT recip-
ients. The appropriate assays include HBV surface
antigen (HBsAg), antibodies to HBV surface antigen
(anti-HBs), and antibodies to HBV core antigen
(anti-HBc) (AII). All anti-HBc positive and HbsAg-
positive donors and recipients should also be tested
for HBV DNA (AIII). HBV-naı¨ve HCT candidates
should not receive transplants from HBsAg-positive
or HBV DNA-positive donors, if another equally suit-
able donor is available (AII). However, the use of
a donor with active HBV replication is not absolutely
contraindicated for an HBV-naı¨ve recipient because
viral transmission is not universal (BIII). The overrid-
ing concern must be HLA matching and other
outcome-related issues.
Vaccination of all HBV-naı¨ve HCT candidates
should be considered (AIII). An attempt should be
made to provide hepatitis B immunization to HBV-
seronegative HCT candidates with HBsAg-positive
donors, preferably prior to chemotherapy for the ini-
tial 2 doses 3 to 4 weeks apart and a third dose 6
months later, ideally prior to HCT (BIII). If this
schedule cannot be met, the third dose should be
administered a few months after completion of chemo-
therapy. Of note, the response to vaccination is likely
to be poor in patients undergoing chemotherapy. If
the postvaccination anti-HBs titer is\10 IU/L or pre-
transplantation vaccination is impractical, HBIG
(0.06 ml/kg) should be administered immediately
prior to infusion of stem cells (AIII). HCT recipients
who fail to respond to pretransplant vaccination but
remain uninfected posttransplant (ie, negative for
HBsAg, anti-HBc, anti-HBs, and HBV DNA) should
be revaccinated after immune recovery with 1 to 3
doses of hepatitis B vaccine (BII).
If the donor has a detectable HBV DNA load, the
following measures are recommended (BIII):
 Administer antiviral treatment to the donor for at
least 4 weeks, or until HBV DNA is undetectable
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this purpose (CIII).
 Reduce harvest volume to the minimum possible
without compromising planned CD341 cell dose
and test an aliquot of the cell product for HBV
DNA.
 If, at the time of harvest, both the donor and the har-
vested cells are HBV DNA-negative, monitor ala-
nine aminotransferase (ALT) levels monthly in the
recipient for the first 6 months. If the ALT level is
increasing, test the recipient for HBV DNA (AIII).
If HBV DNA testing is not available, testing for
HBsAg is an acceptable alternative. If HBV DNA
is detected or a positive HBsAg is identified,
antiviral treatment is indicated (AIII).
 If the donor or cell product is positive for HBV DNA
at the time of harvest, provide the HCT recipient
prophylaxis with lamivudine from day zero through
at least 6 months following discontinuation of immu-
nosuppressive drugs. Consider administration of
a second dose of HBIG at 4 weeks after transplanta-
tion (AIII). Monitor ALT and HBV DNA monthly.
If HBV DNA is positive during lamivudine prophy-
laxis, treatment may be modified as detailed later.
If the donor is anti-HBc positive, but negative for
both HBsAg and anti-HBs, the donor should be tested
for HBV DNA (BIII). If the HBV DNA assay is posi-
tive, treat as described in the bullets earlier for a donor
with a detectable HBV viral load (BIII). If HBV DNA
testing is negative, repeat testing of the donor at the
time of harvest should be considered. If HBV DNA
remains negative, HCT is performed without further
precaution (DIII). If the repeat test is positive, treat
as described before (BIII).
HBV-naı¨ve HCT recipients who are in a monoga-
mous relationship with a known HBsAg carrier, or
who are sexually active and not in a long-term monog-
amous relationship, should always use latex condoms
during sexual contact to reduce their risk of primary
HBV infection (AIII) [370].
Preventing disease
For HCT candidates with evidence of past exposure
to HBV (ie, who are anti-HBc positive), the specific rec-
ommendations depend on the pattern of test results.
Because the risk of post-HCT hepatitis is reduced via
adoptive transfer of a donor’s natural immunity, equally
suitable donors demonstrating natural immunity (anti-
HBs positive, anti-HBc positive) are preferred over do-
nors without natural immunity for recipients with
evidence of prior HBV exposure [364].
If the HCT recipient is anti-HBc positive and anti-
HBs positive, the risk of HBV reactivation is consid-
ered low during chemotherapy/conditioning, but
higher following prolonged treatment with prednisone
for GVHD. Serum ALT should be followed in suchpatients, and if the level increases, HBV DNA load
should be assessed. Patients with a positive HBV
DNA load should receive preemptive antiviral treat-
ment as described later (AIII). Prophylactic antiviral
treatment may be considered for anti-HBc positive
and anti-HBs positive recipients before, and for 1 to
6 months after, HCT (CIII). Additionally, anti-HBs
levels should be monitored every 3 months. Reduction
in anti-HBs titer should prompt HBV DNA testing
(BIII) [371]. Patients who lose anti-HBs responses,
but have no HBV DNA in the serum, should receive
active immunization in an attempt to restore protec-
tive levels of anti-HBs (BIII). Patients with positive
HBV DNA assays should receive antiviral therapy
(AIII). The duration of antiviral treatment in this set-
ting has not been studied, but a common practice is
to continue therapy for at least 6 months following
discontinuation of immune suppressive drugs (BIII)
[372-374]. Rebound HBV replication and clinical hep-
atitis may follow discontinuation of antiviral treatment
and should be monitored by regular measurement of
ALT and HBV DNA (eg, biweekly) (BIII).
HCT candidates with evidence of active HBV rep-
lication (HBsAg positive and/or HBV DNA positive)
should have a liver biopsy prior to HCT, because pre-
existing biopsy-proven cirrhosis and hepatic fibrosis
can increase treatment-related morbidity and mortal-
ity (TRM) (BIII). Antiviral therapy should be initiated
prior to conditioning. If HCT is not urgent, antiviral
treatment should be administered for 3 to 6 months
prior to conditioning. In patients with persisting
HBV DNA while on therapy with lamivudine, treat-
ment may be modified as detailed later. Rebound
HBV replication and fulminant hepatitis may occur
following discontinuation of antiviral treatment.
Therefore, discontinuation of antiviral therapy should
be performed judiciously, with frequent monitoring of
liver function and HBV DNA (BIII).
HCT candidates who are positive for anti-HBc but
negative for HBsAg and anti-Hbs should be tested for
HBV DNA. If HBV DNA is undetectable, the patient
should receive HBV vaccination as described before
and proceed to HCT. Further management regarding
monitoring and antiviral treatment should be per-
formed as described for anti-HBc-positive and anti-
HBs-positive HCT candidates (BIII). If HBV DNA
is positive, proceed to HCT with preemptive antiviral
therapy as described above.
Antiviral treatment. Therapy should be coordi-
nated between the HCT physician and infectious
disease and/or hepatology specialist(s) with expertise
in chronic viral hepatitis. Lamivudine (100 mg/day) is
the first choice for antiviral therapy (AI). Antiviral ther-
apy should be continued for at least 6 months posttrans-
plant in autologous HCT patients, for 6 months
following discontinuation of immune suppressive drugs
in allogeneic HCT patients, and longer in patients
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tended use of lamivudine not only results in reduction
of HBV reactivation and the resultant complications,
but also lowers HBV-associated mortality [375,376].Recommendations Regarding Hepatitis C Virus
(HCV)
HCT from donors who are HCV-RNA-positive
invariably transmits HCV to uninfected recipients,
with development of viremia in the immediate post-
transplantation period [377]. Conversely, the risk of
transmission is decreased if HCV-RNA is undetect-
able at the time of hematopoietic cell donation [377].
There is no evidence of adverse short-term effects of
HCV infection in HCT recipients, and HCV-infected
HCT patients have similar morbidity up to 10 years af-
ter transplant [378]. Subsequently, however, these pa-
tients are at risk for progression to cirrhosis, which
may occur more rapidly than in non-HCT patients.
The cumulative incidence of biopsy-proven cirrhosis
is 11% and 24% at 15 and 20 years posttransplant,
respectively, with a median of 18 years compared
with 40 years for non-HCT HCV-infected patients
[379]. Extrahepatic manifestations and infection with
HCV genotype 3 increase the risk for progression.
Preventing exposure
All HCT candidates should be assessed for the risk
of HCV infection with a careful history, physical
examination, and serum ALT testing (BIII), as well
as measurement of anti-HCV antibody titers (AII).
Even if anti-HCV titers are negative, nucleic acid test-
ing for HCV RNA should be undertaken in patients
whose history indicates increased risk for HCV infec-
tion (eg, transfusion with blood not tested for HCV-
reliable testing of the blood supply began in 1992 in
developed countries; i.v. or inhaled drug abuse; or tat-
toos) or who have an unexplained elevation of serum
ALT (AII) [380].
HCV-infected patients requiring HCT and for
whom there is no alternative donor can proceed with
HCT from an HCV-positive donor, provided they
have full understanding of the long-term side effects
(BIII) [378]. The donor should be assessed for chronic
liver disease and other extrahepatic manifestations of
HCV, which might contraindicate donation (EIII).
Similar to recipients, all donors should be screened
for anti-HCV antibodies, and those found to be anti-
HCV-positive or at high risk for HCV infection should
be tested for HCV-RNA (AII). If feasible, viral
clearance with standard combination antiviral therapy
prior to stem cell harvest may be attempted in donors
with detectable HCV RNA. However, there are few
reports on success of this method [381,382]. Both the
donor and recipient should be counseled on individual
risks (BIII).Preventing disease progression
All HCT candidates with HCV infection must be
assessed for evidence of chronic liver disease. To assess
the risk of conditioning and HCT, liver biopsy is war-
ranted in the following clinical situations (AIII):
 Associated iron overload
 History of excessive alcohol intake
 History of hepatitis C for .10 years
 Clinical evidence of chronic liver disease.
Patients with evidence of cirrhosis or hepatic fibro-
sis should not be considered for conventional MA
conditioning therapy that contains either Cy or TBI
$12 Gy (DIII), because those regimens are associated
with a 9.6-fold increased risk of fatal SOS in these
patients [378]. Instead, regimens that do not contain ei-
ther Cy or TBI, which pose a lower risk for fatal SOS,
should be used [383]. For patients with cirrhosis, how-
ever, even an RIC regimen poses a mortality risk [384].
Treatment for chronic HCV should be considered
in all HCV-infected HCT recipients, because limited
data suggest improved outcome in those who respond
to combination therapy (BIII) [385]. To qualify for
antiviral treatment, the patient must be in complete
remission from the original disease, be $2 years post-
transplant without evidence of either protracted
aGVHD or cGVHD, have been off immunosuppres-
sion for 6 months, and have normal blood counts and
serum creatinine (BIII). Treatment should consist of
full-dose peginterferon and ribavirin (BIII). Dose
modifications should be made if intolerance develops
(eg, development of cytopenias). In survivors whose
neutrophil and platelet counts are below normal at
baseline, daily interferon alpha can be substituted for
peginterferon to assess hematologic toxicity before
moving to peginterferon. Treatment should be contin-
ued for 24 to 48 weeks, depending on response.Human Herpesviruses 6 and 7
Preventing exposure
Human herpesvirus 6 (HHV-6) is the cause of the
classic childhood illness roseola, which is also known
as exanthema subitum or sixth disease [386]. Clinical
disease associated with human herpesvirus 7 (HHV-
7) infection remains to be defined. Nearly all children
are infected with HHV-6 by 2 to 3 years of age
[387-389] and HHV-7 by the age of 5 years [390].
Preventing disease and disease recurrence
The spectrum of HHV-6-associated complications
after HCT has not been completely described. HHV-6
reactivation is common during the early allogeneic
HCT transplant period, with viremia occurring in ap-
proximately 40% to 60% of patients [387,391-394].
The clinical significance of detection of HHV-6
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the posttransplant setting with hepatitis, fever, rash, id-
iopathic pulmonary syndrome, and delayed platelet and
monocyte engraftment. HHV-6 can also be chromoso-
mally integrated, potentially resulting in a false-positive
PCR assay result [395]. A posttransplantation acute lim-
bic encephalitis syndrome associated with HHV-6
reactivation in the cerebral spinal fluid (CSF) has been
reported [396]. This syndrome is uncommon, occur-
ring in approximately 1% to 2% of HCT patients in
some series. It typically occurs 1 to 2 months posttrans-
plantation and appears to be more common after receipt
of a UCB or HLA-mismatched graft. Manifestations in-
clude profound memory loss, seizures, hyponatremia,
mild CSF pleocytosis, and significant mesial temporal
lobe abnormalities on magnetic resonance imaging
(MRI) [396,397]. In addition, HHV-6 may interfere
with MHC class I antigen presentation and augment lo-
cal immunosuppression [398]; however, the implica-
tions of this viral property are unknown. The role of
HHV-7 in posttransplant complications remains to be
defined.
At this time, there are no data to guide preemptive
monitoring or a prophylactic antiviral strategy to pre-
vent potential HHV-6-associated disease (DIII). Gan-
ciclovir, cidofovir, and foscarnet have variable in vitro
activity against HHV-6, and may have a role in treat-
ing HHV-6-associated disease [399,400]. There are
no data to support recommendations for monitoring
of potential HHV-7-associated disease (DIII).Human Herpesvirus 8
Preventing exposure
Human herpesvirus type 8 (HHV-8) is the cause of
Kaposi’s sarcoma, and is also known as KSHV. Unlike
other herpesvirus infections, HHV-8 infection is not
ubiquitous. There is significant geographic variability
in prevalence of HHV-8 infection, with high infection
rates reported in sub-Saharan Africa (50%), modest
rates in the United States (about 5%), and low rates
in Japan (\1%). In the United States, higher rates of
HHV-8 infection have been identified in men who
have sex with men, perhaps indicating sexual transmis-
sion or enhanced transmission through saliva.
Preventing disease and disease recurrence
HHV-8-associated disease (eg, Kaposi’s sarcoma)
occurs only rarely after HCT [401-404]. At this time,
there are no data to guide monitoring or preemptive
antiviral treatment for posttransplant HHV-8-associ-
ated disease (DIII).Human Immunodeficiency Virus
In patients with HIV and receiving HAART ther-
apy, cancer is now the leading cause of death [405].Consequently, HCT may need to be considered for
these patients.
Preventing exposure
As described in the Hematopoietic Cell Graft
Safety section, regulations are in place in both the
United State and the European Union for evaluation
of donors to minimize risk of transmissible diseases
[78-80,82,83]. Using a related donor with known
HIV harbors significant risks that likely outweigh
any benefits of transplantation to a seronegative recip-
ient, and should not be considered (DIII).
Preventing disease and disease recurrence
Patients with HIV and a malignancy treated by
transplantation should not automatically be excluded
from this potentially life-saving therapy. Reports of
autologous transplantation suggest that this is a feasible
approach in patients with controlled HIV disease
(BIII) [406-410]. Outcomes after allogeneic transplan-
tation are quite limited, although 1 report suggests that
in the current era of HAART therapy, this may be con-
sidered (CIII) [411]. Because of significant complexity
in the management of HIV-positive patients, it is rec-
ommended that any HIV-positive patient considered
for HCT be enrolled on a clinical trial and the patient
be comanaged with an HIV specialist.FUNGAL INFECTION PREVENTION
AFTER HCT
K.A. Marr, E. Bow, T. Chiller, G. Maschmeyer, P.
Ribaud, B. Segal, W. Steinbach, J.R. Wingard, M. Nucci
General Recommendations
Preventing exposure
Hematopoietic cell transplantation (HCT) recipi-
ents and candidates undergoing conditioning therapy
should avoid substances, including certain foods
(Table 5), which increase the risk of exposure to fungi
(DIII).
Preventing disease
Growth factors (eg, granulocyte-macrophage col-
ony-stimulating factor [GM-CSF] and G-CSF)
shorten the duration of neutropenia after HCT
[412]. However, a meta-analysis showed that use of
growth factors did not reduce the attack rate of inva-
sive fungal disease [165], and therefore, no recommen-
dation can be made for the use of growth factors for
prophylaxis against invasive fungal disease (CI).
Topical antifungal drugs applied to the skin or
mucosa (eg, nystatin or clotrimazole) might reduce
colonization by yeasts and molds in the area of applica-
tion. However, these agents have not been proved to
able 5. Foods That Hematopoietic Cell Transplant (HCT) Recipients May Eat (BIII) or Should Avoid (DIII) Until Having Reached the Milestone of Live Virus Vaccination following HCT
Food Groups May Eat (BIII) Do Not Eat (DIII)
airy $ All pasteurized, grade ‘‘A’’ milk and milk products including eggnog, yogurt, ice cream, frozen
yogurt, sherbet, ice cream bars, milkshakes, processed cheese slices and spreads, cream cheese,
cottage cheese, and ricotta cheese
$ Dry, refrigerated, or frozen pasteurized whipped topping
$ Commercially packaged hard and semisoft cheeses such as cheddar, mozzarella, parmesan, Swiss,
Monterey Jack, etc.
$ Cooked soft cheeses such as brie, camembert, feta, farmer’s cheese *
$ Commercially sterile ready-to-feed and liquid-concentrate infant formulas (avoid powdered infant
formulas if a ready-to-feed or liquid concentrate
alternative is available)
Note: although not completely risk free, the risk of contracting food borne illness fromCOOKED soft
cheeses is low.
$ Nonpasteurized or raw milk
$ Milk products made from nonpasteurized or raw milk.
$ Cheeses from delicatessens
$ Cheese containing chili peppers or other uncooked vegetables
$ Cheeses with molds (such as blue, Stilton, Roquefort, gorgonzola)
$ Mexican-style soft cheese such as queso fresco, queso blanco
eat and meat substitutes $ All meats cooked to well done (poultry >180 ; other meats >160)
$ Canned meats (beef, pork, lamb, poultry, fish, shellfish, game, ham, bacon, sausage, hot dogs)
$ Eggs cooked until both white and yolk are firm
$ Pasteurized eggs and egg substitutes (such as Egg Beaters), and powdered egg white (all can be
used uncooked)
$ Commercially packaged salami, bologna, hot dogs, ham, and other luncheon meats, heated until
steaming
$ Canned and shelf-stable* smoked fish (refrigerate after opening)
$ Pasteurized or cooked tofu†
$ Refrigerated smoked seafood such as salmon or trout if
cooked to 160F or contained in a cooked dish or casserole
$ Raw or undercooked meat, poultry, fish, game, tofu*
$ Raw or undercooked eggs and nonpasteurized egg
substitutes; no eggs over easy, soft-boiled eggs, or poached eggs.
$ Meats and cold cuts from delicatessens
$ Hard cured salami in natural wrap
$ Uncooked refrigerated smoked seafood such as salmon
or trout labeled as ‘‘nova-style,’’ ‘‘lox,’’
‘‘kippered,’’ ‘‘smoked,’’ or ‘‘jerky’’
$ Pickled fish
$ Tempe (tempeh) products
ruits and nuts $ Well washed‡ raw and frozen fruit;
$ Foods containing well-washed raw fruits
$ Cooked, canned, and frozen fruit
$ Pasteurized juices and frozen juice concentrates
$ Dried fruits
$ Canned or bottled roasted nuts
$ Shelled, roasted nuts, and nuts in baked products
$ Commercially packaged nut butters (such as peanut butter,
almond butter, soybean butter)
$ Unwashed raw fruits
$ Fresh or frozen berries
$ Unroasted raw nuts
$ Roasted nuts in the shell
$ Nonpasteurized fruit and vegetable juices
$ Fresh fruit salsa found in the grocery refrigerator case
$ Nonpasteurized items containing raw fruits found in the
grocery refrigerator case
ntrees, soups $All cooked entrees and soups $All miso products (such as miso soup and miso paste)
egetables $ Well washed‡ raw and frozen vegetables
$ All cooked fresh, frozen, or canned vegetables, including potatoes
$ Shelf-stable* bottled salsa (refrigerate after opening)
$ Cooked vegetable sprouts (such as mung bean sprouts)
$ Fresh, well-washed‡ herbs and dried herbs and spices
(added to raw or cooked foods)
$ Unwashed raw vegetables or herbs
$ Fresh, nonpasteurized vegetable salsa found in the
grocery refrigerator case
$ Nonpasteurized items containing raw vegetables
found in the grocery refrigerator case
$ All raw vegetable sprouts (alfalfa sprouts, clover
sprouts, mung bean sprouts, all others)
$ Salads from delicatessens
read, grain, and cereal products $ All breads, bagels, rolls, English muffins, muffins, pancakes,
sweet rolls, waffles, French toast
$ Potato chips, corn chips, tortilla chips, pretzels, popcorn
$ Cooked grains and grain products, including pasta and rice
$ All cereals, cooked and ready-to-eat
$ Raw (not baked or cooked) grain products (such as raw oats)
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Beverages $ Boiled well water§
$ Tap water and ice made from tap water¶
$ Commercially bottled distilled, spring, and natural waterst
$ All canned, bottled and powdered beverages
$ Instant and brewed coffee and tea; cold brewed tea made with boiling water
$ Herbal teas brewed from commercially packaged tea bags
$ Commercial nutritional supplements,
both liquid and powdered
$ Commercially sterile ready-to-feed and liquid-concentrate
infant formulas (avoid powdered infant formulas if
a ready-to-feed or liquid concentrate alternative is available)
$ Unboiled well water
$ Cold-brewed tea made with warm or cold water
$ Nonpasteurized fruit and vegetable juices
$ Mate´ tea
$ Wine, nonpasteurized beer
(Note: all alcoholic beverages should only be consumed
following physician approval.)
Desserts $ Refrigerated commercial and homemade cakes, pies, pastries, and pudding
$ Refrigerated cream-filled pastries
$ Cookies, both homemade and commercially prepared
$ Shelf-stable‡ cream-filled cupcakes (such as Twinkies, Ding Dongs) and fruit pies (such as
Poptarts and Hostess fruit pies)
$ Canned and refrigerated puddings
$ Ices, popsicles, and similar products
$ Candy, gum
$Unrefrigerated cream-filled pastry products (not shelf-stable‡)
Fats $ Vegetable oils and shortening
$ Refrigerated lard, margarine, butter
$ Commercial, shelf-stable‡ mayonnaise and salad dressings
including Blue Cheese and other cheese-based salad
dressings (refrigerate after opening)
$ Cooked gravy and sauces
$Fresh salad dressings (stored in the grocer’s refrigerated
case) containing raw eggs or cheeses listed as ‘‘Do Not Eat’’ under ‘‘Dairy.’’
Other $ Commercial pasteurized Grade A honey**
$ Salt, granulated sugar, brown sugar
$ Jam, jelly, syrups (refrigerate after opening)
$ Catsup, mustard, BBQ sauce, soy sauce, other condiments (refrigerate after opening)
$ Pickles, pickle relish, olives (refrigerate after opening)
$ Vinegar
$ Raw honey; honey in the comb
$ Herbal and nutrient supplement preparations
$ Brewers yeast, if uncooked
Concern arising from the detection of potential pathogens in food has not been supported by documented evidence of such organisms as the source of opportunistic infections in immunocompromised persons. The
potential benefit of food safety recommendations directed specifically toward HCT recipients must be weighed against the uncertain value of such recommendations [767] and their potential to adversely affect
patients‘ nutritional intake and/or quality of life.
*Shelf-stable refers to unopened canned, bottled, or packaged food products that can be stored before opening at room temperature; container may require refrigeration after opening.
†Aseptically packaged, shelf-stable tofu and pasteurized tofu do not need to be boiled. Nonpasteurized tofu must be cut into 1-inch cubes or smaller, and boiled a minimum of 5 minutes in water or broth before eating
or using in recipes.
‡Rinse under clean, running water before use, including produce that is to be cooked or peeled (such as bananas, oranges, and melon).
§Bring tap water to a rolling boil and boil for 15-20 minutes. Store boiled water in the refrigerator. Discard water not used within 48 hours (2 days).
¶Recommend using boiled or bottled water if using a water service other than city water service. Please see Water Safety Guidelines in ‘‘Food Safety Guidelines.’’
tSee Water Safety Guidelines in ‘‘Food Safety Guidelines’’ for approved bottled water treatments.
**Honey products are not allowed for any child less than 1 year of age and not allowed for children with SCIDS until 9 months posttransplant.
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Table 6. Vaccinations Recommended for Both Autologous and Allogeneic HCT Recipients
Vaccine
Recommended
for Use after HCT
Time Post-HCT to
Initiate Vaccine
Number
of Doses*
Improved by Donor Vaccination
(Practicable Only in Related-Donor Setting)
Pneumococcal
Conjugate (PCV)
Yes (BI) 3-6 months 3-4† Yes; may be considered when the recipient is
at high risk for chronic GVHD
Tetanus, diphtheria,
acellular pertussis‡
Yes
Tetanus-diphtheria: (BII)
Pertussis (CIII)
6-12 months 3§ Tetanus: likely
Diphtheria: likely
Pertussis: unknown
Haemophilus
influenzae
conjugate
Yes (BII) 6-12 months 3 Yes
Meningococcal conjugate Follow country recommendations for
general population (BII)
6-12 months 1 Unknown
Inactivated polio Yes (BII) 6-12 months 3 Unknown
Recombinant
Hepatitis B
Follow country recommendations for
general population (BII)
6-12 months 3 Likely¶
Inactivated
Influenza
Yearly (AII) 4-6 months 1 -2t Unknown
Measles-
Mumps-
Rubella††
Measles: all children and seronegative adults
Measles: BII
Mumps: CIII
Rubella: BIII
24 months 1 -2‡‡ Unknown
(live) EIII (<24 months post-HCT, active GVHD,
on immune suppression)
HCT indicates hematopoietic cell transplant; GVHD, graft-versus-host disease.
*A uniform specific interval between doses cannot be recommended as various intervals have been used in studies. As a general guideline, a minimum of
1 month between doses may be reasonable.
†Following the primary series of 3 PCV doses, a dose of the 23-valent polysaccharide pneumococcal vaccine (PPSV23) to broaden the immune response
might be given (BII). For patients with chronic GVHDwho are likely to respond poorly to PPSV23, a fourth dose of the PCV should be considered instead
of PPSV23 (CIII).
‡DTaP is preferred, however, if only Tdap is available (eg, because DTaP is not licensed for adults), administer Tdap. Acellular pertussis vaccine is pre-
ferred, but the whole-cell pertussis vaccine should be used if it is the only pertussis vaccine available. (See text for more information.)
§See text for consideration of an additional dose(s) of Tdap for older children and adults.
¶Significant improvement of recipient response to hepatitis B vaccine posttransplant can be expected only if the donor receives more than 1 hepatitis
vaccine dose prior to donation.
tFor children <9 years of age, 2 doses are recommended yearly between transplant and 9 years of age [306].
††Measles, mumps, and rubella vaccines are usually given together as a combination vaccine. In females with pregnancy potential, vaccination with rubella
vaccine either as a single or a combination vaccine is indicated.
‡‡In children, 2 doses are favored.
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infections and their use for prophylaxis is unclear
(CIII). Performing fungal surveillance cultures is not
indicated for asymptomatic HCT recipients (DII)
[413,414].
Other recommendations
Patients receiving antifungal prophylaxis who de-
velop clinical signs or symptoms of infection should
be evaluated for breakthrough bloodstream or pulmo-
nary fungal infections (AIII). Such infections may oc-
cur because the prophylactic drug has no activity
against the organism; because the organism has
developed resistance to the drug; or because of other
factors, such as severe immunosuppression or low
serum levels of the prophylactic agent [415].
Recommendations Regarding Yeast Infections
Preventing exposure
The risk for invasive candidiasis is significantly
higher during the early posttransplant period (phase
I) because of neutropenia, severe mucositis, and the
presence of a central venous catheter (CVC) [416].During phase II, the risk factors for invasive candidia-
sis are the presence of a CVC and severe gastrointesti-
nal (GI) graft-versus-host disease (GVHD) [416].
Among autologous HCT recipients, the risk of inva-
sive candidiasis is minimal once neutropenia and
mucositis have resolved.
Invasive candidiasis is usually caused by dissemina-
tion of endogenous Candida species that have
colonized a patient’s GI tract [417]. Consequently,
methods of preventing exogenous yeast exposure usu-
ally do not prevent invasive yeast infections after
HCT. However, because Candida species can be car-
ried on the hands, HCWs and others in contact with
HCT recipients should follow appropriate hand-
washing practices to avoid exposing patients to fungal
pathogens (AII).
Preventing disease
Fluconazole is the drug of choice for the prophy-
laxis of invasive candidiasis before engraftment in
allogeneic HCT recipients, and may be started from
the beginning or just after the end of the conditioning
regimen (AI) [418,419]. Low-dose fluconazole has
variable efficacy; therefore, doses lower than 200 mg
Table 7. Vaccinations Considered Optional or Not Recommended for Both Autologous and Allogeneic HCT Recipients
Optional
Vaccine Recommendations for use Rating
Hepatitis A Follow recommendations for general population in each country
 Ig should be administered to hepatitis A-susceptible HCTrecipients
who anticipate hepatitis A exposure (eg, during travel to
endemic areas) and for postexposure prophylaxis.
CIII
Varicella (Varivax)
(live)
Limited data regarding safety and efficacy. EIII (<24 months post- HCT, active
GVHD, or on immunosuppression)
CIII (>24 months, without active
GVHD, or on immunosuppression)
Human papillomavirus Follow recommendations for general population in each country
No data exist regarding the time after HCTwhen vaccination
can be expected to induce an immune response
CIII
Yellow fever (live) Limited data regarding safety and efficacy.
The risk-benefit balance may favor use of the vaccine in
patients residing in or traveling to endemic areas.
EIII (<24 months, active GVHD,
or on immunosuppression)
CIII (>24 months, without active GVHD,
or on immunosuppression)
Rabies Appropriate for use in HCT recipients with potential
occupational exposures to rabies [827]
Preexposure rabies vaccination should probably be delayed until
12-24 months after HCT.
Postexposure administration of rabies vaccine with human rabies
Ig can be administered any time after HCT as indicated* [827,828]
CIII
Tick-borne encephalitis (TBE) According to local policy in endemic areas.
No data exist regarding the time after HCTwhen
vaccination can be expected to induce an immune response
CIII
Japanese B encephalitis According to local policy when residing in or
traveling to endemic areas.
No data exist regarding the time after HCTwhen
vaccination can be expected to induce an immune response
CIII
Not Recommended
Vaccine Recommendations for use Rating
Bacillus
Calmette-Guerin (live)
Contraindicated for HCTrecipients EII
Oral poliovirus vaccine (live) Should not be given to HCT recipients since an effective, inactivated alternative exist EIII
Intranasal influenza vaccine (live) No data regarding safety and immunogenicity.
Should not be given to HCT recipients since an effective, inactivated alternative exist
EIII
Cholera No data were found regarding safety and immunogenicity among HCT recipients DIII
Typhoid, oral (live) No data were found regarding safety and immunogenicity among HCT recipients. EIII
Typhoid (intramuscular) No data were found regarding safety, immunogenicity, or efficacy among HCTrecipients. DIII
Rotavirus Must be given before 12 weeks of age to be safe. EIII
Zoster vaccine (Zostavax)
(live)
No data regarding safety among HCT recipients. EIII
HCT indicates hematopoietic cell transplantation; GVHD, graft-versus-host disease.
*Current Advisory Committee on Immunization Practices (ACIP) and American Academy of Pediatrics guidelines for postexposure human rabies im-
munoglobulin and vaccine administration should be followed, which include administering 5 doses of rabies vaccine administered on days 0, 3, 7, 14, and
28 postexposure.
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of fluconazole prophylaxis—specifically, whether
prophylaxis confers significant benefits when contin-
ued postengraftment—is not defined. A post hoc anal-
ysis of a randomized clinical trial has shown that
fluconazole given until day 75 posttransplant was
associated with prolonged protection against invasive
candidiasis, even beyond the period of prophylaxis
[420].
Fluconazole is not effective against Candida krusei,
and has variable activity against C. glabrata, which can
become resistant [421]; moreover, the use of flucona-
zole for prophylaxis may result in the selection of
azole-resistant Candida species (principally C. glabrataand C. krusei) [422]. Therefore, fluconazole is not
recommended for prevention of such infections (DI).
This may be a consideration in patients who are known
to be colonized with fluconazole-resistant Candida
species.
Cros-sresistance to azoles (ie, fluconazole, vorico-
nazole, posaconazole) may occur among Candida
species, particularly C. glabrata [423,424]. Therefore,
clinicians should be alert for the possibility of break-
through infection with resistant organisms in patients
receiving prophylaxis with any azole drug (CIII).
Micafungin is an alternative prophylactic agent, as
1 study has shown it to be comparable to fluconazole
for preventing possible or documented fungal
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tic agent is limited by the necessity of i.v. infusion and
cost. There have been case reports of sporadic resis-
tance to echinocandin antifungal agents [426].
Itraconazole oral solution has been shown to pre-
vent invasive fungal infections, but use of this drug is
limited by poor tolerability and toxicities (CI)
[427,428]. If antimold activity is warranted in antifun-
gal prophylaxis, posaconazole and voriconazole are
options [429,430]. Posaconazole has not been studied
in the preengraftment phase of HCT. Few HCT
recipients require prophylaxis against Candida in the
postengraftment period (phases II and III), but if
needed (eg, because of the presence of GVHD),
options include voriconazole (BI) [430] and posacona-
zole (BI) [429].
Oral, nonabsorbable antifungal drugs, including
oral amphotericin B (500 mg suspension every
6 hours), nystatin, and clotrimazole troches, might re-
duce superficial colonization and control local mucosal
candidiasis, but have not been demonstrated to reduce
invasive candidiasis (CIII).Other recommendations
HCT candidates with candidemia or invasive can-
didiasis can safely receive transplants [431] if (1) their
infection was diagnosed early and treated immediately
and aggressively with effective anti-Candida therapy;
and (2) there is evidence of infection control before
the transplant (BIII). Such patients should continue re-
ceiving therapeutic doses of an appropriate antifungal
drug throughout phase I (BII) and until a careful review
of clinical, laboratory, and serial computed tomogra-
phy scans verifies resolution of candidiasis (BII). As ra-
diographic abnormalities may persist for a long period
of time among patients with hepatosplenic candidiasis,
complete resolution is not necessary before transplan-
tation, provided that the patient has received appropri-
ate therapy and shows clinical improvement.
Because autologous recipients generally have an
overall lower risk for invasive fungal infection than al-
logeneic recipients, most autologous recipients do not
require routine antiyeast prophylaxis (CIII). However,
experts recommend administering antiyeast prophy-
laxis to a subpopulation of autologous recipients who
have underlying hematologic malignancies (eg, lym-
phoma, leukemia, or myeloma) and who have or will
have prolonged neutropenia and mucosal damage
from intense conditioning regimens or graft manipula-
tion, or have received fludarabine (Flu) or 2-CDA
within the 6 months prior to HCT (BIII). Recommen-
dations regarding the prevention of invasive yeast
infections are the same among pediatric and adult
HCT recipients, except that appropriate dose adjust-
ments for prophylactic drugs should be made for
pediatric recipients (Appendix 1).When considering continuation of antifungal ther-
apy in patients with prior infection, HCT clinicians
should be mindful of drug interactions, especially with
calcineurin inhibitors, particularly with drugs in the
azole class, which affect cytochrome P450 metabolism
[432]. Results of recent studies suggest differential toxi-
cities and effects on cyclophosphamide (Cy) meta-
bolites with coadministration of different azole drugs
[432,433]. Specifically, coadministration of fluconazole
was associated with fewer early toxicities and different
metabolites compared with itraconazole [433]. This
was hypothesized to be because of fluconazole inhibition
of cytochrome P450 2C9 providing a ‘‘protective’’ effect
compared to itraconazole, which inhibits only P450 3A4
[432]. In general, clinicians should be careful about co-
administering drugs that have an impact on any cyto-
chrome subunits active in conditioning metabolism.Recommendations Regarding Mold Infections
Preventing exposure
Nosocomial mold infections among HCT recipi-
ents result primarily from respiratory exposure to
and direct contact with fungal spores [434]. Measures
for minimizing exposure to mold in HCT candidates
and recipients are discussed in the Infection Preven-
tion and Control in Health care Facilities section.
In addition to air, water may also be a source of
pathogenic fungi. Opportunistic molds (eg, Aspergil-
lus and Fusarium species) are present in the water
and on water-related surfaces of hospitals caring for
cancer patients, and molecular studies have suggested
potential relatedness of environmental and clinical
strains among patients with aspergillosis and fusario-
sis [435-437]. Therefore, hospital water should be
considered a potential source of nosocomial invasive
mold infections. Although some investigators believe
it is necessary to decrease patient exposure during pe-
riods of severe immunosuppression [438], current
data are insufficient to support the formulation of de-
finitive recommendations. Cleaning of water-related
structures in patients’ bathrooms may be attempted
[435,436].
Preventing disease
Invasive mold infections have a trimodal incidence
distribution among allogeneic HCT recipients
[439-441]. Before engraftment (ie, during phase I),
the main risk factor is prolonged neutropenia, and
therefore, the risk is higher with bone marrow (BM)
and umbilical cord blood (UCB) transplants and lower
with peripheral blood (PB) and nonmyeloablative
(NMA) transplants. In addition, the risk is higher
among patients with prolonged low-level neutropenia
prior to transplant, such as aplastic anemia (AA) pa-
tients. In phases II and III, the main risk factor is severe
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and its treatment. Therefore, recipients of transplants
with higher risks for severe GVHD (unrelated donor,
mismatched transplant, haploidentical) are at greater
risk of mold infections. Patients at high risk for mold
infections should be considered for prophylaxis with
mold-active drugs during periods of risk (BI).
Trials assessing the efficacy of cyclodextrin oral
solution and intravenous formulations of itraconazole
have shown efficacy in preventing mold infections (BI),
but the benefit was offset by poor tolerance and toxic-
ity of the oral formulation, with 25% discontinua-
tion for GI side effects [427,433].One study has
shown micafungin to be effective in preventing inva-
sive fungal infections (including fever) when adminis-
tered during neutropenia [425], but the incidence of
invasive aspergillosis is low during the preengraftment
phase, so antimold efficacy could only show a display
of activity rather than efficacy (BI). Experience with
other echinocandins (eg, caspofungin) demonstrates
some efficacy (CII), but breakthrough mold infections
during echinocandin prophylaxis have been reported
[442]. Fluconazole has no activity against molds
[443]. Based on the results of a study presented to
date only in abstract form [430], voriconazole appears
to be an alternative to fluconazole prophylaxis. Be-
cause the results of this study have not been presented
in detail, the committee is not assigning a recommen-
dation. Specific molds are resistant to certain drugs
(eg, voriconazole does not have activity against Zygo-
mycetes, and Scedosporium prolificans is resistant to all
available antifungal agents).
In patients with GVHD, posaconazole has been
reported to prevent invasive mold infections (BI)
[429]. In 1 study, patients with GVHD were random-
ized to receive either fluconazole (400 mg) or posaco-
nazole (200 mg 3 times daily). Results showed a trend
toward a lower incidence of invasive fungal infection,
with particular differences in mold infections. The op-
timal duration of prophylaxis in the setting of GVHD
is not defined.
Aerosolized liposomal amphotericin B has been
found to be effective in reducing invasive pulmonary
aspergillosis in 1 randomized trial that included leuke-
mia and HCT patients and can be considered as an al-
ternative to mold-active azoles (BII) [444]. However,
administration of the drug was interrupted by cough
in many patients, and the optimal aerosol dose and de-
livery device have not yet been determined. Thus, fur-
ther study is needed before its role can be determined.
Other recommendations
Patients with prior invasive aspergillosis should
receive secondary prophylaxis with a mold-active
drug (AII). The optimal drug has not been determined,
but voriconazole has been shown to have benefit for
this indication (AII) [445].Recommendations Regarding Serum Level
Monitoring
Absorption of itraconazole and posaconazole is
poor in patients who are not eating. Meta-analyses
suggest that the efficacy of itraconazole is associated
with bioavailability; blood levels of .0.5 mg/mL are
associated with effective prevention of proven invasive
fungal infection [446]. Posaconazole levels for thera-
peutic effectiveness have not been established. Median
levels of posaconazole are relatively lower in patients
who have aGVHD and symptomatic diarrhea [447].
Voriconazole blood levels of at least 1 mg/mL are
thought to be required for efficacy. Low voriconazole
levels have been reported in patients with documented
breakthrough infections [415].
There is relative controversy over the utility of
routine monitoring of azole drug levels, but most clini-
cians agree that measurement of levels should be con-
sidered in patients who have documented
breakthrough infection. A change to, or addition of,
an antifungal agent of a different class is advisable until
the blood level has been determined. If the level is
found to be low, then consideration can be given to
resuming the earlier drug at a higher dose (CIII)
[415,448].REGIONALLY LIMITED OR RARE
INFECTIONS—PREVENTION AFTER HCT
J. Gea-Banacloche, H. Masur, C. Arns da Cuhna, T.
Chiller, L. Kirchoff, P. Shaw, M. Tomblyn, C. Cordonnier
This section covers infections that are prevalent
only in certain geographic areas, or that occur uncom-
monly among hematopoietic cell transplantation
(HCT) recipients. Diseases covered are tuberculosis,
Pneumocystis jiroveci Pneumonia (PCP), toxoplasmosis,
strongyloidiasis, Chagas disease, leishmaniasis, ma-
laria, and Nocardia infection. Other infections, such
as babesiosis, can be transmitted in the course of trans-
plant via blood products, in addition to the hematopoi-
etic cell graft [449]. Guidelines for prevention of these
graft-transmissible infections are found in the Hema-
topoietic Cell Safety Section.
Recommendations Regarding Mycobacterium
tuberculosis
Tuberculosis (TB) is uncommon among HCT re-
cipients. The main risk factor is undergoing transplant
in a country with a high endemic rate of TB [450,451].
In countries where TB is uncommon, TB is more prev-
alent among patients who have come for HCT from
countries or were born in countries with a higher
rate of endemic TB [452,453]. Patients with household
members at risk (eg, recent immigrants, correctional
facility discharges) also deserve particular attention.
It must always be remembered that there is no
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awareness must be maintained in all immunosup-
pressed patients.
The rate of TB reported after HCT is 10 times less
than after solid organ transplantation [454], as HCT
patients do not receive life-long immunosuppression.
However, patients with prolonged immunosuppres-
sion, such as those with chronic graft-versus-host dis-
ease (cGVHD), remain at risk for TB. Because control
of TB is T cell mediated, restoration of T cell function
over time and with cessation of immunosuppression
reduces the patient’s risk of TB.
Most patients who develop TB after HCT have
not had clearly identified risk factors [455,456]. Most
had normal pretransplant chest radiographs and no
direct history of contact with TB. Most had been
transplanted for leukemia, had received total body ir-
radiation (TBI)-based conditioning, and were allograft
recipients. Most were receiving treatment for GVHD
and were .100 days posttransplant.
Although most cases of TB have occurred in allo-
geneic HCT recipients, 20% have occurred in autolo-
gous recipients. Despite this low rate [454,457],
diagnostic vigilance must be maintained. For example,
mycobacterial infection may occur more frequently in
patients who have undergone autologous HCT for
chronic lymphocytic leukemia (CLL), in whom prior
therapy with fludarabine (Flu) and alemtuzumab in-
duces profound T cell deficiency, and susceptibility
to a variety of opportunistic infections [458].
Preventing exposure
HCT candidates and recipients should avoid expo-
sure to persons or environments where there is a sub-
stantial risk of respiratory contact with individuals
with active TB. It is prudent to advise HCT candidates
and recipients that certain occupations (eg, volunteer
work or employment in health care facilities, correc-
tional institutions, or shelters for the homeless) can
increase their risk for TB exposure (BIII) [459].
Preventing disease
Evaluation of patients before HCT. Experts
recommend evaluation for latent or active TB in
patients who are candidates for HCT (BII). Assess-
ment should include a history of:
 Prior active TB
 Prior exposure—evaluate as high-priority contacts
as per CDC guidelines [460].
 Results of previous tuberculin skin tests (TSTs) or
interferon-gamma release assays (IGRA).
Experts disagree about the convenience or benefit
of routinely obtaining a TST or IGRA in every
transplant candidate. Interpretation of the TST
may also be complicated by a history of prior Bacillus
Calmette-Guerin (BCG) vaccination, although tuber-culin reactivity following BCG tends to wane over
time [461]. The American Thoracic Society (ATS)
states that a positive TST may be considered diag-
nostic of latent M. tuberculosis infection in BCG re-
cipients who are at risk for recent M. tuberculosis
infection or who have a medical condition that in-
creases the risk for progression to active TB (CIII)
[462]. Because of prior chemotherapy-induced im-
munosuppression, the TST is not as sensitive in
HCT candidates as it is in the healthy population.
IGRAs are specific for TB, but a negative test does
not exclude latent TB infection, particularly in the
immunocompromised patient. In a meta-analysis,
IGRAs were found to be more sensitive than TST
in immunocompromised patients suspected of having
TB [463]. This was particularly the case among pa-
tients with autoimmune disease and receiving antitu-
mor necrosis factor therapy (eg, infliximab), who are
at particular risk of TB [464]. Studies specifically in
HCT patients are awaited. However, Canada and
the United States have made recommendations for
use of IGRAs in immunocompromised patients
[465,466].
Any patient with a recently positive TST or IGRA
or a history of a positive test and no prior preventive
therapy, should be evaluated for active TB. At a mini-
mum, the patient should be asked about symptoms of
systemic disease and respiratory symptoms such as
cough and shortness of breath, and a chest radiograph
should be assessed (AII) [462]. If active TB is detected,
therapy and appropriate isolation should be initiated.
HCT should be delayed until the active infection is
deemed controlled based on clinical judgment,
because no objective definition of adequate control
has been formulated. If the TST or IGRA is positive,
but no active TB identified, treatment for latent TB
infection (Appendix 1) should be initiated but the
HCT need not be delayed.
Indications for treatment of latent TB infection
or prophylaxis
Because of high risk of reactivation or new infec-
tion, prophylaxis should be administered to immuno-
compromised HCT recipients or candidates who:
 Have been exposed to someone with active, infec-
tious (ie, sputum-smear positive) pulmonary or
laryngeal TB, regardless of the HCT recipient’s or
candidate’s TST or IGRA status (BIII)
 Have a positive TST result—regardless of prior
BCG vaccination—without previous treatment and
no evidence of active TB disease (BII). A positive
TST with a history of BCG vaccination is still con-
sidered by the ATS as an indication for prophylaxis
in patients who ‘‘have medical conditions that
increase the risk for disease’’ [462], which presum-
ably include HCT (CIII)
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ment and no evidence of active TB (BII).
A report of high frequency of reactivation of previ-
ously treated TB following transplantation, especially
in some parts of the world where the endemic preva-
lence of TB is high, suggests such patients may be at
high risk, and therefore, isoniazid (INH) prophylaxis
should be considered (CIII) [467]. The value of prophy-
laxis in countries with a high rate of TB, or in HCT
patients from such countries, should be considered at
an institutional level. Because of the high prevalence
of multidrug-resistant TB in some of these countries,
single-agent prophylaxis may be ineffective. Conse-
quently, maintaining a very high index of suspicion
and providing early intervention may be preferable to
universal prophylaxis. An HCT candidate or recipient
who has been exposed to an active case of extrapulmo-
nary, and therefore noninfectious, TB does not require
preventive therapy (DIII).
Prophylactic regimens
INH is well tolerated post-HCT even with con-
current fluconazole use [450,467,468]. Concurrent
use with itraconazole is not recommended, and the
impact of voriconazole or posaconazole is not known.
INH with pyridoxine should be continued for at least 9
months and until immunosuppression dosages are
substantially reduced (ie, prednisolone \0.5 mg/kg
in children or\20 mg daily in adults) (Appendix 1).
INH can be started at the completion of conditioning
therapy, or prior to conditioning if feasible or if the
clinical situation puts the patient at higher risk of in-
fection. Rifampin given for 4 months is effective but
the potential for substantial drug-drug interactions
between rifampin and immunosuppressive and other
agents generally makes this option impractical. The
combination of pyrazinamide and rifampin (PZA/
RIF) has known significant liver toxicity and its use
post-HCT is not recommended (EII) [469].
Vaccination
BCG vaccination is contraindicated for HCT
candidates (EII). Disseminated BCG infection has
been reported among immunocompromised persons
receiving BCG [470].
Donor evaluation
Donors who live in or originate from countries
where TB is endemic have an increased risk of TB or
latent TB similar to the rest of the population. There
is no known risk from transplanting hematopoietic
progenitor cells from an untreated donor with latent
or active TB. However, it would be prudent for pro-
spective donors with active TB to defer donation until
the TB is well controlled, as determined by the donor’s
primary physician (EIII).Recommendations Regarding PCP
Preventing exposure
Most cases of PCP were traditionally thought to oc-
cur from reactivation of latent infection. However, sug-
gestive animal data and well-documented human cases
indicate that clinical disease can result from recent in-
fection. Moreover, previously infected patients can be
reinfected with new strains of Pneumocystis [471-476].
These observations and some intriguing clusters of
PCP cases have suggested that person-to-person
transmission is possible [477-480].
Neither the CDC nor most hospitals mandate
respiratory precautions regarding patients with PCP.
However, many clinicians consider it logical that
HCT recipients should avoid exposure to patients
with PCP (CIII). There are no data-based guidelines
for how long such PCP patients should be isolated.
Preventing disease and disease recurrence
Allogeneic stem cell transplant (SCT) recipi-
ents. PCP is a generally preventable complication of
HCT. Programs must have vigorous systems to assure
that PCP prophylaxis is prescribed by providers and
adhered to by patients (AII). PCP prophylaxis is usu-
ally prescribed for allogeneic recipients from engraft-
ment until at least 6 months after HCT (AII) [481].
Some health care providers initiate PCP prophylaxis
prior to transplantation, depending on the underlying
disease and the pretransplant conditioning regimens or
prior chemotherapy (CII). Prophylaxis should be
continued for longer than 6 months in patients who
continue to receive immunosuppressive drugs (AII)
[481-484].
The preferred regimen for PCP prophylaxis is tri-
methoprim-sulfamethoxazole (TMP-SMX), because
of its superior efficacy compared with aerosolized
pentamidine, oral dapsone, or oral atovaquone (AII)
[485,486]. TMP-SMX also provides some protection
against other pathogens, including Toxoplasma, Nocar-
dia, enteric pathogens, Plasmodium species, urinary
pathogens, and some respiratory pathogens. Although
dapsone and atovaquone probably provide some pro-
tection against Toxoplasma, the broader spectrum of
activity of TMP-SMX is among the reasons this drug
is preferred.
TMP-SMX can delay engraftment, and thus is not
usually administered before engraftment occurs.
TMP-SMX is variably tolerated, and toxicities include
myelosuppression, hypersensitivity, hyperkalemia,
nephritis, hepatitis, and pancreatitis. The optimal dos-
age has not been defined in HCT patients. Many HCT
programs use once- or twice-daily regimens (single-
strength or double-strength tablets) 2 to 7 days per
week (CIII), and all appear efficacious.
There are no properly powered trials on which to
base a recommendation for alternative regimens.
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[489], and oral atovaquone [490] have all been used
(CII). However, none is as effective as TMP-SMX
for PCP prophylaxis [491]; therefore, every effort
should be made to administer TMP-SMX. Oral desen-
sitization regimens have been used successfully for
HIV-infected patients and others with rash [492],
and similar protocols have been used in HCT recipi-
ents with a success rate of approximately 80%
[491,493]. Desensitization should be attempted when
feasible (CII) (Appendix 3).
Oral dapsone is convenient, but a substantial
number of patients allergic to TMP-SMX will also
be intolerant of dapsone. Therefore, this drug is
not recommended in patients who have had life-
threatening reactions to TMP-SMX. Adverse reac-
tions to dapsone include hypersensitivity, hemolysis
(especially in patients with glucose-6-phosphate
dehydrogenase [G6PD] deficiency), hepatitis, and
methemoglobinemia. Patients with G6PD deficiency
should not receive this drug [488]. Aerosolized pent-
amidine is well tolerated, with bronchospasm as the
only common adverse effect, but may be less effective
than other regimens [494]. Atovaquone is expensive
but well tolerated; however, it is not well absorbed
unless ingested with fatty foods. Thus, atovaquone
might not be an optimal choice in patients with gut
GVHD.
Recurrence of PCP in HCT recipients is rare.
Nevertheless, patients recovering from PCP should
continue on chemoprophylaxis until their immuno-
suppression is resolved (AII), although there are no
clear parameters for defining this endpoint.
Autologous SCT recipients. PCP develops in
some autologous HCT recipients, although the rate
is much lower than among allogeneic recipients.
PCP prophylaxis should be considered for autologous
HCT recipients whose immunosuppression is sub-
stantial, either from an underlying condition or its
treatment. Such patients include those with
underlying lymphoma, leukemia, or myeloma,
especially when intensive treatment or conditioning
regimens have included purine analogues (Flu, cladri-
bine [2CdA]) or high-dose corticosteroids (BIII)
[480,488]. Duration of PCP prophylaxis in this setting
has not been evaluated, but common practice is to
extend prophylaxis 3 to 6 months posttransplantation
(CIII). For patients with ongoing immunomodulatory
therapy posttransplantation, a longer duration of
prophylaxis may be necessary.
Recommendations Regarding Toxoplasma gondii
Preventing exposure
In immunocompetent hosts, initial acquisition of
Toxoplasma most often occurs through exposure to
cat feces or undercooked meat. All HCT recipientsshould be provided information regarding strategies
to reduce their risk for exposure to Toxoplasma species
(see Strategies for Safe Living). Although an unusual
source of toxoplasmosis after HCT, potential donors
for allogeneic HCT could be tested for IgG antibodies
to T. gondii antibodies [495] because T. gondii has been
reported to be transmitted by leukocyte transfusion
[496] and HCT [497] (CIII).
Preventing disease and disease recurrence
Because most toxoplasmosis among HCT recipi-
ents is caused by disease reactivation, candidates for al-
logeneic HCT should be tested for IgG antibody to
determine whether they are at risk for disease reactiva-
tion after HCT (BIII) [495]. However, toxoplasmosis
has occurred in a limited number of HCT patients
who were seronegative for T. gondii pretransplant
[498]. Most cases observed after allogeneic HCT
occurred between 3 and 26 weeks posttransplant
[499-501], but later occurrence has also been reported
in patients receiving long-term immunosuppression.
The incidence of T. gondii disease varies according to
the seroprevalence in the geographic area. Clinical
reactivation occurs among 2% to 6% of those who
are seropositive prior to HCT [495,500-502]. CB
transplant recipients may be at higher risk than other
HCT recipients [500].
In allogeneic recipients who are seropositive for
toxoplasmosis, the risk of reactivation varies with the
kind of transplant and the degree of immunosuppres-
sion. In a prospective study from Spain, weekly screen-
ing with quantitative PCR testing of blood in allogeneic
seropositive HCT recipients over the first 6 months
after transplant has shown that reactivation occurred
in 16% (8%-21%) of seropositive allogeneic HCT re-
cipients [500]. Nucleic-acid based reactivation typically
precedes clinical symptoms by 4 to 16 days [98,500].
To facilitate early identification of reactivated
infection, PCR screening can be considered in patients
at high risk (ie, patients who were seropositive before
transplant and who received a CB graft, have developed
GVHD and require immunosuppressive treatment, or
who are not receiving TMP-SMX) (BII). PCR should
preferably be performed in a reference laboratory by
a quantitative method, using strict measures to reduce
the risk of false positive results (because of contamina-
tion) and false negative results (because of the presence
of inhibitors) (BIII) [503]. Brain MRI or CT scans in
HCT patients with toxoplasmosis may not demon-
strate the characteristic ring-enhancing lesions of this
disease [504]; therefore, a diagnostic workup (eg,
PCR testing of cerebrospinal fluid (CSF) or bronchoal-
veolar lavage (BAL) samples and/or blood) should be
initiated in patients with brain or pulmonary lesions
who are seropositive for Toxoplasma (CIII).
T. gondii reactivation and disease are both rare, but
have been reported, in patients receiving TMP-SMX
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patients who are intolerant to TMP-SMX, a specific
strategy for T. gondii should be implemented, because
other P. jiroveci prophylactic drugs either do not pene-
trate the body site of reactivation (ie, aerosolized pent-
amidine) or their prophylactic efficacy after HCT is
unknown (ie, dapsone, atovaquone). Such patients
can either be treated prophylactically with 1 or more
drugs effective against T. gondii (ie, clindamycin, pyri-
methamine plus leucovorin, pyrimethamine plus sulfa-
diazine, or pyrimethamine and sulfadoxine plus
leucovorin [506]), or be monitored with PCR testing
and given preemptive treatment (Appendix 1) (CIII)
[506]. There are no published prospective studies on
the benefit/risk ratio of such strategies.
After therapy for toxoplasmosis, HCT recipients
should continue receiving suppressive doses of TMP-
SMZ or an alternate regimen for the duration of their
immunosuppression (BIII) (Appendix 1).
Other recommendations
Except for the rare patients with pretransplant
toxoplasmic chorioretinitis, who may benefit from
secondary prophylaxis [507], recipients of autologous
transplants are at negligible risk for toxoplasmosis
reactivation. No prophylaxis or screening for toxoplas-
mosis infection is recommended for autologous trans-
plant recipients (CIII). Indications for toxoplasmosis
prophylaxis are the same in children and adults, but
children should receive pediatric doses (Appendix 1).
Recommendations Regarding Nocardia
Infection
Preventing exposure
All HCT recipients should be provided informa-
tion on ways to reduce risks of exposure to Nocardia
spp. Specific information should include the ubiqui-
tous nature of this Gram-positive, weakly acid-fast,
aerobic actinomycete. Nocardia spp. are found primar-
ily in dirt and stagnant water. Patients should be ad-
vised to avoid gardening, soil, and plants while
receiving immunosuppressive therapy (CIII). Because
infection occurs via inhalation, patients who wish to
continue gardening may minimize exposure by wearing
protective gear such as an N-95 mask and gloves (CIII).
Preventing disease and disease recurrence
The incidence of Nocardia infections is increased in
patients with HCT compared to the general popula-
tion (128 cases/105 person/years versus 0.3-0.4 cases/
105 person/years) [508-510]. The median time to onset
is approximately 200 days following transplant
[508,510]. Risk factors for disease include immuno-
suppression, corticosteroid use, neutropenia, active
GVHD, and concomitant opportunistic infections,
especially cytomegalovirus (CMV) [510-512].One study suggested that there may be decreased
risk of infection in patients receiving TMP/SMX pro-
phylaxis (CIII) [508]. Notably, between 40% and 60%
of cases in HCT patients occurred while the patient
was receiving TMP/SMX for PCP prophylaxis
[510,512]. Interestingly, most of these breakthrough
cases were successfully treated with high-dose TMP/
SMX. However, therapy for Nocardia infection should
be chosen on the basis of appropriate identification of
the Nocardia isolate and, if available, susceptibility test-
ing, becvause other treatment options are possible.
Recommendations Regarding
Strongyloides stercoralis
Preventing exposure
Allogeneic HCT recipients should avoid contact
with outhouses and cutaneous exposure to soil or other
surfaces that might be contaminated with human feces
(AIII) [513]. Allogeneic HCT recipients who work in
settings where they could be exposed to fecal matter
(eg, hospitals or institutions) should wear gloves
when working with patients or in areas with potential
fecal contamination (AIII).
Preventing disease and disease recurrence
Histories should be obtained for all patients before
HCT to identify potential exposure to Strongyloides
through travel or residence in high-risk areas (ie, moist
temperate areas such as the tropics, subtropics, or the
southeastern United States and Europe) (BIII) [513].
HCT candidates who have unexplained peripheral eo-
sinophilia or who have resided in or traveled to areas
endemic for strongyloidiasis, even during the distant
past, should be screened for asymptomatic strongyloi-
diasis before HCT (BIII). Options available for screen-
ing include stool examination and serologic testing
with an enzyme-linked immunosorbent assay (ELISA)
[514] or an indirect immunofluorescence antibody test
(IFAT) [515]. Generally, ELISA is the preferred
screening method, but its sensitivity may be relatively
low (\70%) in some immunocompromised patients
(BIII) [516]. Although stool examinations for strongy-
loidiasis are specific, the sensitivity achieved with $3
stool examinations is 60% to 70%; the sensitivity
achieved with concentrated stool exams is, at best,
80% [513]. A total of $3 stool examinations should
be performed if serologic tests are unavailable or if
strongyloidiasis is clinically suspected in a seronegative
patient (BIII).
HCT candidates with pretransplant screening tests
positive for Strongyloides species or those with an unex-
plained eosinophilia and a travel or residence history
indicating exposure to Strongyloides stercoralis, should
receive empiric treatment before transplantation, pref-
erably with ivermectin (Appendix 1) (BIII) [517].
There is no evidence supporting universal preemptive
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file and low cost, some clinicians advocate preemptive
treatment for patients from endemic areas who have no
symptoms, no eosinophilia, and negative screening test
results (CIII).
To prevent recurrence among HCT candidates,
parasite clearance after therapy should be verified
with $3 consecutive negative stool examinations
before proceeding with HCT (AIII). Data are insuffi-
cient to recommend a drug prophylaxis regimen after
HCT to prevent recurrence of strongyloidiasis.
HCT recipients who had strongyloidiasis before or
after HCT should be monitored carefully for signs
and symptoms of recurrent infection for at least 6
months after treatment (BIII).
Other recommendations
Unlike with allogeneic HCT, hyperinfection
strongyloidiasis has been reported only rarely after
autologous HCT; however, the same screening pre-
cautions should be used among autologous recipients
(BIII). Indications for empiric treatment for strongy-
loidiasis before HCT are the same among children
and adults except for children weighing \15 kg,
for whom the preferred drug is albendazole (BIII)
(Appendix 1).
Recommendations Regarding Trypanosoma cruzi
and Leishmania
Preventing exposure
Trypanosoma cruzi, the etiologic agent of Chagas
disease, can be transmitted through blood transfusion
[518]. Transfusion-associated transmission of T. cruzi
is a well-known phenomenon in endemic countries,
and 7 instances have been reported in the United States
and Canada, all in immunocompromised patients who
had fulminant courses of acute Chagas disease. Sero-
logic screening of donated blood for T. cruzi in the
United States began in January 2007, and although
the FDA has not mandated screening, more than
70% of donated units are currently being screened.
Sleeping sickness (T. brucei rhodesiense and T.b. gam-
biense) and leishmaniasis (various species belonging to
the genus Leishmania) could also be transmitted via
contaminated transfusions, although the possibility
of leishmaniae or African trypanosomes causing prob-
lems in an HCT patient is extremely remote if the
donor and recipient are from nonendemic areas.
Reactivation of T. cruzi has been reported in HCT
patients, but there are few reports of visceral leishman-
iasis following HCT [519-521], and this case seemed to
be acquired more than a year after transplantation, and
not preexistent or transmitted by the stem cell product.
Donors or recipients who were born, received
a blood transfusion, or ever lived at least 6 months in
a Chagas disease endemic area (eg, parts of Southand Central America and Mexico) should be screened
serologically for anti-T. cruzi serum IgG antibody
(BIII) [522]. Similarly, a donor or recipient whose
mother was born in a Chagas disease endemic area or
who has an extensive maternal family history of cardiac
disease (eg, cardiomegaly and dysrhythmias) should be
screened because of the risk of congenital transmission
(CIII) [518,523]. Persons who lived \6 months in
a Chagas-endemic area but who had high-risk living
conditions (eg, having had extensive exposure to the
Chagas disease vector—the reduviid bug—or having
lived in dwellings with mud walls, unmilled logs and
sticks, or a thatched roof) should also be screened for
evidence of T. cruzi infection (BIII).
In the absence of a gold standard test for Chagas
disease, screening for infection should be performed
with at least 2 serologic tests (eg, enzyme immunoas-
say, indirect hemagglutination, indirect fluorescent
antibody, or radioimmunoprecipitation assay) (BIII)
[524]. Persons with active Chagas disease (DIII) or
a past history of Chagas disease (CIII) should not serve
as HCT donors.
Preventing disease
HCT candidates at risk for infection with T. cruzi
should be screened for serum IgG anti-T. cruzi anti-
body (BIII) [522].T. cruzi seropositivity is not a contra-
indication to HCT [522,525]. However, if an acute
illness occurs in a T. cruzi-seropositive HCT recipient,
particularly during neutropenia, T. cruzi reactivation
should be included in the differential diagnosis (BIII)
[525]. Experts have proposed use of benznidazole or
nifurtimox for preemptive therapy or prophylaxis of
recurrent T. cruzi among seropositive HCT recipients
[526], but insufficient data were found to make a rec-
ommendation. For additional information regarding
the epidemiology of Chagas disease and for questions
regarding evaluation and treatment, contact CDC/
National Center for Zoonotic, Vector-borne and
Enteric Diseases/Division of Parasitic Diseases
(http://www.cdc.gov/chagas, (770) 488-7775, chagas@
cdc.gov).
Other recommendations
Recommendations are the same for autologous or
allogeneic recipients. However, recurrence of Chagas
disease is probably less likely to occur among autolo-
gous recipients because of the shorter duration of
immunosuppression. Recommendations are the same
among children or adults.Recommendations Regarding Malaria
In 2006, there were an estimated 247 million cases
of malaria with more than 880,000 deaths [527].
Malaria is not an opportunistic disease, but it is
increasingly relevant in SCT for several reasons:
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idence in an endemic malaria region are being trans-
planted;
 More residents from endemic regions are being con-
sidered as donors; and
 More recipients are being exposed to malaria after
transplant.Preventing exposure
Preventing transmission through the stem cell
product. Malaria, including falciparum malaria, has
been transmitted by HCT even when the donor smears
pretransplant are reportedly negative [106-108,528].
All donors from endemic regions should be asked
about a malaria history. Donors who have traveled to
an area where malaria transmission occurs should be
deferred from donating for 1 year after their return.
Former or current residents of an area where malaria
transmission occurs should be deferred for 3 years. If
those deferral times are not feasible, the donor should
receive empiric treatment for malaria prior to donating
[108]. Blood smears, immunochromatogenic tests, and
PCR are all inappropriate tests for evaluating asymp-
tomatic potential donors.
If the donor is diagnosed with active infection, col-
lection of the stem cell product should be delayed if
possible until treatment has been completed and neg-
ative confirmatory testing obtained (AIII). If this is not
feasible, preemptive treatment of the recipient seems
reasonable [106], but there is no evidence to make
a recommendation.
Preventing mosquito bites. HCT recipients
who cannot avoid areas with malaria should try to
avoid bites by Plasmodium-carrying mosquitoes.
Anopheles mosquitoes are most active at night. It is
recommended HCT recipients traveling to endemic
malaria areas use insecticide-treated bed nets (ITNs)
if they are sleeping in an open-air setting (AII). This
practice has shown to reduce severe malaria in children
[529] and is recommended by the CDC and the World
Health Organization for malaria control. Individual
infection may be decreased by the use of long sleeves,
long pants, and mosquito repellents (AI) (eg, DEET
[30%-50%]). The use of mosquito repellent seems to
add to the protective effect of ITNs [530].Preventing disease
HCTrecipients fromendemic areas or living in
endemic areas. HCT recipients from endemic
areas should be screened by blood smears, rapid
tests, and/or PCR for active disease before transplan-
tation (AIII). Following HCT, patients should be
screened if they develop fever, pancytopenia, hemo-
phagocytosis syndrome, hepatosplenomegaly, or
other symptoms suggestive of malaria (AIII). How-
ever, reported occurrences of malaria in HCT recip-ients are rare, and evidence is insufficient to make
specific recommendations for prophylaxis even in
patients living in endemic areas. Involvement of
a malarial specialist should be considered for
additional management.
HCT recipients in nonendemic areas who are
traveling to malaria endemic areas. HCT recipi-
ents traveling to areas endemic for malaria should con-
sult their physicians to choose an antimalarial regimen
that is effective against the prevalent Plasmodium and
that can be tolerated and is free of interactions with the
patient’s current medications (AIII). The CDC has
a Web site with comprehensive information regarding
travel (http://wwwn.cdc.gov/travel/default.aspx).INFECTION PREVENTIONANDCONTROL IN
HEALTH CARE FACILITIES WHERE
HEMATOPOIETIC CELLTRANSPLANTATION
RECIPIENTS ARE TREATED
D. Yokoe, C. Casper, E. Dubberke, G. Lee, P. Mun˜oz,
T. Palmore, K. Sepkowitz, J.-A.H. Young, J.P. DonnellyRoom Ventilation
Hematopoietic Cell Transplantation (HCT) cen-
ter personnel should follow published guidelines for
hospital room design and ventilation (BIII) [531,
532]. HCT recipients should ideally be placed in Pro-
tective Environment rooms that incorporate the
following features:
 $12 air exchanges/hour
 Central or point-of-use HEPA filters with 99.97%
efficiency for removing particles$0.3 mm in diame-
ter (AIII) [532-534]. Correct filtration is particularly
critical in HCT centers with ongoing construction
and renovation [535,536]. Filters should be replaced
regularly based on manufacturers’ recommenda-
tions, and, when there is ongoing construction, fil-
tration efficiency should be monitored frequently
to best determine appropriate time for replacement
(AIII).
 Directed airflow so that air intake occurs at 1 side of
the room and air exhaust occurs at the opposite side
(BIII) [531].
 Consistent positive air pressure differential between
the patient’s room and the hallway$2.5 Pa (ie, 0.01
inches by water gauge) (BIII) [531,532].
 Well-sealed rooms (eg, filling the gaps between
walls and windows, outlets, floor, and ceiling)
should always be used for HCT patients to prevent
infiltration of air from outside the room that could
allow entry of spores and hinder maintenance of
proper pressure differential (BIII) [532,534,537].
 Continuous pressure monitoring, especially while
rooms are occupied [531,532] (BIII). Consideration
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will set off an alarm when the pressure differential
between any Protective Environment room and ad-
jacent hallway or anteroom falls to less than 2.5 Pa,
to alert staff to possible engineering failures (CIII).
 Self-closing doors to maintain constant pressure dif-
ferentials (BIII) [532]. To enable the nursing staff to
observe the HCT recipient even when the doors are
closed, windows can be installed in either the door or
the wall of the HCT recipient’s room (CIII) [532].
When a shortage of Protective Environment
rooms to accommodate all HCT patients exists, the al-
location of these rooms should be prioritized for those
at highest risk of invasive mold infection (eg, expected
prolonged neutropenia, receiving treatment for GVHD)
(BIII). In that situation, portable, industrial-grade
HEPA filters may be used in non-Protective Environ-
ment rooms to accommodate other vulnerable pa-
tients, and should be placed centrally in patient
rooms so that space is available around all surfaces to
allow free air circulation (BIII). Portable HEPA filters
have been shown to remove airborne fungal spores
[538] and mycobacteria [539], and have been used as
part of a successful strategy to prevent fungal infec-
tions during construction [540]. However, whether
they are as effective as central, or point of use,
HEPA filters at preventing infection has not been
studied.
A laminar air flow (LAF) room contains HEPA-fil-
tered air that moves in parallel, unidirectional flow (the
air enters the room from 1 wall and exits the room on
the opposite wall) [541]. Some studies have shown that
LAF may protect patients from infection during Asper-
gillosis outbreaks related to hospital construction [542].
However, routine LAF room use for all HCT recipi-
ents has not been shown to provide substantial overall
survival (OS) benefit, and therefore, LAF systems are
not recommended for newly constructed rooms in
HCT centers (DII) [531,532].
There are no recommendations regarding the
pressure differential between a HCT center and ad-
joining buildings, but at least 1 study demonstrated
that negative pressure with respect to an adjoining
building contributed to an Aspergillus outbreak [543].
HCT center maintenance personnel should prevent
birds from nesting near hospital air-intake ducts
(AII) [531,534,544,545]. HCT centers should have
provisions for backup emergency power and redun-
dant air-handling and pressurization systems to main-
tain a constant number of air exchanges and room
pressurization when the central ventilation system is
shut off for maintenance and repair (BIII) [546]. Addi-
tionally, an Infection Control Risk Assessment (ICRA)
should be created by infection control personnel and
maintenance personnel to develop protocols to protect
HCT patients at all times from bursts of mold sporesthat might occur when air-handling systems are re-
started after routine maintenance shut-downs (BIII)
[546]. Because of this risk, air-handling systems should
never be shut off in HCT units for energy conservation
purposes.
Anterooms for HCT center rooms are optional,
except in the case of HCT recipients requiring air-
borne precautions for certain infections (BIII). Ante-
rooms should be used to ensure appropriate air
balance relative to the Protective Environment and
the hallway; independent exhaust of contaminated air
to the outside should be provided, or a HEPA filter
placed in the exhaust duct if return air must be recircu-
lated (BIII) [531,532]. If a Protective Environment air-
borne infection isolation room with an anteroom is not
available, the patient should be placed in a standard
airborne infection isolation room and a portable,
industrial-grade HEPA filter used to enhance removal
of spores in the room (BIII) [531].
Construction, Renovation,
and Building Cleaning
Construction and renovation
Hospital construction and renovation may result in
an increased risk for health care-associated invasive
mold infection, particularly aspergillosis, among
HCT recipients [531,547,548]. Therefore, persons re-
sponsible for HCT center construction or renovation
should consult published recommendations regarding
environmental controls during construction (AIII)
[531,549].
When construction or renovation is undertaken,
plans should include intensified mold-control mea-
sures. An ICRA should be planned prior to construction
on a facility or design of a new facility (AIII)
[531,532,550]. Construction and renovation infection
control planning committees should include engineers,
architects, housekeeping staff, infection control person-
nel, the director of the HCT center, the administration,
construction project managers, and safety officers.
Close coordination among these participants will facil-
itate compliance with infection control measures dur-
ing construction, renovation, and demolition (BIII)
[550,551]. Whenever possible, HCT recipients should
avoid construction or renovation areas (AIII)
[531,543,552,553]. Also, HCT center staff should avoid
transporting equipment and supplies used by HCT
recipients through construction or renovation areas.
During construction or renovation, HCT center
staff should take steps to minimize fungal spore counts
in patient rooms by adhering to room ventilation rec-
ommendations [549]. During outdoor construction
and demolition, the intake air should be sealed
(BIII), if possible; if not, filters should be checked fre-
quently to verify that they are well-seated and replaced
when necessary. Additionally, to protect HCT patient
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stripping should be placed around stairwell doors, or
alternatively, the stairwell air should be filtered to
the level of safety of the adjacent hospital air (BIII).
False ceilings should be avoided whenever possible
(BII) [547]. If use of false ceilings cannot be avoided,
the area above false ceilings should be vacuumed rou-
tinely to minimize dust and, therefore, fungal exposure
to patients (BIII) [547].
A number of measures have been used to minimize
the impact of construction on HCT recipients [554].
During hospital construction or renovation, hospitals
should construct rigid, dust-proof barriers with
airtight seals [531] between patient care and construc-
tion or renovation areas to prevent dust from entering
patient care areas (BIII) [go to www.ashe.org/ashe/
codes/cdc/pdfs/assessment_icra.pdf for more informa-
tion]. These barriers (eg, sealed drywall) should be im-
permeable to Aspergillus spores [531,534,549,552,555].
Construction and renovation areas should have nega-
tive air pressure-relative HCT patient care areas to
ensure that air flows from patient care areas toward
construction areas (AII) [543,549]. If impervious bar-
riers cannot be created around the construction area,
patients should be moved from the area until renova-
tion is complete and the area has been cleaned appro-
priately (BIII). HCT centers should direct pedestrian
traffic occurring near construction or renovation areas
away from patient care areas to limit the opening and
closing of doors or other barriers that might cause
dust dispersion, entry of contaminated air, or tracking
of dust into patient areas [531,556], particularly HCT
center patient care areas (BIII). If possible, specific ac-
cess routes, such as corridors, elevators, entrances,
exits, even bathrooms should be dedicated to construc-
tion use only [531]. Tacky floor mats should be placed
at the threshold of construction areas to minimize
tracking of dust. Visible dust and debris tracked out
of the construction zone should be vacuum cleaned
with HEPA filters in the vacuum exhaust [554]. Con-
struction workers, whose clothing might be contami-
nated with mold spores, should use the construction
elevator and avoid contact with patients, patient care
areas, other elevators, and nonconstruction areas
(BIII). A portable, industrial-grade HEPA filter should
be used between a construction zone and the HCT
unit if a large area is under construction and negative
pressure differential cannot be guaranteed (AII)
[543,550]. Monitoring of air quality during construc-
tion may include, daily particle counts, environmental
air sampling, and more frequent measurements of ven-
tilation pressure differentials (CIII) [543,557].
Monitoring for clinical cases of aspergillosis and
other invasive mold infections should be performed,
with enhanced surveillance of microbiologic, patho-
logic, and radiologic data to identify trends suggesting
an environmental mold source (BIII) (see Surveillancesection). Routine microbiologic air sampling for fun-
gal spores in HCT units is not recommended, as its
role has not been established (DIII) [558-560]. How-
ever, during a suspected outbreak, there may be
a role for microbiologic air sampling in patient care
areas (CIII). If microbiologic air sampling is per-
formed as part of an outbreak investigation, sample
volumes of at least 1000 L may achieve a higher degree
of sensitivity than smaller samples [543,561].
Allogeneic HCT recipients should avoid construc-
tion areas inside and outside the health care facility.
HCT recipients may benefit from wearing N95 respira-
tors while outside of HEPA-filtered areas, especially
during periods of health care facility construction and
renovation (CIII) [543,552,553]. Although they have
been utilized for patient use, there are no commercially
available masks, including N95 respirators, which have
been tested specifically for efficacy in reducing patient
exposure to Aspergillus or other mold in hospital con-
struction or renovation areas. Standard surgical masks
provide negligible protection against mold spores.
Whether or not the addition of mold-active prophylaxis
would provide additional protection during periods of
heavy construction has not been specifically studied,
and, therefore, no recommendation can be made.
Newly constructed or renovated areas should be
cleaned and disinfected before patients are allowed to
enter them (AIII) [534]. Fungal-contaminated mate-
rials that cannot be removed and replaced should be
decontaminated with copper-8-quinolinolate after
cleaning (BIII) [540,562]. Also, areas above dropped
ceilings in rooms located under or adjacent to con-
struction areas should be vacuumed (BIII). Addition-
ally, the ventilation, direction of airflow, and room
pressurization should be tested and correctly adjusted
before patients are allowed to enter (BIII) [549].
Cleaning
HCT centers should be cleaned at least daily with
special attention to dust control (BIII). Wet-dusting
should be performed; dusting techniques that aerosol-
ize dust should be avoided (BIII) [531,563,564]. Many
studies show that surface contamination is associated
with nosocomial infections, but there is a paucity of
data showing that routine surface disinfection reduces
the rate of infections [565]. Nonetheless, exhaust
vents, window sills, and all horizontal surfaces should
be cleaned with cloths and mop heads that have been
premoistened with an approved hospital disinfectant
(BIII) [531,566]. Thorough cleaning during and after
any construction activity, including minor renovation
projects, is critical (BIII) [549].
Floor surfaces and finishes should be smooth, non-
porous, and scrubbable (eg, vinyl, linoleum, tile) to
minimize dust levels (BIII) [144]. Carpeting should
not be installed in HCT center hallways outside of
patient rooms or inside the rooms (DIII) because
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breaks of aspergillosis among HCT recipients
[567,568]. HCT recipients should not be exposed to
vacuuming that could cause aerosolization of fungal
spores (eg, Aspergillus species) (EIII). All vacuum
cleaners used in the HCT center should be fitted
with HEPA filters [531,549]. An approved disinfectant
[539] should be used daily for environmental disinfec-
tion and when wet vacuuming is performed in the
HCT center (BIII). If an HCT center provides care
for infants, phenolic disinfectants can be used to clean
the floors, provided they are diluted according to the
product label. Phenolic compounds, however, should
not be used to clean basinets or incubators
(DIII) [539].
Water leaks should be cleaned up and repaired as
soon as possible but within 72 hours to prevent mold
proliferation in floor and wall coverings, ceiling tiles,
and cabinetry in and around all HCT patients care
areas (BIII) [531,564,569]. If cleanup and repair are de-
layed$72 hours after the water leak, the involved ma-
terials should be assumed to contain fungi and handled
accordingly (eg, discarded preferably or cleaned) [531].
A moisture meter to detect water penetration of walls
should be used whenever possible to guide decision
making (BIII). For example, if the wall does not have
\20% moisture content $72 hours after water pene-
tration, the affected portions of the wall should be
removed (BIII) [531].
Design and selection of furnishings should focus
on creating and maintaining a dust-free environment.
Upholstery should be smooth, nonporous, and easily
disinfected to minimize contamination with potential
nosocomial pathogens [570]. Finishes (ie, wall cover-
ings, window shades, and countertops) used in HCT
centers should also be scrubbable, nonporous, and eas-
ily disinfected to minimize dust accumulation (BIII).Isolation and Barrier Precautions
HCT centers should follow published guidelines
for hospital isolation practices, including CDC guide-
lines for preventing healthcare-associated infections
(AIII) [144,534,571]. However, the efficacy of specific
isolation precautions in preventing health care-associ-
ated infections among HCT recipients has not been
evaluated. HCT recipients should be placed in sin-
gle-patient rooms (BIII), if possible. If the availability
of single-patient rooms is limited, their use should be
prioritized for the most severely immunosuppressed
patients (eg, HCT recipients during their initial trans-
plant admission, particularly allogeneic HCT
recipients, or patients who are receiving immunosup-
pressive therapy for GVHD during readmissions)
(BIII).
In general, allogeneic HCT recipients are likely
to benefit from protective isolation measures (ie,a Protective Environment), including HEPA filtra-
tion and/or laminar airflow, to reduce exposure to en-
vironmental fungi (eg, Aspergillus sp.) and reduce
treatment-related mortality (TRM; see Ventilation
section) (BIII) [144,572]. The efficacy of protective
isolation measures for autologous HCT recipients is
not well established (BIII) [573], and individual cir-
cumstances should guide the prioritization of protec-
tive environment rooms in settings where the number
of these rooms is limited (eg, some patients who
receive tandem autologous HCT may be more im-
munosuppressed than those who receive nonmyeloa-
blative (NMA) allogeneic HCT) (BIII).
At a minimum, standard precautions should be fol-
lowed for all patient contacts (AIII). Standard precau-
tions include hand hygiene and wearing of appropriate
personal protective equipment (ie, gloves, surgical
masks or eye and face protection, and gowns) during
procedures and activities that are likely to generate
splashes or sprays of blood, body fluids, secretions or
excretions, or cause soiling of clothing [144]. Some
centers use additional protective precautions (eg,
gloves and mask, either during respiratory season or
year round) in an attempt to further reduce the risk
of transmission of respiratory viruses from health
care workers and visitors to patients. However, there
are insufficient data to provide recommendations re-
garding the use of additional protective precautions.
When indicated on the basis of coexisting condi-
tions, HCT recipients should also be placed on air-
borne, droplet, or contact precautions in addition to
standard precautions (AIII) [144]. Adherence to isola-
tion precautions is critical in preventing transmission
of infectious agents among HCT recipients, HCWs,
and visitors (AIII). HCT recipients with illnesses be-
cause of respiratory or gastrointestinal viruses can
have prolonged or episodic excretion of organisms
(eg, RSV, adenovirus, rotavirus). Guidance regarding
the duration of isolation precautions for specific path-
ogens is provided in the Control of Specific Health-
care-Associated Infections section.
HCT recipients may benefit from wearing masks
or N95 respirators during the preengraftment period
when they are outside of their hospital rooms, espe-
cially during periods of hospital construction and
renovation (CIII). All HCT recipients who are immu-
nocompromised (phases I-III of immune system re-
covery) and candidates undergoing conditioning
therapy should minimize the time spent in crowded
areas to avoid exposure to persons with CRV infec-
tions (BIII).Hand Hygiene
Hand hygiene is the mainstay of infection preven-
tion in the hospital, and is an essential element of Stan-
dard Precautions for all patients (AII) [144]. Hand
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and handwashing with soap (plain or antimicrobial)
and water. HCT center HCWs whose duties include
direct patient contact should not wear artificial finger-
nails or extenders because these have been associated
with outbreaks of Gram-negative bacillus and candidal
infections (EIII) [574-576]. HCT center policies
should encourage visitors to perform hand hygiene
before and after each patient visit (BIII). HCT recipi-
ents and candidates and their household contacts
should be educated about the importance of hand
hygiene during the HCT hospitalization and after
hospital discharge (BIII).
In the absence of visible soiling of hands or contact
with spore-forming organisms (see Recommendations
regardingC. difficile), the preferred method of hand hy-
giene is with an alcohol-based hand rub because of its
superior microbicidal activity, reduced drying of the
skin, and convenience (AII) [577-581]. When hands
are visibly dirty or soiled with blood or body fluids,
hands should be washed using soap and water (AI)
[579]. Hand hygiene should be performed under the
following circumstances [579]:
 Before direct contact with patients;
 After contact with blood, body fluids or excretions,
mucous membranes, nonintact skin, or wound
dressing;
 After contact with a patient’s skin;
 When hands will be moving from a contaminated to
a clean body site during patient care;
 After contact with medical equipment or the hospi-
tal environment in the immediate vicinity of the
patient; and
 If gloves are worn, before donning and after remov-
ing gloves.
Equipment
Equipment and devices should be cleaned, disin-
fected or sterilized, and maintained as directed by
established guidelines (AIII) [532,534,539,582-586].
Opened and unopened wound-dressing supplies (eg,
adhesive bandages [587,588] and surgical and elastic
adhesive tape [589]) should be examined for factors
that, if left unchecked, could result in mold contamina-
tion and possible subsequent cutaneous transmission
to patients (BII). This should consist of discarding all
bandages and wound dressings that are out of date,
have damaged packaging, or are visually contaminated
by construction debris or moisture (BIII). When arm
boards are used to provide support for intravenous
lines, only sterile dressing materials should be used
[590], and arm boards should be changed frequently
(eg, daily) (BIII). Additionally, nonsterile tongue
depressors inserted into a piece of foam tubing should
not be used as splints for intravenous and arterial cath-
eter sites because these have been associated with anoutbreak of fatal invasive nosocomial Rhizopus micro-
sporus among preterm (ie, very low birthweight) infants
(DII) [591].Plants, Play Areas, and Toys
Although exposure to plants and flowers has not
conclusively caused invasive mold infections among
HCT recipients, most experts recommend that plants
and dried or fresh flowers should not be allowed in
hospital rooms during conditioning or after HCT
(phases I-III of immune system recovery) because
Aspergillus species have been isolated from the soil of
potted ornamental plants (eg, cacti), the surface of
dried flower arrangements, and fresh flowers (DIII)
[533,534,547,592]. In addition, high counts of Gram-
negative bacteria have been found in vase water of
cut flowers, with Pseudomonas most frequently isolated
[531]. To minimize the risk of mold infection, HCT
recipients and candidates should avoid contact with
soil-based materials (eg, clay or potting soil) (DIII).
Toys are commonly colonized with bacteria (eg, S.
aureus, Enterococcus) and viruses associated with respi-
ratory and gastrointestinal (GI) illnesses [593-596].
There is no evidence to date that toys can serve as
a source of mold infection. Water-retaining bath toys
should not be used by immunocompromised HCT re-
cipients and candidates as they have been associated
with an outbreak of Pseudomonas aeruginosa in a pediat-
ric oncology ward (DII) [597].
Published recommendations for washing and dis-
infecting toys should be followed (BIII) [598]. Cloth
or plush toys should be washed in a hot cycle of a wash-
ing machine at least once weekly and more often as
needed (BIII). Alternatively, machine washing in
a cold cycle is acceptable if laundry chemicals for
cold water washing are used in proper concentration
[598]. Hard plastic toys should be scrubbed with
warm soapy water using a brush to clean crevices,
rinsed in clean water, immersed in a mild bleach solu-
tion that should be made fresh daily (see section on
bleach disinfection) for 10 to 20 minutes, rinsed again,
and allowed to air dry [539]. Alternatively, hard plastic
toys can be washed in a dishwasher or hot cycle of
a washing machine (BIII). Broviac dolls (which are
used to demonstrate medical procedures [eg, insertion
of catheters] to children to lessen their fears) should be
disassembled upon completion of play and washed and
disinfected before other children are allowed to play
with them (BIII) [539,582]. Infants, toddlers, and chil-
dren who put toys in their mouths should not share
toys (BIII) [598]. Toys that cannot be washed or disin-
fected after use should be avoided (DIII). Occupa-
tional and physical therapy items should be cleaned
and disinfected as previously described (BIII).
Play areas for pediatric HCT recipients and candi-
dates undergoing conditioning therapy should be
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needed (BIII). Toys, games, and videos should be
allowed in playrooms in HCT centers only if they can
be kept clean and disinfected (BIII). Toys, games, and
videos that are provided in an individual patient room
should be thoroughly washed before they are brought
into the room and thereafter at least once weekly or
more frequently as needed (BIII) [539,582,598].
Disposable play items should be offered whenever
possible to children on contact precautions (BIII). If
a child on contact precautions has used a toy, game,
or video, the item should be thoroughly cleaned and
disinfected before being used by other children
(BIII). When a child no longer requires contact pre-
cautions, any toys, games, and videos used during the
period of isolation should be thoroughly cleaned and
disinfected (BIII) [539,582,598]. All cloth or plush
toys used by a child on contact precautions should be
washed in a washing machine before the toy is given
to another child or placed in a play area (BIII). Toys
that have been used in an isolation room and that can-
not be thoroughly disinfected should be discarded
(BIII).Health care Personnel
HCT centers should provide a written compre-
hensive policy regarding immunizations and vaccina-
tions for HCT center employees that meets current
CDC, Advisory Committee on Immunization Prac-
tices, and Healthcare Infection Control Practices Ad-
visory Committee recommendations (BIII) [304].
Immunization of all HCWs with all recommended
vaccines is critical to prevent transmission of vaccine-
preventable diseases to HCT recipients and candidates
undergoing conditioning therapy. Where an equiva-
lently effective option exists, HCWs caring for HCT
recipients should preferentially receive inactivated
vaccines (eg, trivalent inactivated influenza vaccine, in-
activated polio vaccine) rather than live vaccines to
minimize the theoretical risks of transmission of vac-
cine virus to HCT recipients (see Family Members
Who Receive Live Vaccines section) (AIII).
Every effort should be made to restrict from direct
patient care activities all HCWs with infections that
are potentially transmissible to HCT recipients or
candidates (AII). The extent of work restrictions (eg,
leave from work versus temporary reassignment to
nonpatient care duties) will depend on the specific
infection. HCWs with draining skin and soft tissue
infections or other skin or mucous membrane lesions
(eg, HSV lip lesions) that cannot be completely cov-
ered should also be restricted from patient contact
(BIII). Published recommendations regarding the du-
ration of work restrictions for HCWs with infectious
diseases should be followed (BIII) [599,600]. HCT
center HCWs with blood-borne viral infections (ie,HIV or hepatitis B or C viruses [HBV, HCV]) should
not be restricted from patient contact (DIII) [601,602].
Work exclusion policies should be designed to encour-
age HCWs to report their illnesses or exposures (AII).
HCT Center Visitors
HCT centers should have written policies regard-
ing the screening of all visitors for communicable in-
fections (BIII). In some institutions, trained
personnel (eg, administrative or nursing personnel)
perform active screening at key entry points to HCT
units, particularly during the respiratory virus season.
At a minimum, signs should be posted to inform the
public about visitation restrictions. Ideally, staff should
actively screen visitors daily (Appendix 2). Visitors
with signs or symptoms suggestive of communicable
infections (eg, fever, upper respiratory infection
(URI), or flu-like symptoms, diarrhea, vomiting) or re-
cent known exposure to communicable infections (eg,
chickenpox, mumps, measles, pertussis) should be ex-
cluded from direct contact with HCT recipients or
candidates undergoing conditioning therapy (BII)
[603]. This is particularly important during periods
of widespread CRV activity in the surrounding com-
munity or suspected nosocomial CRV outbreaks. Staff
should request that affected visitors leave the HCT
center until signs and symptoms of infection have re-
solved or, for recent exposures to communicable infec-
tions, until the incubation period for that infection has
passed without the appearance of signs or symptoms
suggestive of active infection (AII). Visitors should
also be screened for recent receipt of live vaccines
and excluded as appropriate (see Family Members
Who Receive Live Vaccines section). The screening
process should include all visitors who stay overnight
in the rooms of HCT recipients or candidates.
No absolute minimum age requirement for HCT
center visitors exists; however, all visitors must be
able to follow appropriate hand hygiene and isolation
precautions (AIII). The number of HCT center visi-
tors at any 1 time should be limited to a number that
permits the nursing staff to perform appropriate infec-
tion screening and adequate instruction and supervi-
sion of hand hygiene and glove and mask use, as
appropriate (BIII).
Hospitals with nearby family lodging facilities (eg,
Ronald McDonald houses), should share information
with these facilities regarding practices to prevent
spread of communicable infections within these types
of facilities and to health care facilities (BIII).
Patient Skin and Oral Care
To optimize skin care, HCT recipients should take
daily showers or baths using a mild soap during and
after transplantation (BIII). For patients with
GVHD, regular lubrication of dry, intact skin with
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tegrity [604]. Ointments and creams are more effective
than lotions and less likely to sting when applied to
sensitive skin [604].
Routine inspection of skin sites likely to be portals
of infection (eg, perineum, intravascular access sites) is
recommended during neutropenia (BIII). HCT recip-
ients and candidates undergoing conditioning therapy
should maintain good perineal hygiene to minimize
loss of skin integrity and risk for infection (BIII). To fa-
cilitate this, HCT centers should develop protocols for
patient perineal care, including recommendations for
gentle but thorough perineal cleaning after each bowel
movement and thorough drying of the perineum after
each episode of urination (BIII). After using the toilet,
females should always wipe the perineum from front to
back to prevent fecal contamination of the urethra and
urinary tract infections (AIII). To prevent vaginal irri-
tation and to avoid the risk for cervical and vaginal abra-
sions that can serve as portals of entry for infection,
menstruating HCT recipients should not use tampons
(DIII). The use of rectal thermometers, enemas, or
suppositories; internal rectal exams; and sexual prac-
tices involving anal penetration are contraindicated
among HCT recipients to avoid skin or mucosal break-
down, which can introduce pathogens (DIII).
To reduce the risk of oral and dental infections, all
HCT candidates and their caregivers should be edu-
cated regarding the importance of maintaining good
oral and dental hygiene for at least the first year after
HCT (AIII). HCT candidates should be informed
that establishment of the best possible periodontal
health before HCT is of substantial benefit in avoiding
short- and long-term oral infections and that mainte-
nance of oral hygiene after HCT can minimize the se-
verity of infections and facilitate healing of mucositis,
particularly before engraftment (BIII) [200,605]. If
time permits, all HCT candidates should undergo
a dental evaluation and relevant treatment before the
start of conditioning therapy (AIII) [606,607]. Patients
with prior exposure to bisphosphonates should be
treated according to established guidelines [608-610].
Prophylaxis against oral mucositis with keratinocyte
growth factor-1 (palifermin) can be considered for pa-
tients undergoing myeloablative transplantation [611].
Palifermin reduces the incidence, severity, and dura-
tion of mucositis, and the incidence of febrile neutro-
penia, and may diminish the risk of bacteremia
following autologous HCT [611]. Elective dentistry
should be postponed until the patient has demon-
strated substantial immune recovery [607]. Patients’
dentists should eliminate likely sources of dental infec-
tion, for example, by restoring teeth with moderate to
severe caries and repairing ill-fitting dental prostheses
(BIII) [607]. Dentists should extract teeth compro-
mised by moderate to severe periodontal disease, non-
restorable carious teeth, and partially impacted teeth[200,607]. Ideally, at least 10 to 14 days should elapse
between the completion of tissue-invasive oral proce-
dures and onset of conditioning therapy, to enable
adequate healing and monitoring for postsurgical
complications (AIII) [607].
HCT recipients with mucositis and HCT candi-
dates undergoing conditioning therapy should main-
tain oral hygiene by performing oral rinses 4 to 6
times/day with sterile water, normal saline, or sodium
bicarbonate solutions (AIII) [605]. HCT recipients
and candidates should brush their teeth 2 to 3 times/
day with a soft regular toothbrush that is replaced reg-
ularly [605,607]. If the recipient cannot tolerate this,
a foam tooth swab can be used (CIII), although these
control plaque and prevent caries less effectively than
toothbrushes and must be used gently as they can exac-
erbate mucositis [607,612]. Using toothpaste is op-
tional, depending on the recipient’s tolerance (CIII)
[607]. HCT recipients and candidates undergoing
conditioning therapy who are skilled at dental flossing
should floss daily if this can be done without trauma
(BIII). Routine dental supervision to monitor and
guide the patient’s maintenance of oral and dental hy-
giene should be provided or encouraged (BIII).
To decrease the risk for mechanical trauma and in-
fection of oral mucosa, HCT patients should not wear
fixed orthodontic appliances or space maintainers from
the start of conditioning therapy until preengraftment
mucositis resolves or during any subsequent periods of
mucositis (EIII) [607]. Dental and transplant teams
and the patient’s community dentist should coordinate
removal of these appliances and long-term rehabilita-
tion of any oral lesions (BIII). Patients should mini-
mize the use of removable dentures during
conditioning and the early posttransplantation period
to reduce the potential for mucosal injury. It is recom-
mended that HCT recipients at risk for mucositis wear
dentures only while eating, clean them twice daily with
a soft toothbrush, and, when not wearing them, soak
dentures in antimicrobial denture soaking solution
that is changed daily (BIII) [607].
Patients with GVHD of the oral cavity should
undergo frequent dental evaluation because of the
accelerated pace of dental caries in those patients
(BIII) [613]. Dental caries, gingivitis, and periodontal
disease must be managed promptly to avoid infec-
tious sequelae, including periodontitis and dental
abscesses. Regular brushing, flossing, rinsing, fluoride
treatments, and management of xerostomia are basic
elements of oral care of patients with GVHD (BIII)
[613].Preventing Intravascular Catheter-Associated
Infections
HCT personnel should follow established prac-
tices for preventing infections related to intravascular
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Regarding Catheter-Associated Infections). For cen-
tral venous access among children, nonimplanted de-
vices are preferred because implantable devices
(defined as central venous catheters [CVCs] that are
tunneled beneath skin with a subcutaneous port that
can be accessed with a needle) have an insufficient
number of lumens for optimal patient management
immediately after HCT (AIII). In addition, especially
among children\4 years old, the skin is often too frag-
ile to tolerate repeated punctures over a port site.
Patients or parents and caretakers should be
trained in the care of intravascular devices (AIII)
[182]. For devices that are not totally implantable, con-
tact with tap water at the central venous catheter skin
site should be avoided (BIII), and patients should cover
and protect the catheter tip or end cap during bathing
or showering to avoid contamination from tap water.
Intravenous infusions given outside of clinic should
be started by a caregiver, not the patient (BII) [614].
Prevention and Control of Specific Healthcare-
Associated Infections
Recommendations Regarding Legionella Species
HCT physicians should always include Legion-
naires’ disease (LD) in the differential diagnosis of
pneumonia among HCT recipients (AIII) [531,534].
Legionella outbreaks have occurred on transplant wards
[615-617]. Appropriate tests to confirm LD include
culture of sputum, BAL, and tissue specimens; testing
BAL specimens for Legionella by direct fluorescent
antibody; and testing for Legionella pneumophila se-
rogroup 1 antigen in urine. However, several of the
Legionella outbreaks in immunocompromised patients
described in the literature were because of species
other than L. pneumophila serogroup 1 species, and
therefore would not have been detected by the urine
antigen assay [615-617]. Currently, sufficient evidence
is lacking to make recommendations regarding Legion-
ella PCR testing.
The incubation period for LD is usually 2 to 10
days. Thus, laboratory-confirmed legionellosis that oc-
curs in a patient who has been hospitalized continu-
ously for $10 days before the onset of illness is
regarded as a definite case of nosocomial LD, and a lab-
oratory-confirmed infection that occurs 2 to 9 days af-
ter hospital admission is a possible case of nosocomial
LD [531,534]. When a definite or possible case of lab-
oratory-confirmed nosocomial LD [615,618] is identi-
fied in a person who was in the inpatient HCT center
during all or part of the 2 to 10 days before illness onset,
or if 2 or more cases of laboratory-confirmed LD occur
among patients who had visited an outpatient HCT
center, the case(s) should be reported to the local or
state health department if the disease is reportable in
that state or country or if assistance is needed (AIII)[531,534]. Additionally, in consultation with the hospi-
tal infection control team, a thorough epidemiologic
and environmental investigation should be conducted
to determine the likely environmental source(s) of
Legionella species (eg, showers, tap water faucets, cool-
ing towers, and hot water tanks) (AI) [531,534]. The
source of Legionella infection should be identified and
decontaminated (AIII). Extensive hospital investiga-
tion of an isolated case of possible nosocomial LD
might not be indicated if the patient has had limited
contact with the inpatient HCT center during most
of the incubation period (CIII).
HCT centers should follow published recommen-
dations regarding prevention of nosocomial Legionel-
losis (BIII) [531,534]. HCT center personnel should
use only sterile water (ie, not distilled nonsterile water)
to fill reservoirs of nebulization devices [534] and to
rinse nebulization devices and other semicritical respi-
ratory-care equipment after cleaning or disinfection
(BII). HCT centers should not use large-volume
room air humidifiers that create aerosols (eg, by Ven-
turi principle, ultrasound, or spinning disk), and thus,
are actually nebulizers (DI) [534] unless these humid-
ifiers are sterilized or subjected to daily high-level dis-
infection and filled with sterile water only (CIII) [534].
When a new hospital with an HCT center is con-
structed, the cooling towers should be placed so that
the tower drift is directed away from the hospital’s
air-intake system, and the cooling towers should be de-
signed so that the volume of aerosol drift is minimized
(BII) [534]. For operational hospital cooling towers,
hospitals should install drift eliminators, regularly
use an effective biocide, maintain cooling towers ac-
cording to the manufacturer’s recommendations, and
keep adequate maintenance records (BII) [534].
Decorative fountains should not be installed in
HCT units or areas in a healthcare facility frequented
by HCT recipients (BIII). A clonal outbreak of LD
linked to a decorative fountain despite efforts to pre-
vent Legionella contamination was recently described
[619]. Available data do not suggest that drinking tap
water poses a risk for Legionella exposure among
HCT recipients in the absence of an outbreak.
Because HCT recipients are at higher risk for dis-
ease and death from legionellosis compared with other
hospitalized persons [615], periodic routine culturing
for Legionella species in water samples from the HCT
center’s potable water supply could be included as
part of an overall strategy for preventing LD (CIII)
[531,534,620,621]. However, the optimal methodol-
ogy (ie, frequency or number of sites) for environmen-
tal surveillance cultures in HCT centers has not been
determined, and the cost-effectiveness of this strategy
has not been evaluated [531,534]. Because a ‘‘safe’’
concentration of Legionella organisms in potable water
has not been established, the goal should be to main-
tain water systems with no detectable organisms
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the water supplying an HCT center, the following
measures should be performed until Legionella species
are no longer detected by culture [531,534]:
 Decontaminate the water supply (AII).
 Prevent patients from showering with LD-contam-
inated water. Instead, provide HCT recipients with
sponge baths using water that is not contaminated
with Legionella species (eg, use water that is not
from the HCT center’s potable water system) (BIII).
 Do not use faucets containing LD-contaminated
water in patient rooms or the HCT center or ambu-
latory HCT clinics to avoid creating infectious aero-
sols (DIII).
 Provide HCT recipients with sterile water instead of
tap water for drinking, brushing teeth, or flushing
nasogastric tubes during proven or suspected Le-
gionellosis outbreaks (BIII).
Recommendations regarding methicillin-
resistant Staphylococcus aureus (MRSA)
HCT centers should follow published recommen-
dations to prevent healthcare-associated transmission
of MRSA [144,622-625]. To prevent MRSA transmis-
sion, adherence to the following infection control
practices is recommended [144,579,623,624]:
 Perform hand hygeine with either an alcohol-based
hand rub or wash hands with soap and water if soiled
before and after all patient contact or contact with
the patients’ potentially contaminated equipment
or environment (AII);
 Use contact precautions for patients colonized or in-
fected with MRSA, including the use of gloves and
gowns (AII);
 Ensure adherence to standard environmental clean-
ing with an effective disinfectant (BIII) [531,539].
There is insufficient evidence at present to rec-
ommend routine screening of all HCT recipients
for MRSA or the use of topical or systemic antimicro-
bial therapy for patients with asymptomatic MRSA
colonization, although these are areas of active re-
search [626,627]. If high rates of MRSA persist de-
spite implementation of basic infection control
practices, HCT centers should consider adjunctive
strategies, such as implementing a program to obtain
MRSA surveillance cultures on admission and serially
(eg, weekly) (BII) [628] with or without decoloniza-
tion therapy (BIII) [627]; routine bathing of patients
with chlorhexidine (BIII) [629]; cohorting of MRSA
patients in designated areas (eg, bays, patient care
areas); or by assigning care to dedicated staff (CIII)
[624]. The potential impact of rapid molecular tech-
niques to identify S. aureus nasal carriage to prevent
MRSA transmission is another area of active research,
and recommendations regarding use of rapid tech-niques for MRSA cannot be provided at this time.
The emergence of community-associated MRSA
infection has further complicated the prevention
and control of MRSA. Optimal strategies for preven-
tion of transmission and infection with community-
associated MRSA are currently unknown.
The optimal duration of contact precautions for
patients with MRSA is unknown, although studies
have shown that patients can remain persistently colo-
nized for extended periods of time. Some HCT centers
may opt to implement MRSA discontinuation criteria
(eg, continue contact precautions until all antimicro-
bials active against the MRSA isolate are discontinued
and 3 consecutive screening cultures taken on separate
days are negative) (CIII) [624].
For patients with recurrent MRSA infection, erad-
ication of the carrier state can be attempted by apply-
ing a 2% mupirocin calcium ointment to the nares, use
of topical antiseptics such as chlorhexidine for bathing,
or administration of systemic antimicrobials, although
these strategies have not been shown to be consistently
effective (Appendix 1) (CII) [630,631]. High-level mu-
pirocin-resistant MRSA has been reported in Europe,
the Middle East, and South America [632-636], but is
less common in the United States. As with any antimi-
crobial agent, incorrect use or overuse of mupirocin
can result in the emergence of mupirocin-resistant
staphylococci; therefore, mupirocin use should be
coordinated with the local hospital infection control
team [632,633].
Selection of systemic antimicrobials used to treat
MRSA infection should be guided by susceptibility
patterns. Recommendations for treatment of MRSA
infections are beyond the scope of this guideline; refer
to published treatment guidelines.Recommendations regarding Staphylococcus
species with reduced susceptibility to vancomycin
All HCT centers should have sufficient laboratory
capability to identify all Staphylococcus isolates and their
antimicrobial susceptibility patterns, including vanco-
mycin susceptibility (AII) [637-639]. Additionally,
HCT centers should conduct routine surveillance for
the emergence of Staphylococcus species strains with re-
duced susceptibility to vancomycin (AIII) [640,641].
Reduced susceptibility to vancomycin is defined as
those S. aureus strains that have a vancomycin mini-
mum inhibitory concentration (MIC) of $2 mg/mL
and those coagulase-negative staphylococci that have
a vancomycin MIC of $4 mg/mL.
If a patient in an HCT center is colonized or in-
fected with a staphylococcal strain that has reduced
susceptibility to vancomycin, infection control person-
nel should follow published guidelines for the control
of such species (BIII) [638,642,643]. Avoiding overuse
and misuse of antimicrobials will decrease the
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ceptibility to vancomycin [641,642]. Therefore, medi-
cal and ancillary staff members who are responsible for
monitoring antimicrobial use patterns in the facility
should routinely review vancomycin use patterns
(AII) [638,642,643]. Additionally, HCT center per-
sonnel should institute prudent use of all antimicro-
bials, including vancomycin, to prevent the
emergence of Staphylococcus with reduced susceptibility
to vancomycin (AII) [638,640,642-645].
Recommendations regarding VRE
HCT recipients frequently have multiple risk fac-
tors for VRE colonization and infection, and VRE in-
fection is associated with poor outcomes among HCT
recipients [646,647]. A history of resolved VRE bacter-
emia or known VRE colonization, however, is not
a contraindication for HCT (BIII).
To reduce the risk of VRE infection, HCT clini-
cians should minimize the use and duration of treat-
ment with vancomycin and antimicrobial agents with
anti-anaerobic coverage (eg, metronidazole and
third-generation cephalosporins) (AII) [638,648-650].
Although both oral vancomycin and metronidazole
promote overgrowth of VRE in stool, the risk of ac-
quiring VRE or promoting VRE overgrowth should
not be a defining consideration when selecting oral
vancomycin for treatment of severe or recurrent C. dif-
ficile infection (BIII) [650,651].
Patients colonized with VRE typically remain col-
onized for long periods extending beyond the hospital-
ization during which the initial VRE-positive culture
result was obtained [652,653]. VRE may ‘‘reemerge’’
after prior negative cultures when the patient is
reexposed to antimicrobials [624,654]. Contact pre-
cautions for HCT recipients with past VRE coloniza-
tion or infection should be continued during hospital
readmissions (AIII). Although there are insufficient
data to provide recommendations regarding the opti-
mal duration of precautions for HCT recipients with
a history of VRE, individual HCT centers can consider
implementing criteria for discontinuation of contact
precautions (eg, 3 consecutive sets of screening cul-
tures negative for VRE obtained on separate days for
a patient who is not receiving antimicrobial therapy ac-
tive against the VRE isolate).
To prevent VRE transmission, the following infec-
tion control measures are recommended [579,655]:
 Perform hand hygiene with an alcohol-based hand
rub or by washing hands with soap and water if
soiled before and after all patient contacts or contact
with the patients’ potentially contaminated equip-
ment or environment (AII);
 Use contact precautions for patients colonized or
infected with VRE, including the use of gloves and
gowns (AII). Ensure adherence to standard environmental clean-
ing with an appropriate disinfectant (BIII) [539].
Antimicrobial treatment of VRE carriers has not
been adequately studied, and carries potential risks, in-
cluding toxicity and the development of drug-resistant
organisms; therefore, it should be discouraged (DIII).
The effectiveness of active surveillance cultures for
VRE to prevent health care-associated transmission
of VRE is unknown. VRE rectal or stool-active sur-
veillance cultures to identify colonized patients can
be considered if there is evidence for ongoing trans-
mission of VRE on a HCT unit (CIII) [622].
Recommendations regarding multidrug-resistant
Gram-negative bacilli (MDR-GNB)
MDR-GNB are defined as GNB that are resistant
to 1 or more classes of antimicrobial agents, including
those producing extended-spectrum beta-lactamases
(ESBLs) and carbapenemases. In addition to Escheri-
chia coli andKlebsiella pneumoniae, MDR-GNB includes
highly resistant strains of Acinetobacter baumannii and
organisms such as Stenotrophomonas maltophilia, Bur-
kholderia cepacia, and Ralstonia pickettii with intrinsically
broad antimicrobial resistance. A detailed discussion of
MDR-GNB and recommendations for prevention was
published in 2006 [624]. Judicious use of antimicrobial
agents is important for control of MDR-GNB (BII).
Several studies have demonstrated a temporal associa-
tion between formulary changes and decreased inci-
dence of targeted MDR-GNB [656].
As with other multiply drug-resistant organisms,
adherence to the following infection control measures
is important to prevent health care-associated trans-
mission [144,579]:
 Perform hand hygiene with an alcohol-based hand
rub or by washing hands with soap and water if
soiled before and after all patient contacts or contact
with the patients’ potentially contaminated equip-
ment or environment (AII);
 Use contact precautions, including gowns and
gloves, for patients colonized or infected with
MDR-GNB that are of epidemiologic importance
for each HCT center (AII);
 Ensure adherence to standard environmental clean-
ing with an effective disinfectant (BIII) [531,539].
Based on current evidence, it is unclear whether
the addition of an active surveillance-culturing (ASC)
program for MDR-GNB to basic infection control
practices is useful. Some studies have reported success-
ful reduction of extended-spectrum beta-lactamase-
producing Enterobacteriaceae over a 6-year period using
a multifaceted control program that included use of
ASC [657,658]. Other reports suggest that the use of
ASC is not necessary to control endemic MDR-
GNBs [659]. However, the CDC and the Health
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now recommends that a single round of surveillence
be conducted in high risk settings (eg, units where pa-
tients are exposed to broad spectrum antimicrobials) if
previously unidentified cases of carbapenem-resistant
or carbapenemase-producing Klebsiella spp. or E. coli
are identified on review of mircobiology records
[660]. Units experiencing high rates of MDR-GNB in-
fection can consider the use of ASC as a component of
their control and prevention program (CIII), although
there is insufficient information to provide a recom-
mendation regarding the use of ASC to prevent trans-
mission of MDR-GNB.
Recommendations regarding C. difficile
HCT centers should follow published recommen-
dations for preventing, controlling, and treating C. dif-
ficile infection (CDI) (AI) [661,662]. Patients with CDI
should be placed on contact precautions for the dura-
tion of illness (BIII) [144,662]. All HCWs who have
contact with a C. difficile-infected patient or the pa-
tient’s environment should don gloves (AI) and gowns
(BIII) before entering the patient’s room [144,661-
664]. Contact precautions should be continued at least
until the patient is asymptomatic (BIII) [661]. A ‘‘test
of cure’’ to determine whether contact precautions
can be discontinued is discouraged (DII) [661].
If there is evidence of ongoing transmission of C.
difficile despite implementation of the basic prevention
practices described above, HCT centers should con-
sider maintaining contact precautions even after diar-
rhea has resolved and until hospital discharge (CIII)
[665]. During nosocomial CDI outbreaks, HCT cen-
ters should work closely with their Infection Preven-
tion and Control staff to ensure implementation of
appropriate control measures (AIII). The following
practices are not recommended for prevention of
C. difficile transmission:
 Performing routine stool surveillance cultures or
toxin assays for C. difficile among asymptomatic pa-
tients or HCWs, even during outbreaks (DIII);
 Culturing HCWs’ hands for C. difficile (EIII);
 Treating asymptomatic C. difficile carriers to prevent
clinical infection (EII) [666].
Hand hygiene compliance may decrease when soap
and water is the preferred method. Alcohol-based hand
rubs are associated with increased hand hygiene com-
pliance and are more effective at removing nonspore-
forming organisms than soap and water [579,667].
However, the use of alcohol-based hand hygiene prod-
ucts after caring for a patient with CDI remains con-
troversial, because alcohol is not sporicidal. Hand
washing with soap and water has been shown to be ef-
fective at removing Bacillus atrophaeus spores [668].
Presumably, if gloves are worn when caring for
a patient with C. difficile infection, spores are physicallyremoved during glove removal. In the setting of an
outbreak or ongoing C. difficile transmission in
a HCT center, the center should consider instructing
visitors and HCWs to wash hands with soap and water
after contact with patients with CDI or their equip-
ment or environment (BIII). If soap and water are
used, proper technique (ie, a minimum 15 to 30 sec-
onds of hand washing) should be ensured (BI) [579].
C. difficile is primarily transmitted from the hands
of HCWs. However, C. difficile can also be acquired
from the hospital environment. Currently there are
no approved sporicidal hospital disinfectants. Sodium
hypochlorite-based cleaning agents (ie, household
bleach in water at a 1:10 dilution or at least
5000 ppm available chlorine) are sporicidal within
10 minutes [669]. One study demonstrated a significant
decline in CDI rates on an HCT unit with the use of
a bleach-based cleaning agent [670]. The use of
bleach-containing cleaning agents for environmental
disinfection should be considered when there is evi-
dence of ongoing C. difficile transmission (BII). The
optimal frequency (eg, daily cleaning or cleaning after
discharge of the patient from the room) and extent (eg,
only rooms of patients with CDI, all patient rooms on
the unit, or the addition of areas outside of patient
rooms) of cleaning with bleach-containing agents are
unresolved issues.Recommendations regarding community
respiratory virus infections
HCT centers should institute appropriate precau-
tions and infection control measures for preventing
transmission of CRV among hospitalized HCT recip-
ients and candidates undergoing conditioning therapy
(AIII) [310,534,563,671]. HCT recipients or candi-
dates with URI or lower respiratory infection (LRI)
symptoms because of suspected CRV infection should
empirically be placed on contact plus droplet precau-
tions until a specific pathogen has been identified. Af-
ter identification, precautions should be adjusted based
on published guidelines to avoid transmitting infection
to other HCT candidates and recipients, HCWs, and
visitors (BIII) [144]. Pathogen-specific CRV isolation
precautions include:
 Contact precautions for RSV and parainfluenza;
 Droplet precautions for influenza;
 Droplet plus contact precautions for adenovirus;
and
 Airborne plus contact precautions for primary or
disseminated varicella infection.
Personal protective equipment (eg, gown, gloves,
surgical mask, and eye protection) should be donned
prior to entering and discarded upon exiting a patient’s
room to ensure that personal protective equipment is
always changed between patients (AIII) [144].
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undergoing conditioning therapy with URI or LRI,
HCWs and visitors should disinfect hands with an
alcohol-based gel or, if hands are visibly soiled, with
soap and water (AII):
 Before and after each contact with a patient;
 After handling respiratory secretions or fomites
potentially contaminated with patients’ secretions;
and,
 Before donning and after removal of gloves
[534,579].
Adherence to hand hygiene is critical because most
respiratory infections are transmitted by direct con-
tact, particularly by hand to nose and eye. Use of
a mask without appropriate hand disinfection, glove-
wearing, or facial protection is insufficient to prevent
transmission of CRV infections. While performing
aerosol-generating procedures (eg, bronchoscopy,
open suctioning of the respiratory tract [ie, unless in-
line suctioning catheters are used], endotracheal intu-
bation), HCWs should wear a face shield that fully
covers the front and side of the face, a mask with an at-
tached shield, or a mask and goggles, along with gloves
and gowns to avoid contamination from the patient’s
respiratory secretions regardless of the presence or
absence of CRV symptoms (AIII).
HCT centers should consider daily screening of all
persons who enter the center, including HCWs and
visitors, for URI symptoms, especially during nosoco-
mial or community outbreaks of CRV infection (Ap-
pendix 2) (BIII). HCT center HCWs with URI
symptoms should be restricted from patient contact
and reassigned to nonpatient care duties until symp-
toms resolve (BII). Visitors with URI symptoms
should be asked to defer their visit to the HCT center
until their URI symptoms resolve (AII) [298]. HCWs
and visitors with infectious conjunctivitis should be
restricted from direct patient contact until the drain-
age resolves (AII) [599].
Respiratory secretions of any hospitalized HCT
candidate or recipient with signs or symptoms of
CRV infection should be tested promptly by viral cul-
ture or rapid diagnostic tests for CRV (BIII) (see Viral
Infections section). Appropriate samples include naso-
pharyngeal washes, swabs, aspirates (with or without
throat swabs), and BAL fluid. This practice permits
timely initiation of isolation precautions to prevent
transmission to other patients and HCWs as well as
preemptive treatment of certain CRVs (eg, influenza)
[672] that might prevent severe disease and death
among HCT recipients [534].
HCT centers should obtain nasopharyngeal swabs,
throat swabs, or aspirates for culture, PCR, or rapid
antigen testing to help determine whether patients
have stopped shedding virus (BIII). To prevent noso-
comial transmission of CRV [673], HCT centersshould recognize that prolonged CRV shedding may
occur. Viral shedding has been reported to last $4
months for influenza [305], $2 years for adenovirus
[674,675], and $22 days for RSV [673], mainly in pa-
tients treated with steroid doses of .1 mg/kg [309].
RSV viral shedding has been reported to last 112
days in a child with severe combined immunodefi-
ciency [676]. HCT recipients with CRV infection
should be placed on the appropriate precautions for
at least the duration of illness (AII) and precautions
should be continued for the duration of hospitalization
or viral shedding to prevent transmission within the
unit (CIII).
Some HCT centers conduct routine CRV surveil-
lance among asymptomatic HCT recipients to detect
outbreaks and implement infection control measures
as early as possible [677]. To date, however, data are
insufficient to provide recommendations regarding
routine surveillance testing of asymptomatic patients
for CRV infections.
During periods of widespread RSV or influenza
activity in the surrounding community or suspected
health care-associated CRV outbreaks, all HCT recip-
ients and candidates with signs or symptoms of respi-
ratory infection should be tested for RSV and
influenza infection (ie, the presence of RSV and/or
influenza antigen in respiratory secretions tested by
enzyme-linked immunosorbent assay and viral
culture). During an outbreak of health care-associated
RSV infection, managers should cohort health care
personnel as much as is practical (ie, restrict personnel
who care for RSV-infected patients from giving care to
uninfected patients) (CIII) [297,298,678]. No recom-
mendation can be made for cohorting of personnel
during an outbreak of other health care-associated
CRV infections.
HCWs and close contacts of HCT recipients
should receive yearly influenza vaccine at the start of
the influenza season, preferably with trivalent inacti-
vated influenza vaccine rather than live attenuated in-
fluenza vaccine to avoid concerns about transmission
of vaccine virus (Table 7) (AI). Use of influenza vaccine
along with prophylaxis and early antiviral therapy
among at-risk healthcare workers and high-risk pa-
tients reduces the spread of influenza within healthcare
facilities [534]. During an outbreak of health care-
associated influenza infection, in addition to use of
droplet precautions for patients with suspected or con-
firmed influenza and rapid influenza virus testing for
symptomatic patients, HCT centers should consider
rapid influenza virus testing of symptomatic HCT
staff; administration of inactivated influenza vaccine
to unvaccinated HCT staff and appropriate patients
(see HCT Recipient Vaccinations section); and admin-
istration of influenza antiviral chemoprophylaxis to
HCT staff and patients according to current recom-
mendations (BIII) [603]. Healthcare personnel with
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lowing the onset of symptoms (AIII) [303,679].
Preventing CRV exposure among HCT recipients
after hospital discharge is more challenging because of
high CRV prevalence. Preventive measures should be
individualized in accordance with the immunologic
status and tolerance of the patient. In outpatient wait-
ing rooms, patients with CRV infections should be
separated to the extent possible from other patients
and should be instructed to use respiratory hygiene/
cough etiquette (BIII).Recommendations Regarding Adenovirus
Adenovirus can cause large outbreaks in hospital
settings and chronic care facilities. Outbreaks of diar-
rheal illness because of adenovirus have been previ-
ously described among adult HCT recipients [680].
Transmission can occur via inhalation of aerosolized
droplets; direct and indirect contact through contam-
inated surfaces; fecal-oral spread; exposure to infected
tissue or blood; and rarely, contaminated water [330].
Sputum or oral secretions of infected adults contain
106 to 107 particles/mL. Nonimmune adults can be
infected by inhaling as few as 5 viral particles [681].
Prolonged fecal shedding has been demonstrated in
HIV-infected patients with and without diarrhea.
Immunocompromised hosts are known to have asymp-
tomatic shedding of adenovirus from the GI and respi-
ratory tracts for months after initial infection.
Furthermore, immunosuppressed individuals may ei-
ther reactivate endogenous infection or acquire new
infection. Adenovirus survives on nonporous surfaces
up to 35 days [682-684].
Recommendations for isolation precautions in the
hospital setting depend on the type of syndrome caused
by adenovirus. HCT recipients with adenoviral gastro-
enteritis should be placed on contact precautions for at
least the duration of illness (AIII), and precautions
should be continued for the duration of hospitalization
or viral shedding (CIII) to prevent transmission within
the unit. For cases of respiratory illness or dissemi-
nated infection associated with adenovirus, droplet
and contact precautions should be maintained for at
least the duration of illness (AIII) [144]. For cases of
adenoviral conjunctivitis in immunosuppressed pa-
tients, contact precautions (AIII) and droplet precau-
tions (CIII) should be instituted for at least the
duration of illness (usually 5-7 days) (CIII) [144].
Hand hygiene with either an alcohol-based hand
rub or soap and water has been shown to be effective
against adenovirus (BIII) [685]. Environmental disin-
fection of surfaces with hospital-approved disinfec-
tants (eg, chlorine-based products, ethyl alcohol,
ethanol mixed with quaternary ammonium com-
pounds) is important to limit the spread of adenoviral
infection [686].Recommendations Regarding
Viral Gastroenteritis
Viral gastroenteritis is most commonly spread by
the fecal-oral route. Common pathogens include rota-
virus, norovirus, astrovirus, and adenovirus (see the
Adenovirus section for adenovirus-specific recommen-
dations). To prevent the acquisition and spread of viral
gastroenteritis among HCT recipients, HCT centers
should ensure adherence to hand hygiene, appropriate
isolation precautions, and environmental disinfection
(AII) [531]. Appropriate precautions should be main-
tained for at least the duration of illness (AII). Because
HCT recipients may continue to shed virus after
symptoms resolve, HCT centers may choose to con-
tinue precautions for the duration of hospitalization,
or the duration of viral shedding if diagnostic labora-
tory testing is available (CIII).
Rotavirus
Rotavirus is the most common cause of severe gas-
troenteritis in infants and young children worldwide.
Virus is shed in high concentrations in the stool of in-
fected children and is transmitted primarily by the fe-
cal-oral route, through person-to-person contact and
fomites [687]. Environmental contamination is com-
mon because rotavirus can survive on nonporous
surfaces for more than 10 days [688,689]. Health
care-associated transmission because of rotavirus in-
fection has been linked to toys [594] and contaminated
hands [690]. Contact precautions should be imple-
mented for HCT recipients with suspected or
confirmed rotavirus gastroenteritis to prevent trans-
mission in the health care setting (AIII). Alcohol-based
hand gel has some virucidal activity against rotavirus
and is sufficient for routine hand hygiene unless hands
are visibly soiled [685]. Because prolonged shedding
can occur in immunocompromised patients, HCT
staff should ensure consistent environmental cleaning
and disinfection and removal of soiled diapers (AIII)
[144]. If soiled diapers need to be weighed outside of
the patient room, it is important to ensure environ-
mental disinfection of items in contact with soiled di-
apers (eg, cover the scale with paper, appropriately
discard soiled diapers and paper, and disinfect the scale
after each use) (BIII).
Norovirus
Noroviruses are the most common cause of out-
breaks of nonbacterial gastroenteritis. Fecal-oral trans-
mission is most common, although environmental and
fomite contaminations are also important sources of in-
fection. Aerosolization of vomitus resulting in droplets
that contaminate surfaces or are swallowed also con-
tribute to transmission. Infected individuals are conta-
gious up to 72 hours after recovery. The low infectious
dose (\100 particles), multiple modes of transmission,
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asymptomatic people, and the ability to survive high
levels of chlorine and varying temps (freezing and
heating to 60 C) contribute to ease of norovirus
transmission. Detection of viral RNA in stools by use
of RT-PCR assays shows that virus can be isolated as
long as 7 days after symptom onset. To reduce trans-
mission of this highly infectious organism, several
strategies need to be employed, including hand wash-
ing with soap and water, contact precautions, wearing
masks while cleaning areas contaminated by feces or
vomitus, and minimal handling of soiled linens and
clothes (BIII). Use of alcohol-based hand rubs may be
inadequate for preventing norovirus transmission
[691-693].
Noroviruses are resistant to usual cleaning and
disinfection agents [144]. A hypochlorite-based clean-
ing agent is recommended for use on hard, nonporous
environmental surfaces at a concentration of 1000 ppm
(1/3 cup bleach in 1 gallon water for 1:50 dilution) to
5,000 ppm (1 and 2/3 cup bleach in 1 gallon water
for 1:10 dilution), depending on the level of soiling
and types of environmental surfaces (BII) [694]. In
HCT centers without access to prediluted bleach
products, staff should prepare a fresh dilution of bleach
daily and discard unused portions. Environmental
cleaning and disinfection with a hypochlorite-based
cleaning agent should be performed at minimum on
patient discharge from the room (ie, terminal cleaning)
and more frequently as needed (BIII). Quaternary am-
monium compounds do not have significant activity
because noroviruses are nonenveloped virus particles.
Phenolic-based disinfectants are active against norovi-
ruses, but may require concentrations 2 to 4 times
higher than manufacturers’ recommendations for
routine use. Heat disinfection (pasteurization to
60 C) has been suggested for items that cannot be
cleaned with bleach-based disinfectants [695].Astroviruses
Outbreaks of astrovirus gastroenteritis have
occurred in hospitals, nursing homes, and daycare
centers [696-698]. Infection can also occur in HCT
recipients [699]. Astroviruses can be transmitted via
the fecal-oral route, direct and indirect contact, and
possibly via contaminated water [700]. Furthermore,
virus can persist on fecally contaminated surfaces
for several months at relatively low humidity
[531,689]. Contact precautions and environmental
disinfection should be used to control the spread of
astrovirus infection among HCT recipients during
known outbreaks (AII). Quaternary ammonium com-
pounds and chlorine solutions can be effective in
inactivating enteric viruses provided a cleaning step
to remove organic matter precedes terminal disinfec-
tion [531].Infection Control Surveillance
Institutions should follow standard guidelines for
surveillance of epidemiologically significant nosoco-
mial pathogens (eg, MRSA, VRE, MDR-GNB, C. dif-
ficile, invasive mold infections) and their susceptibility
patterns (BIII) [624,701]. In the absence of epidemio-
logic clusters of infections, there is no need to perform
routine bacterial surveillance cultures of the HCT cen-
ter environment, equipment, or devices used for respi-
ratory therapy, pulmonary-function testing, or delivery
of inhalation anesthesia (DIII) [534]. Furthermore, in
the absence of a nosocomial fungal outbreak, it is not
necessary to perform routine fungal cultures of devices
or dust (eg, settle plates) in the rooms of HCT recipi-
ents and candidates undergoing conditioning therapy
(DIII). However, HCT center personnel should per-
form routine surveillance for cases of invasive mold dis-
ease, including aspergillosis, occurring among HCT
recipients (BIII). The optimal surveillance definition
for nosocomial invasive mold disease is unclear. Be-
cause HCT recipients have frequent contact with am-
bulatory healthcare facilities and the incubation
period for invasive mold disease is unknown, all cases
of invasive mold infection should be tracked regardless
of time to onset after admission (BIII). Cases of invasive
mold disease with onset of symptoms $7 days after
hospital admission are more likely to be hospital ac-
quired. Surveillance definitions can include definitions
for proven, probable, and possible cases and criteria can
include culture, histology, host factors, indirect tests
for detection of fungal antigen or cell-wall constitu-
ents, and clinical (including radiology) data (BIII)
[702]. An increase in the number of cases or in the inci-
dence of invasive mold disease among HCT recipients
should trigger careful evaluation of the HCT center
environment for sources of mold exposure. In addition,
the ventilation system should be evaluated to ensure ad-
equate filtration, air flow, and air pressure differentials
(see Ventilation section) (BIII) [547].SAFE LIVING AFTER HCT
D. Yokoe, C. Casper, E. Dubberke, G. Lee, P. Mun˜oz,
T. Palmore, K. Sepkowitz, J.-A.H. Young, J.P. Donnelly
Avoiding Environmental Exposures
Hematopoietic cell transplantation (HCT) recipi-
ents and their caregivers should be educated regarding
strategies to avoid environmental exposures to oppor-
tunistic pathogens (AIII).
Preventing infections primarily transmitted by
direct contact
HCT recipients and candidates should perform
frequent and consistent hand hygiene (AII), especially
related to the following;
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 after changing diapers;
 after touching plants or dirt;
 after urinating or defecating;
 after touching animals;
 after touching body fluids or excretions or items that
might have had contact with human or animal feces
(eg, clothing, bedding, toilets, or bedpans);
 after going outdoors or to a public place;
 after removing gloves;
 after collecting or depositing garbage; and
 before and after touching catheters or wounds [579].
Conscientious hand hygiene using an alcohol-based
hand gel or soap and water is especially critical during
the first 6 months after HCT and during other periods
of substantial immunosuppression (eg, treatment of
GVHD, systemic steroid use, or relapse of the underly-
ing disease for which the transplant was performed). Pe-
diatric HCT recipients and candidates should be
supervised by adults during hand disinfection to ensure
thorough cleaning. Hand hygiene should be performed
with an alcohol-based hand gel or with soap and water
(AII) [703,704]. HCT recipients who visit or live on
farms should follow published recommendations for
preventing cryptosporidiosis [705,706].
HCT recipients should avoid changing diapers
whenever possible (BIII). Even if gloves are worn,
hands should always be washed after gloves are
removed, as gloves may have defects that are not easily
visible (AIII) [707,708].
Preventing infections primarily transmitted
through respiratory exposures
CRV infections can cause severe disease and mor-
tality in HCT recipients [709]. To prevent respiratory
infections after hospital discharge, HCT recipients
should observe the following precautions:
 Perform frequent and thorough hand hygiene (BIII)
and avoid touching their eyes, nose, and mouth un-
less they have disinfected their hands to avoid inoc-
ulating themselves with CRV;
 Avoid close contact with persons with respiratory
illnesses (BIII). When close contact is unavoidable,
both the HCT recipient and the symptomatic con-
tact should be encouraged to disinfect their hands
frequently, as this has been shown to reduce the
transmission of respiratory and other illnesses
[710-713]. Symptomatic contacts should also con-
sider wearing surgical masks [714] or, at a minimum,
cover their mouth and nose with a disposable tissue
when sneezing or coughing [715] or, if tissues are
not available, using their upper sleeves [603]. Al-
though HCT recipients can wear masks themselves
when in contact with symptomatic persons, the
degree of protection from wearing masks has not
been determined. Exercise particularly careful hand hygiene when in
crowded areas (eg, shopping malls or public eleva-
tors) where close contact with persons with respira-
tory illnesses is likely, especially during the autumn
and winter months (AII).
Visitors to HCT centers can introduce communi-
cable infections through environmental contamination
or direct spread. All visitors should perform hand
hygiene before and after visits. All visitors should be
screened for symptoms of infection: fever, rash, vomit-
ing, diarrhea, upper respiratory symptoms, or con-
junctivitis, and should not be allowed to visit a HCT
recipient while they are symptomatic (BIII).
HCT recipients and candidates who are undergo-
ing conditioning therapy are also at risk for infections
caused by fungal, parasitic, and bacterial pathogens as-
sociated with exposure to soil, plants, or their aerosols
(eg, Toxoplasma gondii, Histoplasma capsulatum, Crypto-
coccus neoformans, Nocardia species, and Aspergillus spe-
cies). To prevent such infections, HCT recipients and
candidates should follow the following precautions:
 During the first 6 months after HCT and periods of
substantial immunosuppression (eg, treatment for
GVHD, systemic steroid use, or relapse of the
underlying disease for which the transplant was per-
formed), HCT recipients and candidates who are
undergoing conditioning therapy should avoid gar-
dening or direct contact with soil, plants, or their
aerosols (BIII). If such activity is unavoidable, these
individuals should wear protective gloves to prevent
abrasions or lacerations and surgical or N95 masks
while touching plants or soil, although the effective-
ness of gloves and masks to protect against infec-
tions associated with exposure to soil is unknown
[716-721]. HCT recipients should avoid creating
plant or soil aerosols through activities such as
spreading mulch [722,723]. HCT recipients should
always thoroughly wash their hands with soap and
water after soil or plant contact.
 HCT recipients should avoid construction or exca-
vation sites or other dust-laden environments for the
first 6 months after HCT and during other periods
of substantial immunosuppression to avoid expo-
sures to molds [724]. Outpatient HCT recipients
should be advised of travel routes to the HCT center
that will avoid or minimize exposure to construction
sites (CIII).
Coccidioidomycosis is uncommon after allogeneic
HCT, but can present as severe disease [725,726].
HCT recipients traveling to or residing in areas where
coccidioidomycosis is endemic (eg, the American
Southwest, Mexico, and Central and South America)
should avoid activities that cause exposure to dust
[727], and should minimize exposure to dust or dis-
turbed soil, including construction or excavation sites,
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areas (CIII). Histoplasmosis (Histoplasma capsulatum
infection) after allogeneic HCT is also rare. However,
HCT recipients in histoplasmosis-endemic areas
should avoid exposure to bird-roosting sites and caves
[728] and should avoid exposure to bird or bat drop-
pings (CIII) [729,730].
HCT candidates or recipients should be advised
that certain activities and occupations (eg, work in
healthcare settings, prisons, jails, or homeless shelters)
can increase their risk for tuberculosis (TB) exposure
[731,732]. In deciding whether a HCT recipient
should continue activities in these settings, physicians
should evaluate the patient’s specific duties, the precau-
tions used to prevent TB exposure in the workplace,
and the prevalence of TB in the community. The deci-
sion to continue or terminate such activities should be
made jointly between patient and physician. HCT re-
cipients should avoid exposure to persons with active
TB, particularly during the first 6 months after HCT
and during other periods of substantial immunosup-
pression (BIII).
Persons whose occupations involve animal contact
(eg, veterinarians, pet store employees, farmers, or
slaughterhouse workers) may be at increased risk for
toxoplasmosis, Q fever, brucellosis, and other zoonotic
diseases. Although data are insufficient to justify a gen-
eral recommendation against HCT recipients working
in such settings, these exposures should be avoided
during the first 6 months after HCT and during other
periods of substantial immunosuppression (BIII).
HCT recipients should exercise caution when han-
dling household trash. Air surrounding solid waste has
been shown to contain culturable, aerosolized bacteria,
and fungi [733]. Although there have been no cases of
infection definitively linked to routine handling of
solid waste, it is recommended that HCT recipients
wear masks and use gloves when handling substantial
volumes of waste (CIII).
Recommendations Regarding Household
Members who Receive Live-Attenuated
Vaccines
Household members should receive recommended
vaccines to prevent illness in the household and reduce
the risk of transmission of infections to the HCT re-
cipient (Table 7). When a choice between a live-atten-
uated vaccine and an inactivated vaccine exists (eg,
influenza, polio), household members should receive
inactivated vaccine to reduce the potential risk for
transmission of the vaccine virus. To ensure that
HCT patients are optimally protected from vaccine-
preventable diseases through vaccination of household
contacts while minimizing the risk of transmission of
vaccine virus, clinicians should consider the following
data and current recommendations: Polio vaccine (AII): household members of HCT
recipients should receive inactivated polio vaccine
(IPV), because oral polio vaccine (OPV) is a live-at-
tenuated vaccine that has been rarely associated with
paralysis in healthy recipients and their contacts. If
OPV vaccine is inadvertently given to a household
contact, close contact should be avoided for approx-
imately 4 to 6 weeks after vaccination (AII). If this is
not feasible, HCT recipients should perform careful
hand hygiene after any contact with feces from the
vaccinated household member (eg, after changing
the diaper of a vaccinated child) and avoid contact
with saliva (eg, shared food or utensils) to reduce
the risk of transmission of vaccine-associated polio
virus. Infants and children who have recently
received the OPV vaccine should be excluded from
visiting the HCT unit for 4 to 6 weeks after receipt
of vaccine to minimize the risk of transmission and
vaccine-associated paralytic poliomyelitis among
HCT recipients (AII) [734].
 Rotavirus vaccine (CIII): 2 rotavirus vaccines are cur-
rently available. RV5 is a human-bovine reassortant
vaccine available as a 3-dose series for use in infants
at 2, 4, and 6 months of age to prevent rotavirus gas-
troenteritis [735]. RV1 is a human strain that is
available as a 2-dose series for use in children at 2
and 4 months of age [736-738]. Shedding has been
shown to occur up to 15 days after a dose of RV5
and 30 days after RV1, although there have been
no documented cases of transmission of vaccine vi-
rus [735,739]. Thus, routine standard precautions
are currently recommended for recently immunized
infants. To minimize the risk of potential vaccine vi-
rus transmission, HCT recipients should avoid han-
dling diapers if possible. If this is not feasible, HCT
recipients should perform careful hand hygiene after
any contact with feces from the vaccinated house-
hold member (AIII). Until further data on the risks
of transmission of vaccine virus become available,
HCT units may wish to exclude infants who have re-
cently received rotavirus vaccine from visiting for 2
to 4 weeks after receiving a vaccine dose (CIII).
 Live-attenuated influenza vaccine (LAIV): studies have
demonstrated that 80% of vaccine recipients 8 to 36
months of age shed 1 or more vaccine virus strains
for a mean duration of 7.6 days. Thus far, there
have not been any documented cases of transmission
to an immunocompromised host, and only 1 case of
documented transmission has occurred in an immu-
nocompetent host, with an estimated transmission
rate of 0.6% to 2.9% in a population of young
children enrolled in a childcare center [740]. In
adults, shedding mostly occurs within the first 3
days, but can continue for as long as 7 days after vac-
cination [740,741]. In HIV-infected individuals who
had a CDC class of A1-2 and a plasma HIV RNA
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LAIV virus longer than 10 days. Furthermore, clini-
cal trial data suggest that when vaccine virus is shed by
vaccine recipients, none have reverted to wild type
[742,743]. Because an alternative trivalent inactivated
influenza vaccine (TIV) exists, household members
of HCT recipients should receive TIV to avoid po-
tential concerns for transmission of vaccine virus
(AI). Health care center personnel and HCT center
visitors who receive LAIV instead of TIV should
avoid contact with severely immunosuppressed per-
sons for 7 days after vaccination (CIII) [307].
 Zoster vaccine: herpes zoster vaccine is currently rec-
ommended for adults 60 years of age and older in the
United States [744]. There is no evidence to date that
transmission of vaccine-associated virus has oc-
curred. However, HCT centers should exclude visi-
tors who develop a varicella- or zoster-like rash after
vaccination (AIII). If a household member develops
a varicella or zoster-like rash after vaccination, close
contact with the HCT recipient should be avoided
and affected areas should be covered (AIII).
 Varicella vaccine (AIII): In 1 small study of 37 healthy
children receiving vaccine and their 30 immunocom-
promised siblings, there was no evidence of vaccine
virus transmission [745]. In the postlicensure era,
transmission from immunocompetent persons after
vaccination has been documented by PCR from
only 5 persons resulting in 6 secondary infections,
with over 55 million doses estimated to have been
given [282]. Because the risk of vaccine virus trans-
mission is low, particularly in the absence of a vac-
cine-associated rash, household members should
receive varicella vaccine to protect HCT recipients
from potential exposure to wild-type disease (AIII).
Individuals who experience a vaccine-associated
rash within 1 month after varicella vaccination
should be excluded from visiting the HCT center
and should avoid close contact with HCT recipients
in the home setting (BIII). Measures such as removal
of the vaccinee or transplant recipient from the do-
micile have not been studied.
 Measles, mumps, rubella (MMR) vaccine (AIII):
Household members should receive age-appropri-
ate MMR vaccination as recommended. However,
vaccine recipients who develop a fever and/or rash
postvaccination should be excluded from visiting
the HCT center while symptomatic and should
avoid close contact with HCT recipients in the
home setting (BIII).Safe Sex
Sexually active patients who are not in long-term
monogamous relationships should always use latex
condoms during sexual contact to reduce their risk
for exposure to cytomegalovirus (CMV), herpes sim-plex virus (HSV), HIV, human papilloma virus
(HPV), hepatitis b virus (HBV), hepatitis c virus
(HCV), and other sexually transmitted infections
(STIs) (AII). However, even long-time monogamous
partners can be discordant for these infections. Rein-
fection with some STIs has been reported in seropos-
itive recipients with long-term partners years after
transplant [370]. Therefore, sexually active HCT
recipients in long-term monogamous relationships
should consider using latex condoms during sexual
contact to reduce the risk for exposure to these STIs
(CIII). Additionally, contact with oral or genital secre-
tions has been associated with acquisition of many
STIs, including those from HSV, CMV, Epstein-
Barr virus (EBV), HHV-8, and HPV. Severely immu-
nosuppressed HCT recipients should consider com-
pletely avoiding unprotected sexual activity (ie,
activities that involve contact of the HCT recipient’s
mucous membranes with saliva, semen, or vaginal se-
cretions) for as long as they remain severely immuno-
deficient (CIII). Sexually active HCT recipients
should avoid sexual practices that could result in oral
exposure to feces (AIII) [2,746].
Animal Safety
Preventing pet-transmitted zoonotic infections
HCT physicians should advise recipients and can-
didates undergoing conditioning therapy of the poten-
tial infection risks posed by pet ownership; however,
they should not routinely advise HCT recipients to
part with their pets, with limited exceptions. Immuno-
compromised HCT recipients and candidates should
avoid adopting ill or juvenile pets (eg, cats\6 months
old) [747] and any stray animals (BIII) [2,746]. Chil-
dren are more likely to be bitten or scratched by
pets, and thus the acquisition of new pets by children
who are recent HCT recipients or candidates for
HCT is not recommended (DIII). Generally, immu-
nocompromised HCT recipients and candidates
undergoing conditioning therapy should minimize di-
rect contact with animals [99,748,749], particularly
animals that are ill (eg, with diarrhea) (BIII) [747]. Im-
munocompromised persons who choose to own pets
should be aware that the risk of infection varies with
the type of animal and where the pet was acquired,
with larger, mature animals from established vendors
posing a lower risk than other types of animals [747].
Immunocompromised HCT recipients and candidates
should avoid ownership of, or contact with, reptiles
(eg, lizards, snakes, turtles, and iguanas), because of
the risk for salmonellosis (BII) [747,750-752].
Additionally, patients should be informed that
salmonellosis can occur from fomite contact alone
[752]. Therefore, HCT recipients and candidates
should avoid contact with a reptile, its food, or any-
thing that it has touched. If such contact occurs,
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thoroughly afterward (AIII). Immunocompromised
HCT recipients and candidates should avoid owner-
ship of, or contact with, ducklings and chicks because
of the risk for acquiring Salmonella or Campylobacter
species infections (BIII) [753,754]. Immunocompro-
mised HCT recipients and candidates should avoid
ownership of, or contact with, exotic pets (eg, chin-
chillas or monkeys or other nonhuman primates) (BII).
HCT recipients and candidates need to be vigilant
regarding maintenance of their pet’s health (BIII). If
the pet becomes ill, the owner should seek veterinary
care promptly, to minimize the possible transmission
of the pet’s illness to the owner [747]. Any pet that ex-
periences diarrhea should be tested for infection (BIII)
with Cryptosporidium [2,746], Giardia species [747],
Salmonella, and Campylobacter [2,747]. Owners should
ensure that pets are up to date on recommended vacci-
nations (with the exception of live vaccines) (BIII)
[755]. Routine screening of healthy animals for
zoonotic diseases is not recommended (DIII) [747].
Feeding pets only high-quality commercial pet
foods reduces the possibility of illness caused by spoiled
or contaminated foods, thus reducing the possibility of
transmitting illness from the pet to the HCT recipient.
If eggs, poultry, or meat products are given to the pet as
supplements, they should be well cooked. Any dairy
products given to pets should be pasteurized (BIII)
[747]. Pets should be prevented from drinking toilet
bowl water, scavenging, hunting, eating other animals’
feces, and from having access to garbage (BIII) [747].
If HCT recipients handle pets or clean cages, they
should perform hand hygiene with an alcohol-based
hand gel or soap and water (preferred if hands are vis-
ibly soiled or after contact with feces). Adults should
supervise hand disinfection of pediatric HCT recipi-
ents (BIII). HCT candidates and recipients should
avoid contact with animal feces (BIII) to reduce the
risk for toxoplasmosis, cryptosporidiosis, salmonello-
sis, and campylobacteriosis [747], and should not clean
pet litter boxes or cages or dispose of animal waste
(DIII) [1]. If patients are unable to find assistance
with these tasks, they should wear disposable gloves
during such activities and wash their hands thoroughly
afterward (BIII). Bird cage linings and cat litter should
be cleaned regularly (eg, daily) [747]. All persons, but
particularly immunocompromised HCT candidates
and recipients, should wear gloves whenever handling
items contaminated with bird droppings (BIII) because
droppings can be a source of Cryptococcus neoformans,
Mycobacterium avium, or H. capsulatum [747]. To min-
imize potential exposure to Mycobacterium marinum,
immunocompromised HCT recipients and candidates
should not clean fish tanks (DIII). If this task cannot be
avoided, patients should wear disposable gloves during
such activities and disinfect their hands thoroughly
afterward (BIII) [747,754].HCT candidates or recipients may also come into
contact with animals in the medical setting. These
animals are typically divided into 3 categories: service,
therapy, and visitation [756]. In most settings, access to
service animals can not legally be restricted. Animals
are increasingly used as adjunctive therapy for patients
with cancer and other chronic illnesses. Although
many studies attest to the overall benefits of such
‘‘therapy’’ or ‘‘visitation’’ animals in various clinical
settings, the risk of acquiring a zoonotic infection for
immunosuppressed HCT candidates or recipients
needs to be carefully considered, and thus, no recom-
mendation can be given.
Preventing toxoplasmosis
Many cases of primary toxoplasmosis are acquired
through eating undercooked meat [747,749]. How-
ever, all HCT recipients and candidates, particularly
those who are T. gondii seronegative, should be in-
formed of the risks for contracting toxoplasmosis
from ingestion of oocytes after contact with cat feces
(BIII), although they need not be required to give
away their cats (DII). In households with cats, litter
boxes should not be placed in kitchens, dining rooms,
or other areas where food preparation and eating occur
[747]. Additionally, litter boxes should be cleaned daily
by someone other than the HCT recipient during the
first 6 months after HCT and during periods of sub-
stantial immunosuppression to reduce the risk for
transmitting toxoplasmosis to the HCT recipient
(BIII). Daily litter box changes will minimize the risk
for fecal transmission ofT. gondii oocysts, because fecal
oocysts require.1 days of incubation to become infec-
tious. If HCT recipients perform this task during the
first 6 months after HCT and during subsequent pe-
riods of substantial immunocompromise (eg, during
GVHD, systemic steroid use, or relapse of the under-
lying disease for which the transplant was performed),
they should wear disposable gloves [747]. Gloves
should be discarded after a single use (BIII). Soiled,
dried litter should be disposed of carefully to prevent
aerosolizing the T. gondii oocysts (BIII). Cat feces
(but not litter) can be flushed down the toilet, although
this is not recommended because T. gondii oocysts are
not consistently inactivated by sewage systems (DIII).
Also, persons who clean cat litter, particularly HCT
recipients, should wash their hands thoroughly with
soap and water afterward to reduce their risk for
acquiring toxoplasmosis (BIII).
HCT recipients and candidates with cats should
keep their cats inside (BIII) and should not adopt or
handle stray cats (DIII). Cats should be fed only canned
or dried commercial food or well-cooked table food,
not raw or undercooked meats, to eliminate the possi-
bility of causing an illness that could be transmitted
from the cat to the HCT recipient (BIII). Pet cats of
HCT recipients do not need to be tested for
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kept covered when not in use to prevent cats from soil-
ing them (BIII). HCT recipients and candidates under-
going conditioning therapy should avoid drinking raw
goat’s milk, to decrease the risk for acquiring toxoplas-
mosis (DIII). Toxoplasmosis may also be acquired after
contact with cat feces encountered while gardening.
Water and Other Beverage Safety
HCT recipients should avoid walking, wading,
swimming, or playing in recreational water (eg, ponds
or lakes) that is likely to be contaminated with Crypto-
sporidium, E. coli O157:H7 [749,757-759], sewage, or
animal or human waste (DII). HCT recipients should
also avoid swallowing such water (eg, while swimming)
[2,757,759], as well as any water taken directly from
rivers and lakes (EIII) [2,746].
Water and other beverages may pose a risk to im-
munocompromised HCT candidates and recipients
because of bacterial, viral, and parasitic pathogens.
HCT recipients should not use well water from private
wells or from public wells in communities with limited
populations (DIII) because tests for microbial contam-
ination are performed too infrequently (eg, in certain
locations, tests are performed#1 times/month) to de-
tect sporadic bacterial contamination. However,
drinking well water from municipal wells serving
highly populated areas is regarded as safe from bacte-
rial contamination because the water is tested $2
times/day for bacterial contamination. If HCT recipi-
ents consume tap water, they should routinely monitor
mass media (eg, radio, television, or newspapers) in
their area and immediately implement any boil-water
advisories that might be issued for immunocompro-
mised persons by state or local governments (BIII). A
boil-water advisory means that all tap water should
be boiled for .1 minute before it is consumed [760].
Although municipal tap water is generally safe, it
may not be completely free of Cryptosporidium. Al-
though limited data exist regarding the risks for and
epidemiology of Cryptosporidium disease among HCT
recipients [761], HCT recipients should avoid possible
exposures to Cryptosporidium (DIII) because this path-
ogen has been reported to cause severe, chronic diar-
rhea, malnutrition, and death among other
immunocompromised persons [746,762,763]. To
eliminate the risk for Cryptosporidium exposure from
tap water, HCT recipients can boil tap water for
$1 minute before consuming it (CIII) [746]. Alterna-
tively, they can use certain types of water filters or
a home distiller to reduce their risk for exposure to
Cryptosporidium [746] and other waterborne pathogens
(CIII). If a home water filter is used, it should be capa-
ble of removing particles$1 mm in diameter, or should
filter by reverse osmosis (for a list of filters certified un-
der National Sanitation Foundation [NSF] Standard
053 for cyst (ie, Cryptosporidium) removal, contact theNSF International consumer line or http://
www.nsf.org). However, the majority of these filters
are not capable of removing smaller microbes (eg, bac-
teria or viruses), and therefore, should be used only on
properly treated municipal water. The majority of
these devices are inappropriate for use on water from
an unchlorinated private well to control viral or bacte-
rial pathogens.
Bottled water can be consumed if it conforms to re-
gional standards (eg, the FDA for the United States
and Directive 80/777/EEC for the EU) and has been
processed to remove Cryptosporidium by 1 of 3 pro-
cesses: reverse osmosis, distillation, or 1-mm particu-
late absolute filtration. HCT recipients should
contact the bottler directly to confirm that a specific
bottled water has undergone 1 of these processes.
The International Bottled Water Association can be
contacted in the United States at (703) 683-5213
from 9 a.m. to 5 p.m. EST or anytime at their Internet
site (http://www.bottledwater.org) to obtain contact
information regarding water bottlers.
Patients can take other precautions in the absence
of boil-water advisories to further reduce their risk for
cryptosporidiosis. These extra precautions include
avoiding fountain beverages and ice made from tap wa-
ter at restaurants, bars, and theaters; fruit drinks made
from frozen concentrate mixed with tap water; and
iced tea or coffee made with tap water [746]. Drinks
that are likely to be Cryptosporidium-safe for HCT re-
cipients include nationally distributed brands of bot-
tled or canned carbonated soft drinks; commercially
packaged noncarbonated drinks that contain fruit
juice; fruit juices that do not require refrigeration until
after opening (eg, those that are stored unrefrigerated
on grocery shelves); canned or bottled soda, seltzer, or
fruit drinks; steaming hot (.175 F [80 C]) tea or cof-
fee; juices labeled as pasteurized; and nationally dis-
tributed brands of frozen fruit juice concentrate that
are reconstituted with water from a safe source
[705,746]. HCT recipients should not drink nonpas-
teurized milk or fruit or vegetable juices (eg, apple ci-
der or orange juice), to avoid infection with Brucella
species, E. coli O157:H7, Salmonella species, Cryptospo-
ridium, and other pathogens (DII) [763-766].
Food Safety
Recommendations on food safety are based largely
on observations in the general population. Concern
arising from the detection of potential pathogens in
food has not been supported by documented evidence
of such organisms as the source of opportunistic infec-
tions in immunocompromised persons. The potential
benefit of food safety recommendations directed spe-
cifically toward HCT recipients must be weighed
against the uncertain value of such recommendations
[767] and their potential to adversely affect patients‘
nutritional intake and/or quality of life.
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food for them after HCT should review general food
safety practices (AIII) [768] and should be educated
regarding additional food safety practices appropriate
for HCT recipients. This review and education should
be done before the conditioning regimen (ie, chemo-
therapy and radiation) begins (BIII). Adherence to
these guidelines will decrease the risk for food-borne
disease among HCT recipients.
Food safety practices appropriate for all persons
Raw poultry, meats, fish, and seafood should be
handled on separate surfaces (eg, cutting board or
counter top) from other food items. Persons preparing
food should always use separate cutting boards or wash
the board(s) with warm water and soap between cutting
different food items (AIII). To prevent foodborne ill-
nesses caused by Campylobacter jejuni and Salmonella en-
teritidis, which can cause severe and invasive infections
among immunocompromised persons [769], uncooked
meats should not come in contact with other foods
(DIII). After preparing raw poultry, meats, fish, and sea-
food and before preparing other foods, food handlers
should wash their hands thoroughly in warm, soapy wa-
ter. Any cutting boards, counters, knives, and other
utensils used should also be washed thoroughly in
warm, soapy water (AIII). Food preparers should keep
shelves, countertops, refrigerators, freezers, utensils,
sponges, towels, and other kitchen items clean (AIII).
All fresh produce should be washed thoroughly under
running water before serving (AIII) [768]. Persons pre-
paring food should follow published recommendations
regarding safe food thawing (BIII) [770].
Persons cooking food for HCT recipients should
follow established guidelines for monitoring internal
cooking temperatures for meats, which is the only
method for determining if meat has been adequately
cooked (AII). Different kinds of meat should be cooked
to varying internal temperatures, all .150F (66 C)
(AII). Specifically, food oversight agencies such as
the U.S. Department of Agriculture recommend that
poultry be cooked to an internal temperature of
180F (82 C). Other meats and egg-containing casse-
roles and souffles should be cooked to an internal tem-
perature of .160F (71 C). Cold foods should be
stored at\40F (4 C), and hot foods should be kept
at .140F (60 C) (BIII). Food preparers should
wash their hands before and after handling leftovers
(AIII); use clean utensils and food-preparation surfaces
(AIII); divide leftovers into small units and store in
shallow containers for quick cooling (AII); refrigerate
leftovers within 2 hours of cooking (AII) or discard
leftovers that were kept at room temperature for
.2 hours (AIII); reheat leftovers or heat partially
cooked foods to .165F (74 C) throughout before
serving (AII); bring leftover soups, sauces, and gravies
to a rolling boil before serving (AIII); and follow pub-lished guidelines for cold storage of food (AII). Left-
over foods placed in the refrigerator should be dated
and discarded after 72 hours.
Additional food safety practices appropriate for
HCT recipients
HCT recipients’ diets should be restricted prior to
engraftment to decrease the risk for exposure to food-
borne infections from bacteria, yeasts, molds, viruses,
and parasites. A low-microbial diet is recommended
for HCT recipients prior to engraftment [771,772],
although evidence for its efficacy to prevent infection
is lacking (CIII) [773].
Once HCT recipients have engrafted, they should
follow a diet that balances the risk for acquiring food-
borne illnesses with the importance of proper nutri-
tional supplementation, as recommended below and
outlined in Table 5. This diet should be continued
for 3 months after autologous HCT, and allogeneic
HCT recipients should remain on this diet until all
immunosuppressive drugs are discontinued and the
patient has reached the milestone of receiving live virus
vaccines. However, the HCT physician should have
final responsibility for determining when the diet can
be discontinued safely.
HCT recipients should not eat raw or under-
cooked meat, including beef, poultry, pork, lamb, ven-
ison or other wild game, or combination dishes
containing raw or undercooked meats or sweetbreads
from these animals (eg, sausages or casseroles) (EII).
HCT recipients and candidates should only consume
meat that is well done when they or their caretakers
do not have direct control over food preparation (eg,
when eating in a restaurant) (AI). Hot dogs and deli-
style ready-to-eat meats should be avoided unless
heated until steaming (AII).
HCT recipients should not consume raw or under-
cooked eggs or foods that might contain them (eg, cer-
tain preparations of hollandaise sauce, Caesar and
other salad dressings, homemade mayonnaise, and
homemade eggnog) because of the risk for infection
with Salmonella enteritidis (EII) [774]. HCT recipients
should not consume raw or undercooked seafood (eg,
oysters or clams), to prevent exposure to Vibrio species,
viral gastroenteritis, and Cryptosporidium parvum
(EII) [769].
Fruits and vegetables provide essential nutritional
elements to HCT patients, but certain precautions
should be taken to prevent acquisition of infection.
In general, it may be helpful to remind patients of
the adage ‘‘If you can’t peel or wash it, don’t eat it.’’
Most infections from agricultural products are ac-
quired either through contamination of the item while
in the field or subsequent to harvesting during process-
ing. Washing of fruits and vegetables in tap water is ad-
visable even for those with skin or rinds, organic foods,
and prepackaged items labeled as ‘‘prewashed’’ (BIII).
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lated infections, but not all. HCT recipients should
avoid fruits and vegetables that may confer higher
risk of infection, including raw vegetable sprouts (E.
coli and Salmonella), fresh salsa, and berries (EII).
Other food items that have been associated with
food-borne outbreaks in the past and, therefore, which
HCT patients should avoid, include unroasted raw nuts
or nuts in the shell, miso products, raw grain products,
nonpasteurized milk products (milk, cheese, yogurt),
cheeses containing uncooked vegetables, cheeses with
molds (ie, blue, Stilton, Roquefort, and gorgonzola),
soft cheeses (eg, brie and feta), smoked or pickled sea-
food, raw honey, and tempe products (EII).
To date, no evidence exists that there is a greater
risk for acquiring infection from eating at a fast food
restaurant than at a conventional sit-down restaurant.
Several steps can be taken to ensure the safety of
food consumed at such establishments (AIII): (1) ask
that food be freshly prepared (ie, avoid food that has
been sitting under heat lamps); (2) ask if fruit juices
are pasteurized; (3) avoid any raw fruits and vegetables
when dining out; (4) ask for single-serving condiment
packages (avoid use of public self-serve condiment
containers); (5) avoid salad bars, delicatessens, buffets,
smorgasbords, etc.; (6) set utensils on a napkin or clean
tablecloth or placemat (rather than directly on the
table); and (7) if planning to take the leftovers home,
transfer the food directly to a box at the table. Simi-
larly, although consumption of prepared food pur-
chased from street vendors in industrialized countries
has not been associated with infection, food prepara-
tion under stringent sanitary conditions cannot be
guaranteed and therefore such food should be avoided
(DIII); the same is true of food brought by others to
gatherings such as potlucks or picnics.
The consumption of foods with ‘‘active’’ or ‘‘live’’
yeast cultures (‘‘probiotics’’) has been promoted as an
effective means of preventing infections. Studies to
date have not been definitive, but there is some support
in the literature for the possibility that consumption of
probiotics reduces antibiotic-associated diarrhea [775]
or genitourinary infections [776]. The use of probiot-
ics has not been examined in the setting of HCT. Dis-
seminated infection from probiotic administration has
been reported in HCT patients, however [777], and
HCT recipients should avoid the use of probiotics
(DIII). HCT candidates undergoing conditioning
therapy and HCT recipients with neutropenia (ie,
ANC \1000/mL3) or during periods of substantial
immunocompromise should also avoid exposure to
naturopathic medicines that might contain molds
(DIII) [778]. HCT recipients wishing to take naturo-
pathic medications are advised to use them only as pre-
scribed by a licensed naturopathic physician working
in consultation with the recipient’s transplant and
infectious disease physicians (CIII).Travel Safety
For HCT recipients, particularly allogeneic recipi-
ents who are chronically immunosuppressed, travel to
developing countries can pose substantial risks for ex-
posure to opportunistic pathogens. HCT recipients
should not plan travel to developing countries without
consulting their physicians (EIII), and should not un-
dertake such travel until the period of severe immuno-
suppression has resolved. Generally, allogeneic
recipients should not plan travel to developing coun-
tries for 6 to 12 months after HCT, and should refrain
from travel in the setting of immunosuppressive treat-
ment for GVHD. Autologous recipients can travel to
developing countries 3 to 6 months after HCT if their
HCT providers agree that this is safe and appropriate.
HCT recipients should be educated about regard-
ing strategies to minimize the risk for acquiring infec-
tions while traveling. Selected strategies include the
following:
HCT recipients should obtain updated, detailed
health information for international travelers from
health organizations (AIII) [779];
 ‘‘Adventure’’ travel (eg, kayaking, participating in
triathlons), has been associated with epidemic infec-
tions (such as leptospirosis), and should be avoided
(DIII) [780-782];
 Air travel is generally safe, although rarely may be
associated with acquisition of respiratory illnesses
(eg, influenza, tuberculosis, measles) [783]. HCT
recipients should use techniques such as social dis-
tancing and hand hygiene to avoid infections from
other passengers in close proximity who exhibit
respiratory symptoms (BIII)
 Cruise ships are generally considered to be safe, but
may be associated with acquisition of GI (eg, noro-
virus) and Legionella infections. HCT recipients
should be fastidious about washing hands with
soap and water frequently while on cruises and
should promptly report any symptoms that may
arise to their transplant team (AII).
 Food safety is of paramount importance while trav-
eling to developing countries. HCT recipients
should avoid consuming (DIII) raw fruits and vege-
tables; tap water or any potentially untreated or con-
taminated water; ice made from tap water or any
potentially contaminated water; nonpasteurized
milk or any nonpasteurized dairy products; fresh
fruit juices, food, and drinks from street vendors;
and raw or undercooked eggs. Steaming hot foods,
fruits peeled by oneself, bottled and canned pro-
cessed drinks, and hot coffee or tea are probably
safe [784]. Travelers should plan for treating their
drinking water while in developing countries. If bot-
tled water is not available, boiling is the best method
of making water safe. However, if boiling of water is
not feasible, the traveler should carry supplies for
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disinfection tablets or a portable water filter) (BIII)
[784,785]. As referenced in the food safety section,
water disinfection does not mitigate the risk for
cryptosporidiosis and viral infections.
Antimicrobial prophylaxis for traveler’s diarrhea is
not recommended routinely for HCT recipients trav-
eling to developing countries (DIII). However, HCT
physicians who wish to provide prophylaxis to HCT
recipients who are traveling can prescribe a fluoroqui-
nolone (eg, ciprofloxacin) (Appendix 1) (CIII). Some
clinicians recommend using bismuth subsalicylate to
prevent traveler’s diarrhea in adults [784]. However,
no data were found regarding safety and efficacy
among HCT recipients, and salicylates are not recom-
mended for use among persons younger than 18 years
of age, because salicylates are associated with Reye’s
syndrome [784].
HCT recipients’ immunization status should be
assessed and their vaccinations updated as needed
before travel (Table 6) [784]. Influenza chemoprophy-
laxis with oseltamivir or zanamivir (depending on the
circulating strain and susceptibilities) can be used for
immunocompromised HCT recipients who could be
exposed to influenza while traveling (CIII), but trav-
elers should be vigilant about the risk of pandemic
influenza or severe acute respiratory syndrome
(SARS).VACCINATION OF HCT RECIPIENTS
P. Ljungman, C. Cordonnier, H. Einsele, J. Englund,
C.M. Machado, J. Storek, T. Small
Vaccination recommendations have previously
been developed and published separately by the
EBMT and the CDC, the IDSA, and the ASBMT
[1,786,787]. The purpose of the vaccination schedule
in these joint updated guidelines is to provide guidance
for HCT centers around the globe.
Antibody titers to vaccine-preventable diseases (eg,
tetanus, polio, measles, mumps, rubella) decline dur-
ing the 1 to 10 years after allogeneic or autologous he-
matopoietic cell transplantation (HCT) [788-792] if
the recipient is not revaccinated. The clinical relevance
of decreased antibodies to vaccine-preventable dis-
eases among HCT recipients is not immediately
apparent because a limited number of cases of vac-
cine-preventable diseases are reported among HCT
recipients. However, vaccine-preventable diseases still
pose risks to the population. Additionally, evidence ex-
ists that certain vaccine-preventable diseases such as
pneumococcal infection, Haemophilus influenzae type
b (Hib) infection, measles, varicella, and influenza
can pose increased risk for HCT recipients
[193,309,793-798]. Therefore, HCT recipients should
be routinely revaccinated after HCT so that they canexperience immunity to the same vaccine-preventable
diseases as others (Table 6). Although several studies
have evaluated safety and immunogenicity (eg, sero-
logic studies of antibody titers after vaccination) of dif-
ferent vaccines in allogeneic HCT recipients, limited
and only indirect data were found regarding vaccine
efficacy among HCT recipients (ie, whether vacci-
nated HCT recipients have decreased attack rates of
infections compared with unvaccinated HCT recipi-
ents) [798].
For a vaccine to mount a response thought to be
clinically relevant (eg, a 4-fold rise in specific antibody
levels or a rise to a level considered protective), adap-
tive (T and B cell) immunity posttransplant must
have been at least partially reconstituted. B cell counts,
which are typically zero or near-zero in the first 1 to 3
months after HCT, return to normal by 3 to 12
months posttransplant [799,800]. In patients treated
with rituximab posttransplant, B cell recovery is gener-
ally delayed for 6 months following the last dose [801].
Regardless of the time to recovery, the newly gener-
ated B cells often demonstrate impaired antigen-spe-
cific responses because of a limited capability of
naı¨ve B cells to undergo somatic mutation and isotype
switching during the first year after transplant. T cell
counts are low in the first 1 to 3 months posttransplant
(CD41 counts are typically\200/mL). Thereafter, the
recovery of T cells, particularly CD41 T cells, is influ-
enced by patient age at HCT, substantial T cell deple-
tion (TCD) of the graft, and the presence or absence of
cGVHD. Most patients \18 years at HCT without
cGVHD will recover CD41 cell counts of .200/mL
by 6 to 9 months after transplant, whereas adults, par-
ticularly those with cGVHD, may require .2 years.
Most of the circulating T cells in the first year after
transplantation, particularly in adults, are memory/ef-
fector T cells, likely derived from the T cells infused
with the graft and capable of responding to antigens
encountered by the donor prior to the transplant. Na-
ı¨ve T cells capable of responding to new antigens start
to be generated only at 6 to 12 months posttransplant,
earlier in young children and later in older adults. Be-
cause HCT recipients have varying immune system re-
covery after HCT, it has been proposed that different
vaccination schedules be recommended for recipients
of different types of HCT, with the rationale that,
for example, autologous HCT patients do not lose im-
munity as frequently or rapidly as patients after alloge-
neic HCT. The existing evidence suggests, however,
that loss of immunity is also common after autologous
HCT (particularly in patients who have received mul-
tiple courses of chemotherapy before HCT), and that
responses to vaccination are similar to those that occur
after allogeneic HCT [194,790,791,802-805]. It
should also be recognized that limited information re-
garding vaccine immunogenicity exists for patients
transplanted with umbilical cord blood (UCB) or
Table 8. Vaccinations for Family, Close Contacts, and Healthcare Workers (HCWs) of HCT Recipients
Vaccine Recommendations for Use Rating
Hepatitis A [829] Routine vaccination is recommended for:
 Children $12 months of age; and
 Other persons at increased risk for hepatitis A or its adverse consequences
BIII
Inactivated Influenza*† [307,308]
NOTE: Use of intranasal influenza
vaccine is contraindicated (EIII)
Family and close contacts
Vaccination with trivalent inactivated vaccine (TIV) is strongly recommended annually for all during each influenza
season, beginning in the season before the transplant and continuing as long as there is contact with an
immunocompromised HCT recipient
HCWs
Annual vaccination with TIV is strongly recommended during each influenza season.
AII
AI
Polio‡ Not routinely recommended for adults but inactivated§ polio vaccine should be administered when polio
vaccination is indicated
AII
Rotavirus Vaccination not contraindicated in contacts of HCT transplant patients.
Follow recommendations for general population in each country
CIII
Measles-mumps-rubella
(MMR) (live)
Vaccination is recommended for all persons who are
$ 12 months old and are not pregnant or immunocompromised.
No evidence exists that live-attenuated vaccine-strain viruses in MMR vaccine are transmitted from person to
person
AIII
Pertussis Vaccination with DTaP is recommended for children < 7 years and with Tdap for adolescents and adults. BIII
Varicella¶
(live)
Vaccination should be administered to all persons $12 months old and who are not pregnant or
immunocompromised and who have a negative or uncertain history of varicella disease with a negative serologic
screen.
Note: Two doses should be given separated by at least 28 dayst
AIII
HCT indicates hematopoietic cell transplant.
*Children aged 6 months to <9 years receiving influenza vaccination for the first time require 2 doses and those who only receive 1 dose in the first year
should receive 2 doses the following year [304,307].
†If HCWs, family members, or other close contacts of HCTrecipients receive influenza vaccination during an influenza outbreak, they should also re-
ceive chemoprophylaxis, based on strain susceptibility (BI), while the vaccinee develops an immunologic response to the vaccine. However, if a nosoco-
mial outbreak occurs with an influenza strain that is not contained in the available influenza vaccine, HCWs, family members, and other close contacts of
HCT recipients and candidates should be administered influenza chemoprophylaxis based on strain susceptibility, until the end of the outbreak (BIII)
[307,830,831].
‡Vaccine-strain polio virus in oral polio vaccine can be transmitted person to person; therefore, oral polio vaccine administration is contraindicated
among household contacts of immunocompromised persons. If oral polio vaccine is inadvertently administered to a household contact of an HCTre-
cipient, ACIP’s and the American Academy of Pediatrics’ recommendations should be followed to minimize close contact with the immunocompromised
person for 4-6 weeks after vaccination [304,832,833].
§Although vaccine-associated paralytic poliomyelitis has not been reported among HCTrecipients after exposure to household contacts inadvertently
vaccinated with oral polio vaccine, inactivated polio vaccine should be used among family members, close contacts, and HCWs to avoid person-to-per-
son transmission of vaccine-strain polio virus [832].
¶HCWs, family members, close contacts, and visitors who do not have a documented history of varicella-zoster infection or who are seronegative
should receive varicella vaccine before being allowed to visit or have direct contact with an HCT recipient (AIII). Ideally, varicella-zoster- susceptible
HCWs, family members, household contacts, and potential visitors of immunocompromised HCTrecipients should be vaccinated as soon as the de-
cision to perform an HCT is made. The vaccination dose or doses should be completed >4 weeks before the conditioning regimen begins or >6 weeks
(42 days) before contact with the HCTrecipient is planned (BIII). If a varicella vaccinee develops a postvaccination rash within 42 days of vaccination, the
vaccinee should avoid contact with HCTrecipients until all rash lesions are crusted or the rash has resolved [282,304]
tChildren 12 months to 12 years should receive two doses 3 months apart; adolescents $13 years and adults should receive 2 doses 4 weeks apart.
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tioning (RIC). For the sake of simplicity, therefore, the
committee has chosen to recommend the same vacci-
nation schedule for all HCT recipients until additional
data are published.
T cell response to vaccines for pathogens encoun-
tered pretransplant (eg, varicella zoster virus [VZV])
can be observed as soon as 1 to 6 months posttransplant.
Antibody response to vaccines for pathogens encoun-
tered pretransplant (eg, tetanus toxoid) can be observed
at 6 to 12 months after HCT. T cell or antibody re-
sponse to vaccines for pathogens not encountered pre-
transplant (eg, hepatitis B virus [HBV] in most
European and American adults) can usually be ob-
served later (1 year or more posttransplant). HCT re-
cipients are similar to young children in that they
respond poorly to pure polysaccharide antigens suchas those included in the 23-valent polysaccharide
pneumococcal vaccine. Pure polysaccharide antigens
elicit antibody responses later after HCT than protein
antigens (eg, diphtheria toxoid) or polysaccharide-pro-
tein conjugates (eg, Hib capsular polysaccharide conju-
gated to a carrier protein). Graft-versus-host disease
(GVHD) and/or its treatment hamper T cell and anti-
body responses to vaccines. Because studies have shown
that patients with chronic GVHD (cGVHD) can
mount responses to vaccines and clearly need protec-
tion against pneumococci, these guidelines do not rec-
ommend postponing vaccination in patients with
GVHD with the exception of withholding live vac-
cines. However, when vaccinating patients with active
GVHD, it may be prudent to measure specific antibody
levels before and after vaccination, to determine their
level of protection and need for booster immunizations.
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into different categories. In Table 6, the vaccines are
listed for which evidence exists regarding safety and
immunogenicity and that are generally recommended
to be used in HCT recipients. Since the previous ver-
sion of the vaccination guidelines was published, new
vaccines have been introduced. In addition, clinicians
at HCT centers get questions from patients, family
members, and HCWs regarding vaccinations in spe-
cial situations, such as after disease exposure or before
travel to areas endemic for infections not previously
considered in these recommendations. Therefore,
comments are made regarding these vaccines and situ-
ations (Table 7), although very limited or no data exist.
Finally, there are situations when vaccination of family
members, household contacts, and HCWs is recom-
mended to minimize exposure of vaccine-preventable
diseases among HCT recipients (Table 8).Donor vaccination
Vaccination of the donor has been shown to
improve the posttransplant immunity of the patient
in the case of tetanus toxoid, 7-valent PCV, and Hib-
conjugate vaccines. No recommendations are made
regarding donor vaccination, because of practical and
ethical difficulties surrounding this issue.
Serological testing
HCT patients are immunosuppressed to varying
degrees, and it is therefore prudent to test immunity
to some infections before or after vaccination.
Testing before vaccination. Testing for anti-
bodies to measles is recommended in adults, with vac-
cination performed only if the patient is seronegative
(CIII) (Table 6). If vaccination against varicella is con-
templated, testing of immunity should be performed
and vaccination given to seronegative patients only
(CIII) (Table 6).
Testing after vaccination. Testing after vaccina-
tion can be indicated either to assess the response to
vaccination and the need for additional doses or to
check durability of response during long-term fol-
low-up. Testing to assess the response to vaccination
against pneumococcal disease is recommended at 1
month or later after the third or fourth dose of pneu-
mococcal vaccine (BIII) (Table 6). There are different
methods for assessment of pneumococcal antibody
levels, each having advantages and disadvantages;
thus, no specific method can be recommended. Like-
wise, as a widely accepted definition of adequate
response to pneumococcal vaccine is lacking, guide-
lines for revaccination of nonresponders are not given.
Testing to assess the response to HBV vaccination is
also recommended. Testing should be done 1 month
or later after the third vaccine dose (BIII). A second
3-dose vaccination schedule is recommended in non-responders (CIII). The interval between the first and
second series has to be determined individually be-
cause nonresponsiveness to HBV vaccine can have dif-
ferent causes (eg, cGVHD, in which case it may be
prudent to revaccinate only after GVHD has abated).
Regular testing of long-term HCT survivors for
maintenance of antibody levels is recommended
(BIII). Testing should be conducted approximately
every 4 to 5 years to assess for immunity to HBV, mea-
sles, tetanus, diphtheria, and polio (BIII). Testing for
immunity to pneumococcus might reasonably be
repeated every 2 years for the first 4 years (BIII).
The need for revaccination has to be assessed on an
individual basis.
Comments Regarding Specific Vaccines
Pneumococcal vaccine
There are 2 types of pneumococcal vaccine: a con-
jugate vaccine (PCV) and a polysaccharide vaccine
(PPSV23). As with most conjugate vaccines compared
with polysaccharide vaccines, PCV is more immuno-
genic than PPSV23. However, the spectrum of protec-
tion is narrower, as PCV7 covers only 7 strains of
pneumococci whereas PPSV23 covers 23 strains.
When given during the first year after transplantation,
PPSV23 elicits inadequate responses. Four prospec-
tive trials demonstrate better responses with PCV in
HCT recipients [195,797,806,807]; thus, PCV is the
preferred vaccine. It is likely beneficial to use
PPSV23 for the fourth dose (after 3 doses of PCV)
(BII), to broaden the immune response [808]. A fourth
dose of PCV might increase the response rate in pa-
tients with cGVHD, who are less likely to respond to
PPSV23 (CIII).
If a microbiologically documented pneumococcal
infection occurs after pneumococcal vaccination, doc-
umenting the serotype of the strain is recommended
(BIII), to know whether the serotype is among those
included in the vaccine, which can be indicative of
a nonresponse to the vaccine(s). Such patients should
receive additional doses of pneumococcal vaccine,
with the choice of vaccine (ie, PCV or PPSV23) de-
pending on the documented strain (BIII).
The time posttransplant to initiate routine vaccina-
tion with PCV is controversial. One trial showed simi-
lar antibody responses with vaccination started at 3
months (early) and 9 months (late) posttransplant
[808]. Thus, early vaccination may be preferred as it
may protect against not only late but also early pneumo-
coccal disease. It should be noted that early vaccination
may not prime for a PPSV23 boost as efficiently as the
late vaccination. Also, early vaccination may result in
a shorter lasting antibody response. Therefore, if vacci-
nation is started early, it may be particularly important
to determine pneumococcal antibody levels and, if
these are ‘‘low,’’ revaccinate (BIII).
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There are 2 general types of diphtheria and tetanus
vaccines: those containing ‘‘full’’-dose diphtheria tox-
oid in combination with tetanus toxoid (DT) and those
containing reduced dose diphtheria toxoid (such as
Td; the lower case ‘‘d’’ indicates reduced diphtheria
toxoid, while the tetanus content is essentially the
same in TD and Td). Use of reduced diphtheria toxoid
vaccines following transplant can be associated with
lack of response. Therefore, posttransplant patients
should be viewed as ‘‘never vaccinated’’ and full toxoid
vaccines should be used if possible. The DT vaccine is
not approved in individuals .7 years of age in the
United States because of side effects, although experi-
ence with adult HCT recipients receiving DT vaccine
indicates a lower risk for side effects than in previously
vaccinated healthy adults. Adult transplant recipients
might have an adequate response to the diphtheria
portion of Td. However, whether the response is equal
to TD has not been studied. Checking diphtheria an-
tibody level after vaccination with Td might therefore
be warranted in situations where an increased risk for
diphtheria might be envisaged.Pertussis vaccine
For the general population, the Advisory Commit-
tee on Immunization Practices and the CDC have rec-
ommended use of acellular (rather than whole cell)
pertussis vaccine in pediatric vaccination regimens
since 1997. Because of the steady increase in pertussis
over the last decade and the licensing of 2 vaccines con-
taining tetanus, reduced dose diphtheria, and reduced
dose pertussis (Tdap), the CDC now recommends that
adolescents (10-18 years of age) and adults (19-64
years of age) receive a single dose of Tdap to replace
their routine adult tetanus and diphtheria toxoids
(Td) booster. For adolescents, the preferred age range
is 11 to 12 years. For adults (11-64 years), a single
Tdap is recommended to replace their routine Td
booster if given $10 years earlier. The recommended
interval of 10 years between Td and Tdap was because
of concerns of local site reactions. However, for adults
who have contact with infants\12 months, HCWs,
and those in community outbreaks of pertussis, inter-
vals as short as 2 years after the last Td is now recom-
mended. The aim is to decrease the reservoir of
pertussis that affects infants and immunocompromised
individuals regardless of age.
HCT recipients may be particularly vulnerable to
complications from pertussis because of pulmonary
damage from chemotherapy and/or TBI, even in the
absence of cGVHD. Because posttransplant patients
should be viewed as ‘‘never vaccinated’’ and receive
full doses of toxoids, their ‘‘DT’’ vaccine should in-
clude full-dose (not reduced dose) acellular pertussis
toxoid (DTaP) if available. In the United States,DTaP is available for children \7 years. The adult
pertussis vaccine used frequently by community physi-
cians, Tdap, contains tetanus toxoid, reduced-dose
diphtheria toxoid, and reduced-dose acellular pertussis
toxoid. Tdap is different from the DTaP vaccine cur-
rently given to babies and young children, as it con-
tains lesser quantities of diphtheria and pertussis
proteins and is much less likely than DTaP to cause
side effects such as pain, redness, and tenderness.
Preliminary data in autologous and allogeneic
transplant recipients demonstrate that the response
to reduced dose pertussis in Tdap is poor, regardless
of when the vaccine is given [809,810]. Use of Tdap
as the initial tetanus-containing vaccine in adult au-
tologous HCT recipients was associated with lack
of response to the tetanus as well as the pertussis por-
tion, suggesting that this vaccine should be used as
a booster vaccine rather than as part of the primary
series [810]. Vaccines with higher tetanus and pertus-
sis content may be more immunogenic in HCT
recipients and thus should be considered for the
initial vaccination.
Influenza vaccine
Life-long seasonal influenza vaccination with inac-
tivated influenza vaccine is recommended for all HCT
candidates and recipients (AII). When vaccination
should be initiated after HCT depends on the epide-
miologic situation, but it is likely that the effectiveness
is better later after HCT. Whether influenza vaccina-
tion is beneficial during the first months following
nonmyeloablative conditioning is unknown. If the vac-
cine is given earlier than 6 months after HCT regard-
less of conditioning intensity, a second dose could be
contemplated (CIII). The live intranasal influenza vac-
cine should not be used because an inactivated alterna-
tive exists (EIII).
During community outbreaks, HCT recipients
who have not yet received a current influenza vaccina-
tion should be vaccinated against influenza immediately
if they are more than 4 months after HCT (BIII). A sec-
ond dose can also be given, especially if the first dose is
given\6 months after HCT (CIII). For pediatric HCT
recipients and candidates .6 months old, annual sea-
sonal influenza vaccination is recommended (BIII).
Children\9 years old who are receiving influenza vac-
cination for the first time require 2 doses administered
z1 month apart (AI).
Varicella vaccines
There are 2 main varicella vaccines, directed
against preventing chickenpox (Varivax) or shingles
(Zostavax). The difference between these vaccines is
the number of plaque forming units of attenuated
virus. The chickenpox vaccine has lower viral titers
and can be used for all HCT recipients who have
met the criteria for live virus vaccination. The new
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much higher viral titers.
HBV vaccine
Vaccination is recommended for HBsAg or
HBcAb-positive patients, because vaccination can
reduce the risk for reverse seroconversion (BII). For
HBsAg or HBcAb-negative HCT patients, the recom-
mendations for the general population in their country
of residence should be followed.
Meningococcal vaccine
Both polysaccharide-based and conjugate vaccines
exist. It is reasonable to assume that, as is true of
vaccines against pneumococci and Hib, conjugated
meningococcal vaccine will give more stable immune
responses than polysaccharide-based vaccines, al-
though no comparative study of the 2 vaccine types
has been performed [811,812].REFERENCES
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PatientsI. BACTERIAL INFECTIONSPathogen: Bacterial infections during the first 100 days after HCT
Indication First Choice Alternatives
Prevention of bacterial infections for adultHCT
patients with anticipated neutropenic periods
of 7 days or more
A fluoroquinolone with antipseudomonal
activity (ie, levofloxacin 500 mg once daily (BI)
or ciprofloxacin 500 mg twice daily (BII))
 Start at the time of stem cell infusion and
continue until recovery from neutropenia or
initiation of empirical antibacterial therapy for
febrile neutropenia;
 Local epidemiological data regarding
fluoroquinolone resistance patterns should
be carefully considered before applying its
prophylaxis (AIII). Closely monitor for
emergence of fluoroquinolone resistance
(AIII)
Azithromycin 250 mg once daily (CIII)
Prevention of bacterial infections among adult
or adolescent HCT recipients with severe
hypogammaglobulinemia (ie, serum IgG level
<400 mg/dL)
IVIG, 500 mg/kg/week (CIII)*† None
Prevention of bacterial infections among
allogeneic pediatric HCT recipients with
severe hypogammaglobulinemia (ie, serum
IgG level <400 mg/dL)
IVIG, 400 mg/kg/month (CIII)*† None
IVIG indicates intravenous immunoglobulin; HCT, hematopoietic cell transplantation.
*Persons with IgA deficiency should not receive standard immunoglobulin products (DIII). Researchers have reported that use of IgA-depleted
immunoglobulin preparations can be used with caution among these persons [834-836].
†Researchers propose checking serum IgG levels every 2 weeks among patients receiving IVIG replacement therapy.Pathogen: Bacterial infections beyond 100 days post-HCT
Indication First Choice Alternatives
Prevention of late bacterial infections with antibiotic prophylaxis Prolonged antibiotic prophylaxis is recommended only for
preventing infection with S. pneumoniae among allogeneic
recipients with cGVHD (see below).
Prevention of late bacterial infections with vaccinations Immunizations (Table 6) are recommended for preventing infection
with S. pneumoniae and H. influenzae type b
Prevention of bacterial infections among HCTrecipients with severe
hypogammaglobulinemia (ie, serum IgG level <400 mg/dL)
IVIG, 500 g/kg every 3-4 weeks (CIII) None
IVIG indicates intravenous immunoglobulin; HCT, hematopoietic cell transplantation; cGVHD, chronic graft-versus-host disease.
Notes: See the note in the previous table for IVIG administration for IgA-deficient patients.
Pathogen: Haemophilus influenzae type b (Hib)
Indication First Choice Alternatives
Immunization against Hib for adult or pediatric HCT recipients Hib conjugate vaccine
 Initial dose: 6-12 months after HCT (BII)
 Subsequent doses: every 2 months for 2 doses (BII)
None
Prevention of invasive disease among HCT recipients who are
household contacts of a person with Hib disease
Note: Prophylaxis is not needed for HCT recipients who are
household contacts of a person with Hib disease if all household
contacts <4 years old are fully vaccinated
Rifampin* [204]
Adult/Adolescents:
600 mg orally daily for 4 days (BIII)
PPediatrics:
0-1 mo: 10 mg/kg orally daily for 4 days
>1 month: 20 mg/kg orally daily for 4 days
Maximum dose: 600 mg/day (BIII)
None
HCT indicates hematopoietic cell transplantation.
*There is potential for substantial drug-drug interactions between rifampin and immunosuppressive agents and other drugs
Pathogen: Methicillin-resistant Staphylococcus aureus (MRSA)
Indication First Choice Alternatives
Elimination of methicillin- resistant Staphylococcus
aureus (MRSA) carrier state among HCT
patients with recurrent MRSA infection (CIII)
Mupirocin calcium ointment 2% apply
 To nares 2 times/day for 5 days; or
 To wounds daily for 2 weeks
Daily bathing with a chlorhexidine product
Note: Safety of mupirocin in children <12 years old
has not been established
Systemic antimicrobials
(eg, rifampin, doxycycline)
HCT indicates hematopoietic cell transplantation.
Note: No regimen for MRSA decolonization has proved consistently effective, but a decrease in MRSA burden may be accomplished.
Pathogen: Streptococcus pneumoniae
Indication First Choice Alternatives
Immunization against pneumococcal
disease for adult or pediatric HCT recipients
Pneumococcal 7-valent (PCV) conjugate
 Initial dose: 3-6 months after HCT (BI)
 Subsequent doses: every 2 months for 2 doses (BI)
 Following the 3 doses of PCV, consider a dose of the 23-valent
polysaccharide pneumococcal vaccine (PPSV23) at 12 months
to broaden the immune response for adults or children >2
years old (BII).
 For patients with cGVHD, a fourth dose of PCV should be
considered (BII) because of poor response to PPSV23. If
possible, give the fourth dose of PCV before administering
PPV23.
Antibiotic prophylaxis among HCT recipients for
the following indications regardless of prior
vaccination (AIII):
Chronic GVHD
Low IgG levels
Penicillin, in areas where the incidence of penicillin-resistant
Streptococcus pneumoniae is not high (AIII)
Adults and adolescents: 250-500mg orally twice daily or 500-
1000mg once daily
Pediatrics:
2 months to 3 years: 125mg twice daily
>3 years: 250mg twice daily
Macrolides or
fluoroquinolones* or
second-generation
cephalosporins (CIII)
HCT indicates hematopoietic cell transplantation; GVHD, graft-versus-host disease.
*Fluoroquinolones generally should not be used in children. However, if a fluoroquinolone is considered, suggested dosing is as follows: levofloxacin
10 mg/kg/dose daily or ciprofloxacin 10-15 mg/kg/dose twice daily.
Pathogen: Bordetella pertussis
Indication First Choice Alternatives
Immunization against pertussis for adult
or pediatric HCT recipients
Acellular pertussis vaccine
 Initial dose at 6-12 months post-HCT
 A total of 3 doses should be given at least
1 month apart
Azithromycin orally daily for
persons with incomplete vaccination series
Adults and adolescents: 250 mg
Pediatrics: 5 mg/kg daily
Postexposure prophylaxis for adult or pediatric
HCT recipients, regardless of vaccination status
Azithromycin:
Adults and adolescents: 500 mg for 1 day
then 250 mg daily for 4 days
Pediatrics: 10 mg/kg loading dose then
5 mg/kg daily for 4 days
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Indication First Choice Alternatives
Preemptive Therapy (< 100 days post-
HCT)
 Administer to all allogeneic HCT
recipients (all ages) with evidence of
CMV infection in blood by antigenemia,
PCR for CMV DNA or detection of
CMV mRNA
 CMV seropositive autologous HCT
recipients (all ages) at high risk (TBI,
recent fludarabine or 2-
chlorodeoxyadenosine) when CMV
antigenemia is$5 cell/slide (or any level
for recipients of CD34+ selected grafts)
[245]
Note: Continue screening for CMV
reactivation and re-treat if screening tests
become positive after discontinuation of
therapy (BI)
Ganciclovir, 5mg/kg/dose, intravenously (i.v.)
Allogeneic HCT(all ages):
Induction: Twice daily for 7-14 days.
Maintenance: Daily if CMV is still detetable and declining
and continue until the indicator test is negative
Note: Minimum total induction and maintenance
treatment is 2 weeks when 14 days of twice daily is
used and 3 weeks when a 7-day induction course is used (AI)
Autologous HCT (all ages):
Induction: Twice daily for 7 days
Maintenance: Continue daily until the indicator test
is negative but a minimum of 2 weeks (BII)
Note: CMV detection methods
should be negative when therapy is stopped
Note: Criteria for duration of induction
and maintenance doses are the same as
those listed for Ganciclovir
Foscarnet, i.v. (AI)
Induction: 60 mg/kg twice daily
Maintenance: 90 mg/kg daily
Valganciclovir (oral)
(persons >40 kg with good oral intake)
(BII)
Induction: 900 mg twice daily
Maintenance: 900 mg daily
Cidofovir, i.v. (CII)
Induction: 5 mg/kg per week for 2 doses
Maintenance: 5 mg/kg every other week
(prehydration and probenecid needed as
per package insert)
Prophylactic Therapy (engraftment to day
100 post- HCT, ie, Phase II)
 Allogeneic HCT recipients (all ages)
Ganciclovir, 5mg/kg/dose, i.v.
Induction: Twice daily for 5-7 days;
Maintenance: Daily until day
100 after HCT (AI)
Foscarnet, 60 mg/kg
i.v. twice daily for 7 days, followed by 90-
120 mg/kg i.v. once daily until day 100 after
HCT (CIII)
Acyclovir, (in combination with
screening
for CMV reactivation): 500 mg/m2 i.v. 3
times
per day; or 800 mg orally 4 times daily
($40 kg);
or 600 mg/m2 orally 4 times daily (<40 kg)
(CI)
Valacyclovir:
in combination with screening for CMV
reactivation: 2 g 3-4 times per day
($40 kg) (CI)
Preemptive Therapy (>100 days post-
HCT) for:
 Allogeneic HCT recipients (all ages)
 All patients receiving steroids for
GVHD
 All patients who received CMV therapy
<100 days after HCT
when:
a) antigenemia is $5 cells/slide; or b) the
patient has had $2
consecutively positive viremia or
polymerase chain reaction tests
Ganciclovir, 5 mg/kg/dose, i.v.
Induction: Twice daily for 7-14 days
Maintenance: Daily for 1-2 weeks or
until the indicator test is negative (BIII)
Or
Valganciclovir (persons .$40 kg with good oral intake)
Induction: 900 mg orally twice daily for 7-14 days;
Maintenance: 900 mg orally daily for 1-2 weeks until indicator test is
negative (BIII)
Note: Minimum treatment course is 14 days regardless of drug used
Foscarnet, 60 mg/kg
i.v. every 12 hours for 14 days; continue
treatment at 90 mg/kg/day daily for 7-4
days
or until the indicator test is negative (AI)
GVHD indicates graft-versus-host disease; HCT, hematopoietic cell transplantation; PCR, polymerase chain reaction; CMV, cytomegalovirus; TBI, total
body irradiation.
Notes: Patients who do not tolerate standard doses of ganciclovir should be treated with foscarnet.
Ganciclovir and foscarnet doses should be reduced in patients with renal impairment. Prehydration is required for foscarnet and cidofovir
administration.
Pathogen: Epstein-Barr virus
Indication First Choice Alternatives
Prevention of Epstein-Barr virus-related posttransplant
lymphoproliferative disease in high-risk patients (BII)
Rituximab, 375 mg/m2
Note: Number and frequency of doses is undefined. Consider
administration weekly until the indicator test is negative (CIII)
None
Pathogen: Herpes simplex virus
Indication First Choice Alternatives
Prevention of early reactivation among
seropositive HCT recipients (regardless of donor
HSV serostatus)
Note: Start prophylaxis at the beginning
of conditioning therapy and continue until
engraftment or until mucositis resolves
Acyclovir
Adults/Adolescents ($40 kg):
 400-800 mg orally twice daily; or
 250 mg/m2/dose i.v. every 12 hours (AI);
Pediatrics (<40 kg):
 250 mg/m2/dose i.v. every 8 hours (BIII); or
 125 mg/m2/dose i.v. every 6 hours
 Maximum dose, 80 mg/kg/day
Adults/Adolescents ($40 kg):
Valacyclovir, 500 mg orally daily (CIII); or
500 mg orally twice daily in highly immune
suppressed patients (eg, T cell depletion, anti-T
cell antibodies, high-dose steroids) (BIII)
Pediatrics (<40 kg): Acyclovir 60 - 90 mg/kg/
24 hours orally, divided in 2-3 doses/day;
or Valacyclovir 250 mg orally twice daily
Prevention of late reactivation among
seropositive HCT recipients
Acyclovir
Adults/Adolescents ($40 kg): 800 mg orally
twice daily during the first year after HCT (BIII)*
Pediatrics (<40 kg): 60-90 mg/kg orally divided in 2-3
doses daily (not to exceed 800 mg twice daily)
Valacyclovir, oral dosing throughout
the first year after HCT (BIII)
Adults: 500 mg twice daily
Pediatrics: 250 mg twice daily
HCT indicates hematopoietic cell transplantation; HSV, herpes simplex virus.
Note: For patients requiring prophylaxis for cytomegalovirus and herpes simplex virus after engraftment, ganciclovir alone provides effective prophylaxis
for both pathogens.
*For long-term prophylaxis, the higher dose of acyclovir is recommended for maximal viral suppression and minimization of resistance.
Pathogen: Varicella-zoster virus
Indication First Choice Alternatives
Postexposure prophylaxis
HCT recipients who are exposed to varicella (AII)
or zoster (AII) or exposed to a VZV vaccinee who
develops a rash (BIII):
 <24 months after HCT; or
 >24 months after HCT and on immune
suppressive therapy or have chronic GVHD
Note: Ideally, administer prophylaxis within 96
hours (preferably, within 48 hours) after close
contact with a person who has chickenpox or
shingles
Varicella-zoster immunoglobulin, if available
Adult/Adolescents ($40 kg):
5 vials (125 units each or 625 units total)
intramuscularly (AII)
Pediatrics (<40 kg):
125 units (1.25 mL)/10 kg body weight administered
intramuscularly (AII), maximum dose of 625 units
Note: For drug therapy, continue until
22 days from exposure
Adults/Adolescents ($40 kg):
Valacyclovir 1g 3 times per day, day 3-22 after
exposure (CII)
Pediatrics (<40 kg):
Valacyclovir 500 mg 3 times daily orally; or
600 mg/m2 orally 4 times daily (CIII)
Prophylaxis of disease reactivation in adults or
adolescents following:
 Allogeneic HCT (BI)
 Autologous HCT (CII)
Acyclovir*
Adults/Adolescents ($40 kg): 800 mg orally
twice daily for 1 year (BI)
Pediatric (<40 kg): 60-80 mg/kg orally
divided in 2-3 doses daily
Adult/Adolescent ($40 kg): Valacyclovir 500 mg
orally twice daily (BII)
Pediatric (<40 kg): Valacyclovir 250 mg orally
twice daily (BII)
GVHD indicates graft-versus-host disease; HCT, hematopoietic cell transplantation; VZV, varicella zoster virus.
*Lower doses of acyclovir, as low as 200 mg twice daily (BII) (at this dose there is no prevention of HSV reactivation disease).
Pathogen: Adenovirus
Indication First Choice Alternatives
Preemptive therapy among high-risk
seropositive HCT recipients (CII)
Cidofovir, i.v. (BII)
All Ages
5mg/kg once weekly or 1 mg/kg 3 times
per week† for 2-4 weeks or until immune
recovery, if tolerated and effective
Ribavirin (CIII)
All Ages
15 mg/kgb 3 times daily for 4 days
followed by 8 mg/kg‡ 3 times daily for up to 10 days
HCT indicates hematopoietic cell transplant.
*Data on optimal dosing of oral ribavirin for adenovirus infection are very limited and based onmaximum tolerated doses [837,838]; dose reductionmay
be required when hemolytic anemia occurs.
†The 1 mg/kg 3 times aweek dose may cause less renal toxicity, but it is insufficient to treat concomitant CMV infection; if concomitant CMV infection is
present, the 5 mg/kg/week is recommended.
‡Dose may be rounded to nearest dose that can be divided by 200 (capsule size); an oral suspension is available.
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Pathogen: Influenza
Indication First Choice Alternatives
Prevention of influenza A or B Life-long annual seasonal influenza vaccination, starting
before HCT and restarting 6 months after HCT (AII)
Adult/Adolescents:
Whole- or split-virus influenza vaccine, 0.5 mL/dose
intramuscularly or deeply subcutaneously
Pediatrics: Type of influenza
Age Dose vaccine
6-35 months 0.25 mL Split-virus*
3-8 years 0.5 mL Split-virus*
9-12 years 0.5 mL Split-virus*
> 12 years 0.5 mL Whole- or
split-virus*
None
Prophylaxis and preemptive treatment during
community and nosocomial outbreaks of
influenza A (BII) for HCT recipients (regardless
of prior vaccination status) who are:
 <24 months post-HCT; or
 >24 months post-HCT and are on
immunosuppression or have cGVHD
Note: Choice of drug depends on susceptibility
of the circulating strain
Note: Longer treatment courses may be
required in HCT recipients because of
prolonged shedding and slow clinical recovery
Adult/Adolescents:
Oseltamivir, 75 mg orally 2 times/day for 5 days
(treatment); or
Oseltamivir, 75 mg orally daily (prophylaxis)
Rimantadine, 100 mg orally 2 times/day (CIII)
Zanamivir: For prevention, 5 mg inhaled twice daily for
10-28 days, with duration depending on type of
exposure; for treatment, 10mg inhaled twice daily for 5
days
Pediatrics:
Rimantadine
Children 1-9 years old, 5 mg/kg/day once daily or divided
in 2 doses (CIII); maximum daily dose, 150 mg;
Children $10 years old (weight, <40 kg), 5 mg/kg/day
orally, divided in 2 doses;
children$10 years old (weight,$40 kg), 100 mg orally 2
times/day
Oseltamivir, 2 mg/kg (rounded for convenient dosing)
orally 2 times/day for 5 days
Zanamivir
For prevention in children $5 years old, 5 mg inhaled
twice daily for 10-28 days
For treatment in children $7 years old, 10 mg inhaled
twice daily for 5 days
Adult/Adolescents:
Amantadine, 100 mg orally 2
times/day (CIII)
Pediatrics:
Amantadine
Children 1-9 years old, 5 mg/kg/day;
maximum daily dose, 150 mg;
Children $10 years old (weight,
<40 kg), 5 mg/kg/day orally, divided in 2
doses;
Children $10 years old (weight,
$40 kg), 100 mg
orally 2 times/day
HCT indicates hematopoietic cell transplantation; cGVHD, chronic graft-versus-host disease.
Notes: Rimantadine dose should be reduced for patients with impaired renal function or for severely impaired hepatic function.
Amantadine dose should be reduced for renal impairment.
Neither rimantadine nor amantadine are Federal Drug Administration-approved for children <1 year old.
*Children <9 years old receiving influenza vaccination for the first time require 2 doses of vaccine spaced $1 month apart.
Pathogen: Respiratory syncytial virus
Indication First Choice Alternatives
Prophylaxis for respiratory syncytial virus (RSV) lower respiratory
infection among hypogammaglobulinemic pediatric HCTrecipients at
risk for primary RSV disease during RSV season
RSV monoclonal antibody (palivizumab)
15 mg/kg intramuscularly once per month (CIII)
Note: Use of palivizumab does not eliminate the need to administer
pooled IVIG that may be required to maintain serum IgG >400 mg/
dL. RSV IVIG, if available, may be administered instead of pooled IVIG
None
Preemptive treatment of RSV upper respiratory infection in the
presence of lymphopenia
Aerosolized ribavirin, [319] 6 g/300 mL
sterile water to make a concentration
of 20 mg/mL; administer 2 g for 2hours every 8 hours or 6 g over
18 hours/day for 7-10 days in a tent
(CIII); use small-particle aerosol generator model SPAG-2
IVIG indicates intravenous immunoglobulin; HCT, hematopoietic cell transplant.
Notes: Persons with IgA deficiency should not receive standard immunoglobulin products (DIII). Researchers have reported that use of IgA-depleted
immunoglobulin preparations can be used with caution among these persons [834-836].
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Indication First Choice Alternatives
Prophylaxis for
a) allogeneic HCT recipients; or b) autologous
HCT recipients who have or will have prolonged
neutropenia and mucosal damage from intense
conditioning regimens, graft manipulation, or who
have recently received purine analogues.
Note: Administer prophylaxis from the start of
conditioning (or day of transplantation for
advanced-generation azoles) until engraftment (ie,
approximately 30 days after HCT) or until 7 days
after the absolute neutrophil count >1000 cells/
mm3
Fluconazole
Adult/Adolescents:
400 mg orally or i.v. daily (AI)
Pediatrics:
Children 6 months to 13 years: 3-6 mg/kg/day
orally or i.v., maximum dose 600 mg per day (AI)
Adults/Adolescents:
Fluconazole, 200 mg orally or i.v. daily (BI)
Itraconazole, oral solution 200 mg orally twice
daily (CI);
Micafungin, 50 mg i.v. once daily (BI);
Voriconazole, 4 mg/kg twice daily i.v. or 200 mg
twice daily orally (BI);
Posaconazole, 200 mg orally 3 times daily (BI)
Pediatrics: None
HCT indicates hematopoietic cell transplantation.Patients at high risk for infections from molds or fluconazole-resistant Candida species
Indication First Choice Alternatives
Prophylaxis in the setting of
prolonged neutropenia
Micafungin, 50 mg i.v. once daily (BI)
Prophylaxis in the setting of
GVHD
Posaconazole, 200 mg orally 3 times
daily (BI)
Voriconazole (BII)
Adults >40 kg: 4 mg/kg twice daily i.v. or 200 mg twice daily orally;
Pediatrics:
$ 20 kg: 100 mg twice daily i.v. or orally
< 20 kg: 50 mg twice daily i.v. or orally
GVHD indicates graft-versus-host disease.IV. REGIONALLY LIMITED OR RARE INFECTIONSPathogen: Pneumocystis jiroveci
Indication First Choice Alternatives
Prophylaxis among
a) all allogeneic HCT recipients (AII); or
b) autologous HCT recipients with underlying
hematologic malignancies, those receiving
intense conditioning regimens or graft
manipulation, or those who have recently
received purine analogues (BIII) [481]
Note: Administer prophylaxis from time of
engraftment for at least 6 months after
HCT(AII)
Note: Continue prophylaxis beyond 6 months
(AII) for the duration of immune suppression for
all persons who:
a) are receiving immunosuppressive therapy (eg,
prednisone or cyclosporine); or
b) have cGVHD
Note: Some researchers also recommend
administering prophylaxis for 1-2 weeks before
HCT (ie, day –14 to –2) (CIII)
Trimethoprim-sulfamethoxazole (AII)
Adult/Adolescents:
 1 double-strength (160/800 mg) tablet orally
daily; or
 1 single-strength (80/400 mg) tablet orally
daily; or
 1 double-strength tablet orally 3 times/week
Pediatrics:
150 mg trimethoprim/750 mg
sulfamethoxazole/m2/day by
mouth as 1 of the following:
 2 divided doses 3 times/week on consecutive
days (AII); or
 a single dose orally
3 times/week on consecutive
days; or
 2 divided doses daily for 7 days; or
 2 divided doses 3 times/week on alternate
days
Adult/Adolescents:
Dapsone 50 mg orally 2 times/day; or 100 mg
orally daily (CII)
Atovaquone 750 mg twice daily or 1500 mg
once daily, orally (CII)
Pentamidine 300 mg every 3-4 weeks by
Respirgard II nebulizer (CII)
Pediatrics:
Dapsone ($1 month old) 2 mg/kg (maximum
dose, 100 mg) orally daily (CII)
Atovaquone 15 mg/kg twice daily or 30 mg/kg
once daily,orally (CII)
Pentamidine IV
4 mg/kg i.v. every 2-4 weeks
Pentamidine administered every month by
Respirgard II nebulizer (CIII)
#5 years old: 9 mg/kg/dose; or
>5 years, 300 mg
HCT indicates hematopoietic cell transplant; cGVHD, chronic graft-versus-host disease.
Notes: Patients who are receiving sulfadiazine-pyrimethamine for toxoplasmosis therapy are protected against Pneumocystis jiroveci and do not need ad-
ditional prophylaxis.Trimethoprim-sulfamethoxazole is not recommended for patients <2 months old, because of risk for kernicterus.
Pathogen: Toxoplasma gondii
Indication First Choice Alternatives
Prophylaxis among seropositive allogeneic HCT
recipients
Note: Start after engraftment and administer as
long as patients remain on immunosuppressive
therapy (ie, generally, until 6 months after HCT)
(BIII)
Trimethoprim-sulfamethoxazole
Adult/Adolescents (AII):
 1 double-strength (160/800 mg) tablet orally
daily; or
 1 single-strength (80/400 mg) tablet orally
daily; or
 1 double-strength tablet orally 3 times/week
Pediatrics:
150 mg trimethoprim/750 mg
sulfamethoxazole/m2/day by
mouth as 1 of the following:
 2 divided doses 3 times/week on consecutive
days (AII); or
 a single dose orally
3 times/week on consecutive
days; or
 2 divided doses daily for 7 days; or
 2 divided doses 3 times/week on alternate
days
Clindamycin plus pyrimethamine plus leucovorin
(CIII)
Adult/Adolescents
Clindamycin: 300-450 mg orally every 6-8 hours;
plus pyrimethamine: 25-75 mg orally daily; plus
leucovorin: 10-25 mg orally daily
Pediatrics:
Clindamycin: 20-30 mg/kg/day by
mouth, divided in 4 doses daily; plus
Pyrimethamine: 1 mg/kg orally daily; plus
Leucovorin: 5 mg orally every 3 days
HCT indicates hematopoietic cell transplantation.
Note: Among allogeneic HCTrecipients, clinical toxoplasmosis has occurred despite the use of trimethoprim-sulfamethoxazole for Pneumocystis jiroveci
prophylaxis [100].
Trimethoprim-sulfamethoxazole is not recommended for patients <2 months old, because of risk for kernicterus.
Pathogen: Strongyloides species
Indication First choice Alternatives
Prevention of strongyloidiasis hyperinfection
among HCT candidates who demonstrate:
a) positive screening tests for Strongyloides
species (BIII); or
b) unexplained eosinophilia and a travel or
residence history suggestive of exposure to
Strongyloides stercoralis (BIII)
Note: Administer prophylaxis before HCT
Ivermectin 200 mg/kg/day orally daily for 2
consecutive days; repeat after 2 weeks (BIII)
[513,839]
Dosing by Weight:
Body
weight (kg) Oral dose
< 15 Not recommended
$ 15-24 3 mg
25-35 6 mg
36-50 9 mg
51-65 12 mg
66-79 15 mg
$ 80 200 mg/kg
Adults/Adolescents
Albendazole: 400 mg orally twice daily for 7
days; or Thiabendazole:
25 mg/kg (maximum 3 gm/day) orally 2 times/
day for 2 days (BIII)
Pediatrics
Albendazole 400 mg po twice a day for 7 days; or
Thiabendazole:
25 mg/kg (maximum 3 gm/day) orally 2 times/
day for 2 days (BIII)
HCT indicates hematopoietic cell transplant.
Notes: Among immunocompromised patients, multiple courses at 2-week intervals might be required; however, cure might not be achievable.
Safety and efficacy of ivermectin has not been established during pregnancy.
Albendazole and thiabendazole are contraindicated during pregnancy.
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Pathogen:Mycobacterium tuberculosis
Indication First Choice Alternatives
Prevention of Mycobacteria tuberculosis infection
among:
a) highly immunocompromised HCT recipients
or candidates who have been substantially
exposed to someone with active, infectious (eg,
sputum smear positive) pulmonary or laryngeal
tuberculosis, regardless of the HCT recipient’s
or candidate’s tuberculin skin test status (BIII);
or
b) HCT recipients or candidates with a positive
TST (BII) or a positive IGRA (BII) and who were
not previously treated and have no evidence of
active tuberculosis disease
Note: A positive TST
Isoniazid (plus pyridoxine)
Adult/Adolescents:
Isoniazid: 5 mg/kg/day orally or intramuscularly
for 9 months (ie, forz270 doses) [841],
maximum dose, 300 mg/day; give with
pyridoxine: 25-50 mg orally daily for 9 months
(BIII)
Pediatrics:
Isoniazid: 10-20 mg/kg/day by
mouth or intramuscularly for
9 months (ie, forz270 doses) [842]
maximum dose, 300 mg/day; give with
pyridoxine: 1-2 mg/kg/day orally daily for 9
months; dose required might vary by age and
condition) (BIII) [842]
Rifampin, 600 mg orally once daily for 4 months
* (CIII)
HCT indicates hematopoietic cell transplant; TST, tuberculin skin tests; IGRA, interferon-gamma release assays.
Notes: A twice-weekly schedule of isoniazid and pyridoxine can be administered (CIII). The twice-weekly isoniazid dose is 15 mg/kg orally or intramus-
cularly (maximum dose, 900 mg). The twice-weekly pyridoxine dose is 50-100 mg orally.
A 2-month pyrazinamide/rifampin preventive therapy regimen should not be used because of the risk of fatal hepatitis (EIII) [469].
Persons who are intolerant to isoniazid or have been exposed to isoniazid-resistant tuberculosis should be referred to a tuberculosis specialist (AIII).
All intermittent dosing strategies should be administered as directly observed therapy (AIII).
*There is potential for substantial drug-drug interactions between rifampin and immunosuppressive agents and other drugs.
Pathogen: Traveler’s diarrhea
Indication First Choice Alternatives
Prophylaxis among HCT recipients who are
immunocompromised and who plan to travel in
developing countries
Note: Administer for duration of stay in
developing country
Adults/Adolescents:
Ciprofloxacin, 500 mg orally daily for the
duration of stay in developing countries (BIII); or
Bismuth subsalicylate, 2 oz orally 4 times/day or
2 tablets orally 4 times/day for #3 weeks in
adults > 18 years old [824]
Pediatrics:
150 mg trimethoprim/750 mg
sulfamethoxazole/m2/day by mouth as 2 divided
doses 3 times/week on consecutive days (CIII)
Adults/Adolescents:
Trimethoprim-sulfamethoxazole,
1 double-strength (160/800 mg) tablet by
mouth daily (CIII)
Pediatrics:
Trimethoprim-sulfamethoxazole, single dose
orally 3 times/week on consecutive days
HCT indciates hematopoietic cell transplantation.
Notes: Use of aspirin-containing products, including bismuth subsalicylate, is contraindicated in persons <18 years old unless prescribed by a physician,
because these products have been associated with Reye’s syndrome [840].
Trimethoprim-sulfamethoxazole is not recommended for patients <2 months old, because of risk for kernicterus.
Resistance to trimethoprim-sulfamethoxazole is common in tropical areas.
Usual doses of trimethoprim-sulfamethoxazole for Pneumocystis jiroveci pneumonia prophylaxis should provide limited protection against traveler’s di-
arrhea
Fluoroquinolones are not approved for use among children <18 years old.
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(adapted from a questionnaire developed by Chil-
dren’s Hospital Boston)
At our institution, it is a top priority to ensure
a safe environment for all patients, families, visitors
and staff. Part of this commitment includes daily
wellness screening of parents/guardians, other family
members, and visitors here to see hospitalized pa-
tients. This screening process helps us to prevent
the spread of infection. To assist us in this effort,
please read and answer the questions on this form
carefully.
The name of the patient you are visiting:
___________________________________
The nursing unit that the patient is on:
_____________________________________
Number of Adults visiting (age 18 and older)
__________
Number of Adolescents visiting (age 13 to 17)
__________
Number of Children visiting (12 and younger)
__________
Note: on certain units, children 12 and younger
must be siblings of the patient
If you answer Yes to either of the following
questions, please let the front desk staff member
know that you need to speak with the charge nurse
or the patient’s bedside nurse before proceeding
into the unit.1. In the past 3 weeks have any of the visitors indicated
above had contact with a person who is ill with
chickenpox, measles, mumps, or whooping cough
(also known as pertussis), such as in daycare, school,
at home or work?Yes, No,2. Have any of the visitors been sick with fever, diar-
rhea or vomiting in the past 3 days or had any
cold symptoms including fever, cough, sore throat,
or runny nose in the past 3 days?Yes, No,If yes, please explain: _____________________
_____________________________________________
_____________________________________________
___________________________
__________________________________________
________________
Signature of Adult Relationship to patient Date
Screening reviewer ____________________
_____________________________________
Hospital personnel action: ________________
___________________________________
__________________________________________
______________________________
__________________________________________
_______________________________
1238 Biol Blood Marrow Transplant 15:1143-1238, 2009M. Tomblyn et al.APPENDIX 3: Desensitization Protocol for HCT Patients with Sulfa Allergies*All HCT patients with sulfa allergies should un-
dergo desensitization at the earliest possible time. If
desensitization cannot be performed before transplan-
tation, the desensitization process should be started
posttransplantation when an absolute neutrophil count
.500/mm3 is sustained for 72 hours or by day 130.
A stock solution (Standard Pediatric Oral Suspen-
sion, trimethoprim [TMP] 40 mg/sulfamethoxazole
[SMX] 200 mg per 5 mL is used, followed by single-
strength tablets (80 mg TMP/400 mg SMX).Adult Sulfa Desensitization Schedule
On days 1 through 5: the stock suspension is di-
luted: One (1) mL of stock 1
9 mL saline in a 10-mL syringe5 4 mg/mL SMX
Day 1: Take 0.25 mL5 1 mg SMX
Day 2: Take 0.50 mL5 2 mg SMX
Day 3: Take 1 mL5 4 mg SMX
Day 4: Take 2 mL5 8 mg SMX
Day 5: Take 4 mL5 16 mg SMX
On days 6 through 9, the stock solution is used
full strength:
Day 6: Take 0.5 mL of stock5 20 mg SMX
Day 7: Take 1 mL of stock5 40 mg SMX
Day 8: Take 2 mL of stock5 80 mg SMX
Day 9: Take 4 mL of stock5 160 mg SMX
Day 10: Take 1 single-strength tablet (400 mg
SMX).
If no rash appears, continue dosing at 1 single-
strength tablet twice daily for 30 days. If the desensiti-
zation process is interrupted at this point for reasons
other than TMP/SMX allergy, then give a test dose
of half a single-strength tablet. If the patient tolerates
this test dose, then restart dosing at 1 single-strength
tablet twice daily. After 30 days of continuous therapy,
if no reaction has occurred, full therapy can be given.Pediatric Adult Sulfa Desensitization Schedule
On days 1 through 5, the stock suspension is di-
luted: One (1) mL of stock 1
9 mL saline in a 10 mL syringe5 0.8 mg/mL
TMP (4 mg/mL SMX)
Day 1: Take 0.25 mL5 0.2 mg TMP
Day 2: Take 0.50 mL5 0.4 mg TMP
Day 3: Take 1 mL5 0.8 mg TMP
Day 4: Take 2 mL5 1.6 mg TMP
Day 5: Take 4 mL5 3.2 mg TMP
On days 6 through 9, the stock solution is used
full strength:
Day 6: Take 0.5 mL of stock5 4 mg TMP
Day 7: Take 1 mL of stock5 8 mg TMP
Day 8: Take 2 mL of stock5 16 mg TMP
Day 9: Take 4 mL of stock5 32 mg TMP
Day 10: If\12 years old, take 1/2 single-strength
tablet (40 mg TMP);
if .12 years old: take 1 single-strength tablet
(80 mg TMP)
Day 11: If\12 years old: Take 1/2 single-strength
tablet (40 mg TMP) twice daily;
if .12 years old: Take 1 single-strength tablet
(80 mg TMP) twice daily
If no rash appears, continue dosing as above twice
daily for 30 days. If the desensitization process is inter-
rupted at this point for reasons other than TMP/SMX
allergy, then give a test dose of half a single-strength
tablet if the patient is .12 years old, and 1/4 single-
strength tablet if the patient is\12 years old. If the pa-
tient tolerates this test dose, then restart dosing at 1
single-strength tablet twice daily for children .12
years old and 1/2 single strength-table twice daily for
children\12 years old. After 30 days of continuous
therapy, if no reaction has occurred, full therapy can
be given.
*Modified from Purdy et al.,45 Ann Intern Med.
1984:100;512-514.
